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ABSTRACT
Implementing Partially Effective HIV Prevention Programs:
Changes in Sexual Risk Behavior and Epidemic Impact in Sub-Saharan Africa
Kyeen Mesesan
2007

While there is no magic bullet that can completely prevent HIV transmission and
halt the HIV/AIDS pandemic, governments and policy makers have an array of partiallyeffective HIV prevention programs from which to choose, including the use of existing
interventions (e.g. education and condom use) and technologies under development (e.g.
microbicides and vaccines). Complex decisions regarding if, when, and how to
implement various programs with partial efficacy must be made, often in the absence of
data on program outcomes. Additionally, the quantitative tradeoff between programrelated decreases in HIV transmission and the effects of risk behavior change is often
unknown. The potential for changes in risk behavior to influence outcomes at the
individual and population levels raises significant operational and ethical concerns
regarding the magnitude of program benefits.
Epidemiological data collection of sexual risk-taking behavior and mathematical
modeling of population HIV transmission dynamics are used here in a multidisciplinary
approach to examine the implications o f risk behavior change surrounding the

implementation of HIV prevention programs with less than 100% efficacy. This topic is
explored within a South African context—specifically, the urban township of Soweto,
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which has a generalized, predominantly heterosexual HIV epidemic representative of
populations throughout sub-Saharan Africa.
The subject of risk behavior change associated with prevention program
implementation arises most frequently in discussions regarding HIV vaccine
development and use. The first and second papers contain analyses of self-reported data
on current and anticipated sexual risk-taking behavior from adults undergoing screening
and enrollment into HIV vaccine trials. The third paper describes a mathematical model
to simulate the dynamics of heterosexual HIV transmission, including gender differences
in the negotiation of safe sexual practices, in these populations. The potential impact of
future HIV vaccination programs is considered, focusing on the interactions between
vaccine efficacy and risk behavior change. The analysis is extended in the fourth paper
by adapting the framework developed for HIV vaccines, likely not available for at least a
decade, to consider adult male circumcision—another potential, partially-effective HIV
prevention program for which clinical trial efficacy data have recently been released and
for which the technology is available immediately.
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Overview and rationale for dissertation research
While there is no magic bullet that can completely prevent HIV transmission and
halt the HIV/AIDS pandemic, governments and policy makers have an array of partially
effective HIV prevention programs from which to choose. Program interventions to
prevent sexually-transmitted HIV infection include both existing methods, such as those
increasing education, access to volunteer counseling and testing (VCT), condom use,
socioeconomic empowerment, and treatment of other sexually transmitted diseases[1], as
well as technologies still in development, such as microbicides, vaccines, and pre
exposure prophylaxis regimens121. None of these prevention methods are perfect, and the
evolving policy notion is that ‘cocktails’ of imperfect prevention programs will be
required to fight the epidemical Complex decisions regarding if, when, and how to
implement these various programs must be made, often in the absence of data on program
outcomes.
Although some prevention programs may have only positive outcomes, such as
those promoting HIV awareness education, the majority of prevention programs can not
guarantee success: they may prevent HIV infections, but they also risk a potential
rebound effect—the notion that sex might be considered ‘safer’ in light of individual or
population reductions in HIV transmission. There are significant operational and ethical
concerns regarding the use of partially effective HIV prevention programs and whether
individuals will increase their risk-taking behavior because of presumed decreases in risk
of HIV infection13,41. At the individual level, a person who increases their risk behavior
might increase their own likelihood of HIV infection, while at the population level
increased risk behavior could lead to increased HIV incidence, thus worsening the
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epidemic overall. Conversely, decreases in risk behavior would have beneficial effects at
both the individual and program outcome levels. For many prevention programs, the
quantitative tradeoff between decreases in HIV transmission and potential increases in
risk behavior is unknown.
I employed both epidemiological data collection of sexual risk-taking behavior and
mathematical modeling of population HIV transmission dynamics in a multidisciplinary
approach to examine the implications of risk behavior change surrounding the
implementation of HIV prevention programs with less than 100% efficacy. The subject
of risk compensation is most frequently discussed within the context of vaccine trials and
the use of vaccines with only partial efficacy in future mass vaccination campaigns[5'9].
Thus, to explore the potential benefits or harms of partially effective programs, I
examined risk behavior associated with the use of vaccines in current clinical trials and
future vaccination programs. I then extended the analysis by adapting the framework
developed for predicting the impact of partially effective HIV vaccines, which may not
be available for at least a decade, and applied it to adult male circumcision—another
potential partially effective HIV prevention program for which new clinical trial efficacy
data have recently been released and for which the technology is available immediately.
I explored these research areas within a South African context, specifically in the urban
township of Soweto, which has a generalized, predominantly heterosexual HIV epidemic
and high rates of risky sexual behavior similar to many populations throughout subSaharan Africa.
Numerous clinical trials designed to test various HIV prevention technologies are
currently being conducted in Soweto, including the first HIV vaccine trials on the African
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continent. When clinical trials for prevention technologies are concluded and show
significant efficacy in reducing HIV transmission, immediate decisions must be made
regarding their use. Given the various HIV prevention trials being conducted in Soweto,
local and national authorities in South Africa may need to consider implementation of
large prevention programs in the near future. Because there will be no data on program
outcomes initially, policy makers must rely on available empirical and modeling data for
decisions regarding program implementation. I addressed this need in two ways for my
dissertation research: (1)1 collected current and anticipated sexual risk behavior data
from participants actively undergoing screening and enrollment into HIV vaccine trials in
Soweto; and, (2) I employed epidemic modeling to estimate the potential impact of
partially effective HIV prevention programs for vaccines and male circumcision on the
entire population of Soweto.
Background information
The greatest concentration of HIV infections worldwide lies in sub-Saharan
Africa1-a n d , for both practical and ethical reasons, controlling the global HIV/AIDS
epidemic must include interventions which specifically address prevention of infections
in this region1-10,111 Within the sub-Saharan region, countries in Southern Africa have the
highest estimates of national HIV prevalance: Mozambique (16%), Zambia (17%), South
Africa (19%), Namibia (20%), Zimbabwe (20%), Lesotho (23%), Botswana (24%), and
Swaziland (33%)[1]. South Africa has the highest number of infected individuals in the
world, and is representative of most countries in the Southern African region in having
regional variations in HIV prevalence rates as high as 30-50%^’12’13^.
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In South Africa, detailed national surveys have been conducted on the factors and
behaviors which place individuals at risk of HIV infection114'191. Despite the existence of
several national surveys, sexual practices and HIV risk vary widely by geography and
culture in South Africa. For example, the national Nelson Mandela household survey
revealed that the percentage of males reporting more than one sexual partner in the
previous year varied widely: by location, from 9% in ‘rural formal’ localities to 20% in
‘urban informal’ localities; by ethnicity, from 4% in Whites and Indians to 11% in
Coloreds and 19% in Africans; and by age, from 27% in young men aged 15-24 to 10%
in men 50 years or older[18]. These differences in reported risk behaviors contribute to the
variation in HIV risk from exposure to HIV, with HIV prevalence found to be 9% for
individuals living in ‘urban formal’ localities compared to 18% in ‘urban informal’
localities; 13% for African individuals compared to 1-2% for other populations; and, 11%
for individuals living in Gauteng Province, the province where Soweto is located1181. For
studies of risk behavior, these variations emphasize the importance of collecting data for
specific populations or geographic regions.
Many tools already exist for the prevention of sexual HIV transmission and are
being used in prevention programs in Southern Africa. Although increasing the
allocation of resources for existing prevention program packages to coverage levels of
80% could prevent half of the infections projected for sub-Saharan Africa in the next
decade1201, the majority of programs focus on (1) condom distribution and education
surrounding correct condom use and (2) education on reduction in sexual partners,
including abstinence and monogamy111: Current prevention technologies work, but they
do not provide complete or lifelong protection and they are largely related to risk-
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reduction behaviors which must be practiced effectively and consistently with every sex
act. These prevention programs must be implemented on a widespread basis with
continuous funding for an indefinite period of time, and eventually experience decreased
responsiveness to program messages. Compounding these problems, current prevention
tools require that women and girls have the power to negotiate safe sexual practices
where, for cultural and economic reasons, in many low- and middle-income country
settings they do not. The lack of practical female-controlled methods, such as
microbicides and diaphragms, to prevent HIV transmission is in part responsible for the
higher prevalence of HIV seen in younger women.
Current prevention efforts have not been adequate to control the HIV epidemic, but
numerous prevention technologies are under development121; in particular, the design of
an HIV vaccine to prevent HIV transmission which remains a realistic objective. At least
35 potential preventive HIV vaccine candidates are in various stages of human testing
around the world1211, and numerous additional strategies for effective preventive HIV
vaccines are under development in laboratories worldwide1221. When a potential vaccine
candidate is approved for human testing, three successive phases of evaluation are
required1231. Phase I testing involves the evaluation of vaccine safety—whether it causes
any severe reactions or side effects—in a small group of volunteers and usually lasts for
approximately one year. Phase II testing involves the evaluation of vaccine
immunogenicity—whether it stimulates an immune response—in several hundred
volunteers and lasts approximately two years. Phase III testing involves the evaluation of
vaccine efficacy—whether it can prevent HIV transmission and/or HIV infection—in
several thousand volunteers and can last for three to four years. The majority of clinical
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trials being conducted are currently in Phase I testing, however eight candidates are in
Phase II testing, two candidates are in Phase III testing, and two candidates are in Phase
lib testing—a hybrid between Phase II and III that provides an earlier indication of
potential vaccine efficacy[21]. For Phase II, Phase lib and Phase III testing, clinical trials
are generally conducted at the multi-country level. In sub-Saharan Africa, seven
countries are already participating in international clinical trials testing HIV vaccine
candidates and more will soon follow121,24,251.
Increases in risk behavior associated with small HIV vaccine trials1-26-1, large
Hepatitis B vaccine efficacy trials1271, and treatment of HIV-infected individuals with
anti-retroviral therapy1281 have already been observed. Although several large HIV
vaccine efficacy trials have been conducted worldwide and showed no increase in risk
behavior129'331, none have been completed in sub-Saharan Africa where little is known
regarding potential HIV vaccine trial-related risk behavior change134,351. In South Africa,
which is conducting more trials than any other African nation, baseline sexual practices,
risk behavior, and attitudes towards a partially effective vaccine have not been fully
assessed in the populations from which vaccine trial participants will be drawn136'381.
Although there are many vaccine candidates progressing through the global HIV
vaccine pipeline, extensive time is required to complete multiple phases of testing and
clinical trials. Therefore it is probable that the first preventive HIV vaccine will be
licensed only within the next decade. While eventually the hope is to develop a highly
effective vaccine, the first licensed vaccine will likely have only moderate efficacy and
could even have an efficacy as low as 30%18,22,391. Previous modeling studies have shown
that even a partially effective HIV vaccine with minimal efficacy could have enormous
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population impact on the HIV epidemic in high-risk groups or areas with a high
prevalence of HIV[40'46], but that the magnitude of this impact depends on a fine balance
between the efficacy of the vaccine, the vaccine coverage level, and the change in risky
behavior[43,45,47'51]. For this reason, whether individuals might increase their sexual risk
behavior in response to future mass vaccination campaigns represents a significant
concem[7'9,52]. This concern is even greater for the majority of African nations, with
substantial HIV epidemics and limited resources, which may implement the first
generation of HIV vaccines. However, only a small number of studies exist that have
addressed either epidemic modeling or the potential for risk behavior change specific to
the African setting[35,40~43,45,531.
Summary of dissertation projects'
In the first paper, I collected data on current sexual risk-taking behavior from adults
who are undergoing screening and enrollment into multiple Phase I/II HIV vaccine trials
in Soweto. Baseline sexual risk behavior characteristics have not been well-documented
in the township of Soweto, from which individuals are recruited for HIV vaccine trials.
Further, sexual risk behavior has not been characterized in the individuals who are
volunteering for screening and enrollment into HIV vaccine trials in Soweto. These
issues are true for many sites across sub-Saharan Africa which are conducting or
preparing for HIV vaccine trials. In addition, any analysis of sexual risk behavior change
depends on the ability to collect accurate behavioral data at these sites. This paper
addresses the need for a detailed risk behavior assessment tool and for the risk behavior
characterization of participants enrolling into HIV vaccine trials in South Africa.
1This section also specifies my role in the design and conduct o f this research. Because this dissertation
uses the collected manuscript format, I have written the four individual papers in the plural narrative to
account for multiple authorship, consistent with scientific publishing standards.
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After conducting focus groups amongst patients and staff at the Perinatal HIV
Research Unit (PHRU) in South Africa, I developed a survey using culturally-appropriate
language for use in this population to collect self-reported data on participant
sociodemographics, substance use, sexual history, and partnership-specific sexual
behaviors for the previous 6 months. I incorporated my survey into the existing protocol
for adults undergoing screening for HIV vaccine trials, known as the Pre-Screening
Protocol, at the PHRU[54,55]. I pilot-tested several versions of my survey on participants
in the Pre-Screening Protocol. Then, working with the PHRU data management team, I
converted all of the Pre-Screening Protocol forms—including my survey—into a format
for automated data scanning and entry. I worked with the PHRU data management team
to create a database for all of the Pre-Screening Protocol data, including the data
collected by my survey, and I coordinated a team of PHRU nurses and physicians to
transcribe all data collected prior to the initiation of the automated format data collection.
I then trained counselors to administer my survey using a combination of group and
individual teaching sessions, and provided additional guidance and feedback over several
years.
As part of the overall Pre-Screening Protocol, the PHRU staff collected data with
my survey and performed manual reviews of the data for accuracy. Following automated
data entry, the PHRU data management team performed three levels of data validation
and then generated quality control reports. I supervised the resolution of incomplete or
missing data in these reports by PHRU nurses and physicians in order to generate the
final data collected for the Pre-Screening Protocol. I created a data analysis plan and
then, working with a PHRU statistician and de-identified data from the database, I
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cleaned the data and conducted statistical analyses. In addition to providing a detailed
description of this cohort and baseline levels of sexual risk behavior, I used these data
further to identify predictors of higher levels of risk behavior which could be used for
both present HIV vaccine trial screening and future vaccination programs.
The second paper considers anticipated sexual risk behavior changes in response to
receiving a hypothetical low-efficacy vaccine. In the absence of actual data on risk
behavior change, this study addresses the need to estimate the magnitude of potential
changes in behavior that could occur in the future. Using the same methods described
above, I developed and implemented an additional survey for use in the same population
of individuals volunteering for current HIV vaccine trials in Soweto and analyzed the
data which were collected. I designed the survey and associated script to collect data on
comprehension of the hypothetical low-efficacy vaccine concept, on anticipated changes
in condom use behaviors with sex partners, and on anticipated changes in frequency of
sex with non-primary sex partners. The survey and results provide a foundation for
examining potential behavior change in individuals contemplating participation in a
future vaccination program. Although I conducted this study to assess anticipated change
in behavior following vaccination, the results may be applicable to other HIV prevention
programs with partial efficacy.
For the third and fourth papers, I developed a mathematical model11to simulate the
dynamics of heterosexual HIV transmission in adult populations where gender
differences in negotiation of safe sexual practices exist. As such, the model is pertinent
11Compartmental models are an established methodology for analyzing epidemics and hypothetical
program intervention scenarios. Their use entails the delineation of various health ‘states’ in a population
as well as differential equations that specify flow between these various states. Mathematical models allow
for sensitivity analyses on a variety o f parameters and are helpful in situations where a historical precedent
for program implementation is lacking.
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to heterosexual transmission of HIV throughout much of sub-Saharan Africa. I collected
detailed input parameters and assumptions from various sources, including data from
published literature and communication with scientists and government officials in South
Africa, to initialize the model for the high-risk heterosexual transmission of HIV that
occurs within the population of Soweto. I adapted the model to estimate the impact of
various partially effective HIV prevention program scenarios on the epidemic, in terms of
HIV infections prevented and changes in population HIV prevalence over time.
I examined the potential impact of future vaccination programs on the HIV
epidemic in Soweto in the third paper. Although a vaccine will not be available for some
time, this paper addresses the need for a detailed consideration of the dynamics of risk
behavior change in preparation for the eventual use of low-efficacy HIV vaccines in
African populations. I adapted the model to incorporate the effects of prevention
programs using HIV vaccines with varying levels of protection against HIV and post
vaccination changes in sexual risk-taking behavior. I compared various program
outcomes to two base-case scenarios: one with no vaccination or one using a 40%
effective vaccine with no post-vaccination change in behavior. The simulations consider
vaccination programs which cover a significant proportion of the population over a 10year period, and program outcomes are given during the same time period.
In the fourth paper, I explored the potential impact of programs to expand the
number of adult males who are circumcised in Soweto. This paper addresses the urgent
need for research to inform decisions regarding the immediate implementation of
expanded adult male circumcision programs in the African setting. I adapted the model
to specify the influence of current levels of circumcision on female-to-male HIV
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transmission and to examine the impact of programs which circumcised an additional
proportion of adult males. The simulations consider expanded adult male circumcision
programs with only modest increases in the level of circumcision coverage over a 5-year
period, and the program outcomes are estimated over a 20-year period. I compared the
program outcomes with scenarios in which male circumcision levels remained the same
over time.
While these two HIV prevention technologies are similar on a general level—both
preventive vaccines and male circumcision can reduce HIV transmission with a certain
degree of effectiveness—there are substantial differences that exist at both the modeling
and policy levels: (1) Although vaccines will not be available in the near future, the
efficacy of circumcision has recently been proven and the technology is available now.
(2) Vaccination programs require giving a population of men and women a vaccine that
may not provide lifelong protection and may not be fully immunogenic, whereas
circumcision programs involve a one-time procedure, performed only on men, which is
presumed to provide lifelong benefits. (3) No one has yet received an HIV vaccine
whereas many men are already circumcised. (4) Increasing levels of vaccine efficacy
directly influence the benefits of vaccination programs, which contrasts with the situation
for circumcision. The fourth paper demonstrates that increasing levels of circumcision
efficacy do not necessarily increase the benefits of circumcision programs. (5)
Vaccination provides equal benefits to men and women whereas circumcision provides a
direct benefit to men and a lesser, indirect benefit to women. (6) For potential risk
behavior change in individuals who have received the intervention (a direct, or primary
effect), risk behavior change resulting from vaccination programs would entail only those
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vaccinated whereas risk behavior change resulting from circumcision programs would
entail both those men who are circumcised as well as those men who were previously
circumcised. (7) With vaccination programs, women receive direct protection against
increases in male risk behavior, whereas with circumcision programs, they do not. This
difference is particularly important when considering societies in which the male partner
may dominate risk behavior decisions such as condom use. (8) Finally, high coverage
levels would be desirable for vaccination programs whereas more modest coverage level
goals would be sufficient for expanded adult male circumcision programs.
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INTRODUCTION
A major concern regarding the conduct of HIV vaccine trials is that individuals may
increase their risk-taking behavior, assuming that they are protected from HIV infection
when, in actuality, they might not be[1'4l In addition to putting individual vaccine trial
participants at greater risk for HIV infection, changes in risk-taking behavior can also
affect both the sample size and efficacy calculations that determine trial outcomes and,
ultimately, whether a vaccine candidate is licensed for use[5‘8]. Further, despite multiple
HIV vaccine trials being conducted globally, appropriate methods for assessing risk are
still under debate and are particularly important in low- and middle-income countries and
communities where baseline sexual practices and customs are not well known. For these
reasons, appropriate and accurate assessment of risk behavior during vaccine trials
remains a priority.
Data on the sexual risk behaviors of African cohorts entering HIV vaccine trials are
scarce and no effective tools have been published that measure risk behavior in low- and
middle-income country populations. Seven countries on the African continent—Rwanda,
Kenya, Uganda, Tanzania, Zambia, Botswana and South Africa—are enrolling volunteers
and conducting HIV vaccine trials to date, while site development is underway in Malawi
and Cote d’Ivoire[9'11]. As the first African country to initiate HIV vaccine trials, South
Africa provides an important example for studying African risk behavior in potential HIV
vaccine trial participants. The baseline sexual risk behaviors of South Africans enrolling
into HIV vaccine trials, both individually and in the communities from which they
originate, have not been characterized to date. Although one study has characterized the
risk behavior of participants in an observational cohort group examining incidence and
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retention in preparation for vaccine trials,[12] further research is needed on participants
being actively enrolled into vaccine trials, characterizing different communities, and
examining sexual risk behaviors within specific partnerships.
In this study111, we report the initial results of risk behavior monitoring of a
predominantly heterosexual cohort of potential vaccine trial participants undergoing
screening and enrollment into Phase I and Phase II HIV vaccine trials in Soweto, using a
detailed risk behavior assessment tool adapted to South African language and customs
developed for this purpose[13'16]. The results we report here provide one of the first
characterizations of risk behaviors in an African population participating in HIV vaccine
trials. In addition, these baseline data represent a first step in determining whether sexual
risk behavior could change in South Africans volunteering to participate in early Phase
I/II HIV vaccine clinical trials.

111Partial data from this manuscript have been previously reported at the XV International AIDS Conference
(Bangkok, 2004), the AIDS Vaccine International Conference (Montreal, 2005), and the AIDS Vaccine
International Conference (Amsterdam, 2006).
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METHODS
Study Setting
We assessed sexual risk behavior within the context of ongoing screening and
enrollment into Phase I/II adult HIV vaccine trials at the Perinatal HIV Research Unit
(PHRU). The PHRU is affiliated with the University of the Witwatersrand in
Johannesburg and is located at the Chris Hani Baragwanath Hospital in Soweto. Soweto
is the largest black urban township in South Africa with a population of approximately
1.1 million[17^ (calculated from census data, with assistance from the Johannesburg City
Council) and antenatal HIV prevalence of 30% (personal communication, Avy Violari,
PHRU); it is situated southwest of Johannesburg in Gauteng province, which has an
overall HIV prevalence of 16% in residents 15-49 years of age^18].
The positioning of the PHRU provides important access to the Soweto population,
as the hospital serves a vast majority of the area and is the location for both medical and
community activities. The HIV/AIDS Vaccine Division (HAVD), within the PHRU, is
the location of all adult HIV vaccine research and clinical trials. The HAVD provides
free access to HIV voluntary counseling and testing (VCT), and identifies HIV-negative
Soweto residents in this manner for recruitment into clinical trials. Seroprevalence of
HIV infection among potential participants screened is between 50% and 60%; of those
that test HIV-negative, approximately 20% volunteer to undergo screening for enrollment
into HIV vaccine trials[19].
Potential HIV-negative vaccine trial volunteers are recruited from VCT into a
generic “Pre-Screening Protocol” which was designed to allow the accumulation of
suitably informed, healthy, low-risk HIV-negative cohorts for Phase I/II HIV vaccine
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trials being conducted at HAVD[20,21]. The Pre-Screening Protocol provides information
sessions about HIV vaccines, baseline and follow-up assessments of understanding, as
well as risk behavior assessment and clinical screening for physical health. HIV
prevention services are offered to participants at each visit including VCT, provision of
free condoms, risk-reduction counseling, and referral for treatment of sexually
transmitted infections (STI). Following completion of the Pre-Screening Protocol,
potential volunteers may be referred to one of several Phase I/II HIV vaccine trials being
conducted at HAVD.
Administration of the risk behavior survey described here has been included in the
Pre-Screening Protocol since June 2003. This study represents a cross-sectional analysis
of the initial risk behavior assessment at the first clinical visit for each potential vaccine
trial volunteer enrolled into the Pre-Screening Protocol, thereby providing a baseline
characterization of the sexual risk behavior of this cohort.
Study Participants
Eligibility criteria for enrollment into the Pre-Screening Protocol included having a
minimum of 12 years of schooling (irrespective of education level achieved), being a
resident of Soweto, 18-60 years of age, HIV-negative, healthy, able to provide informed
consent, and, for women, not pregnant or planning to become pregnant. To remain in the
Pre-Screening Protocol and to be eligible for Phase I/II HIV vaccine trials, volunteers had
to remain HIV-negative, be in general good health, not become pregnant, not engage in
high-risk behaviors (determined by PHRU nurses and physicians, from patient interviews
and chart reviews), demonstrate good understanding of vaccine trials, and attend all
appointments consistently.
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All participants gave written informed consent for the study and received nominal
financial compensation for transportation costs at each study visit, under the auspices of
the Pre-Screening Protocol. The Committee for Research on Human Subjects at the
University of the Witwatersrand in Johannesburg approved this study as an addendum to
the original Pre-Screening Protocol. The Human Investigations Committee at the Yale
University School of Medicine approved this study under exemption category
45CFR46.101(b)(2); this category includes the use of survey procedures in which
information is obtained in such a way that participants can not be identified.
Risk Behavior Assessment
We developed the risk behavior assessment tool for use in South Africa following
six focus groups at HAVD conducted with experienced HIV counselors and staff
focusing on appropriate local language, specific practices and customs of the population,
and question content and clarityiv. We pilot-tested preliminary versions of the survey
with 20 participants for comprehension, feasibility and cultural appropriateness. We
trained interviewers to accurately administer the survey in a non-judgmental manner
using a combination of individual and group teaching sessions on interviewing
techniques as well as practice survey administration with observation and feedback.
We administered the risk behavior survey to participants in a structured, face-toface private interview using trained, multilingual interviewers. The survey took
approximately 45 minutes to complete per individual and was generally conducted in a
mixture of Sotho, Zulu, and English according to the language needs of the participant.
We collected the risk behavior data presented in this analysis from surveys administered

lv Relevant questions were adapted from existing unpublished surveys addressing similar research questions
used in ongoing research and modified as needed.
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at the first clinic visit in the Pre-Screening Protocol; however, participants received prior
risk-reduction counseling and education from VCT services in the preceding month.
Basic sociodemographic information collected included age, gender, race and
ethnicity, education, marital status, employment status, migrant labor status, number of
residents in the household, occupation of the major breadwinner in the household and
overall household income. We collected general risk behavior information including
history of receiving blood products, substance use (alcohol and recreational drug use),
history of STIs, age of sexual debut, history of forced sex, and reasons for choosing
recent sexual partners. We then collected partnership data, which involved a structured
recall of sexual partners in the prior six months and specific risk behavior information for
each sexual partner identified. This included the type of sexual relationship (anonymous,
casual, or steady/stable) and the partner’s gender, age, migrant labor status, additional sex
partners, and HIV status as well as the numbers of oral, vaginal, and anal sex acts with
each partner, whether or not a condom was used and additional sexual activities. The full
survey is contained in the Appendix.
Statistical Analyses
We formatted the risk behavior questionnaire and coded it for use with DataFax
software (Clinical DataFax Systems, Inc., Hamilton, Canada). Following a manual clinic
review and automated data entry, data were then subjected to automated edit checking as
well as manual review by three separate individuals trained in data validation. Clinic
staff routinely resolved quality control reports listing incomplete or incorrect data entries.
We conducted all statistical analyses with SAS Version 9.1 software (SAS Institute
Inc., Cary, North Carolina). We created additional variables to describe per capita
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household income, having a partner with an age difference of 15 years or more,
percentage condom use, and numbers of unprotected sex acts. For statistical
comparisons, we used t tests for continuous variables and either the chi-square or Fisher’s
exact test for categorical variables.
For bivariate and multivariate analyses, we employed logistic regression to estimate
odds ratios (OR) and 95% confidence intervals (Cl) using covariates from the
sociodemographic, sexual history, and sexual risk data. We created four outcome
variables and dichotomized them to reflect higher and lower participant risk behavior in
the previous six months: (1) engaging in any unprotected vaginal or anal sex, (2)
engaging in any unprotected vaginal or anal sex with a known or suspected HIV-positive
partner, (3) reporting any casual or anonymous sexual partners, and (4) reporting 3 or
more sexual partners. Analyses for outcomes (1) and (2) used only the participants
sexually active in the previous six months with complete data on reported sex acts.
Analyses for outcome (3) used only participants sexually active in the previous six
months. Analyses for outcome (4) used all participants ever sexually active.
We dichotomized continuous covariates at the median and categorical covariates
evenly to the extent possible. We first used the covariates in bivariate models to
determine independent predictors of higher risk behavior for each of the four outcomes.
We included covariates that were associated with an outcome of/7-value < 0.20 in
multivariate models for each of the four outcomes. We then eliminated covariates not
significantly associated with the outcome at level /7-value < 0.05 from the model one at a
time, using a manual backwards selection procedure. The final multivariate model
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contained covariates with statistical significance ofp-value < 0.05. All multivariate
models retained age and gender covariates due to their potential role as confounders.
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RESULTS
Participant characteristics
We administered an initial risk behavior survey to a total of 488 participants in the
Pre-Screening Protocol between June 11,2003 and February 13,2006 for this analysis.
Table 1 presents the results of the sociodemographic portion of the survey. The
participants included 219 men and 269 women, with a mean age of 26.8 years (median
25; range 18-59). The majority of participants comprised a multi-ethnic sample of Zulu,
Xhosa, Northern Sotho, Southern Sotho, Swazi, Venda, Tsonga, Tswana, and other black
Africans. Most participants were single and had never been married. Almost all of the
participants had already achieved at least a high school education and 22% of the
participants had completed either a technical college or a university degree. Only 24% of
the participants were currently employed. The mean household per capita income in
South African rands (ZAR) was ZAR695 (median ZAR450; range ZAR25-4,450) per
month (1 USD ~ 6 ZAR during this time period). Half of the participants (51%) were
from households with a monthly per capita income below poverty level (defined as
ZAR500 per capita). There were no significant gender differences in sociodemographic
information except as noted.
Substance use, sexual history and general sexual risk behaviors
Male participants reported higher levels of alcohol and drug use than female
participants. Overall, 62% of men reported at least one day of heavy drinkingv in the past
six months compared with 33% of women (p < 0.001). Men reported more days of heavy
drinking in the past six months than women overall (16.6 vs. 3.4 days; t = 5.8;p < 0.001)

v Defined as consumption o f >5 alcoholic beverages, with one beverage defined as 6 oz. wine, 12 oz. beer,
or 1 oz. liquor

-30-

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

as well as amongst just those men and women reporting at least one episode of heavy
drinking (26.6 vs. 10.4 days; t = 4.3; p < 0.001). More men than women reported
marijuana use (19% vs. 3% ,p < 0.001) and other recreational drug use (4.1% vs. 0.4% ,p
< 0.01) in the past six months. Only two participants reported injection drug use.
Most participants (97%) reported prior sexual activity (defined as vaginal, anal, or
oral sex). Prior STIs were reported by 30% of participants overall, with 7% of
participants reporting an STI diagnosis in the past six months. Additionally, 35% of all
males and 24% of all females (p < 0.01) reported having a partner within the past six
months with whom they did not have vaginal, anal, or oral sex.
Of those ever sexually active (Table 2), males reported a lower mean age of sexual
debut than females (15.8 vs. 17.5 years; t = -7.1; p < 0.001). Significantly more females
than males reported a forced first sexual encounter as well as forced sex within the past
six months. Overall, males had a higher mean number of sexual partners than females
(1.7 vs. 1.1 partners; t = 4.8; p < 0.001) in the past six months. Of participants who were
ever sexually active, 13% reported abstinence during the preceding six months. While
more males than females had no sexual partners in the past six months, significantly more
males than females reported 3 or more sexual partners. ‘Attracted to that person’ was the
most common reason (65%) reported for choosing a recent sexual partner.
Six-month sexual partner history and risk behaviors
Analysis of risk behaviors for participants sexually active during the previous six
months revealed further gender differences (Table 3). More men reported at least one
casual and/or anonymous sex partner (55% vs. 20%, p < 0.001), ‘one night stand’ (29%
vs. 4%, p < 0.001), known or suspected HIV-infected sex partner (18% vs. 7%, p <
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0.001), and sex partner at least 15 years older or younger (6% vs. 2% ,p = 0.03). There
were no significant gender differences in participants reporting at least one sex partner
with known HIV infection (3% overall), who must travel away from their homes for one
or more nights at a time because of their job (18% overall), and who is of the same
gender (4% overall).
For sexually active participants reporting steady partners in the past 6 months
(Table 4), 96.4% of men but 99.5% of women (p < 0.05) reported vaginal sex, 6%
reported anal sex, 40% reported oral sex, and 11% reported other sex acts (dry sex,
rimming, fisting, or sharing sexual toys). Specifically, mean condom use for vaginal sex
with steady partners was 53% (median 50%) per participant, with 32% of participants
reporting never using condoms and 37% reporting always using condoms. Participants
reported an average of 32.0 unprotected vaginal sex acts (median 5.0, range 0-300) with
steady partners in the previous six months. Mean condom use for anal sex with steady
partners was 50% (median 40%) per participant, with an average of 3.4 unprotected anal
sex acts (median 1, range 0-48) with steady partners in the previous six months. Overall,
4% of participants with steady partners reported unprotected vaginal or anal sex with at
least one partner with known or suspected HIV infection.
For sexually active participants reporting casual or anonymous partners in the past
six months (Table 4), 96% reported vaginal sex, 9% reported anal sex, 33% reported oral
sex, and 9% reported other sex acts. Specifically, mean condom use for vaginal sex with
casual/anonymous partners was 73% (median 100%) per participant, with 18% of
participants reporting never using condoms and 60% reporting always using condoms.
Participants reported an average of 7.2 unprotected vaginal sex acts (median 0, range 0-
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192) with casual/anonymous partners in the previous six months. Mean condom use for
anal sex with casual/anonymous partners was 73% (median 100%), with an average of
0.8 (median 0, range 0-6) unprotected sex acts over the previous six months. Overall, 9%
of participants reported unprotected vaginal or anal sex with at least one
casual/anonymous partner with known or suspected HIV infection.
In general, when comparing risk behaviors in the previous 6 months by partner
type, mean condom use was higher and the number of unprotected sex acts were lower
for casual/anonymous sex partners as compared to steady partners. Further, more
participants reported unprotected vaginal or anal sex with known or suspected HIVpositive casual/anonymous partners as compared to steady partners.
Predictors of higher risk sexual behavior
Predictors for higher risk sexual behaviors for the following four outcomes were
first assessed in bivariate analyses, followed by multivariate analyses: (1) “<100%
condom use”, any incidence of unprotected vaginal or anal sex in the previous six
months; (2) “<100% condom use with HIV+”, any incidence of unprotected vaginal or
anal sex with a known or suspected HIV-positive partner in the previous six months; (3)
“casual sex partners”, any incidence of vaginal, anal, or oral sex with a casual or
anonymous partner in the previous six months; and (4) “>2 sex partners”, having had
three or more sex partners in the previous six months. For these outcomes, 55% reported
<100% condom use, 4% reported <100% condom use with a known or suspected HIVpositive partner, 35% reported sex with a casual or anonymous partner, and 13% reported
having 3 or more sex partners.
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In bivariate analyses, individual factors associated (p < 0.05) with <100% condom
use were age 25 years or older and reporting an STD in the previous 6 months. In the
adjusted model, factors associated with <100% condom use were female gender (OR =
0.6 for male gender; OR =1.7 for female gender, 95% Cl = 1.1, 2.6), age 25 years or
older (OR = 0.6 for age < 25 years; OR =1.7 for age > 25 years, 95% Cl = 1.1, 2.5), and
any recreational drug use (OR = 2.3,95% Cl = 1.1,4.8).
Having more than five people in the household and any recreational drug use were
each associated with <100% condom use with a known or suspected HIV-positive
partner. Both of these were retained in the adjusted model as the only significant
predictors. Thus, factors associated with <100% condom use with a known or suspected
HIV-positive partner were having more than five people in the household (OR = 4.2, 95%
CI= 1.2,13.9) and reporting any recreational drug use (OR = 5.1,95% Cl = 1.4, 18.4).
Male gender, any heavy alcohol use, any recreational drug use, sexual debut before
the age of 18 years, choosing a partner without concern for HIV/personal safety, having a
partner older or younger by 15 years or more, and having a partner who works away from
home were individually associated with sex with a casual or anonymous partner.
However, in the adjusted model, factors associated with sex with a casual or anonymous
partner were male gender (OR = 4.8, 95% Cl = 2.9, 7.8), any heavy alcohol use (OR =
3.0, 95% Cl = 1.9,4.9), choosing a partner without concern for HIV/personal safety (OR
= 2.1, 95% Cl = 1.2, 3.8) and having a partner who works away from home (OR = 2.4,
95% Cl =1.3,4.3).
Male gender, any heavy alcohol use, any recreational drug use, sexual debut before
the age of 18 years, having a partner older or younger by 15 years or more, and having a
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partner who works away from home were each associated with having 3 or more sex
partners. In the adjusted model, factors associated with having 3 or more sex partners
were male gender (OR = 12.3, 95% Cl = 4.7, 32.4), any heavy alcohol use (OR = 3.1,
95% Cl = 1.4, 6.9), having a partner older or younger by 15 years or more (OR = 6.0,
95% Cl = 1.5,23.1), and having a partner who works away from home (OR = 4.5, 95%
Cl = 2.1,10.0).
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DISCUSSION
Our study has described the sexual risk-taking behavior profile of potential Phase I
and II HIV vaccine trial volunteers undergoing pre-screening in Soweto, South Africa for
the first HIV vaccine trials being conducted in Southern Africa. We designed a survey
adapted for local use, which is an important component of measuring risk behavior in
HIV vaccine trials in low- and middle-income countries12,221. We assessed risk behavior
by self-reported condom use and self-reported numbers and types of sex acts, which have
been shown to be appropriate, reliable, and accurate indicators for the risk of acquiring an
STD[23,24]. We administered this survey as a component of the Pre-Screening Protocol, a
generic protocol applied to all HIV-negative potential volunteers expressing an interest in
participating in Phase I/II HIV vaccine trials at the vaccine trial site in Soweto, regardless
of which HIV vaccine trial they might be enrolled into and which risk assessment tool
was used by that particular vaccine trial.
South Africa is extraordinarily diverse, with eleven national languages and a variety
of cultures. Although risk behaviors have been well documented on a national level, little
has been published on Soweto in particular, and even less on the residents of Soweto who
actually volunteer to enroll in various clinical trials for HIV prevention and treatment. In
our study, we showed this to be a young, predominantly single and unemployed, multi
ethnic population, of whom half reside in households with incomes below poverty level.
While almost all reported prior sexual activity, 13% of these participants reported
abstinence over the preceding six months. Although this might have represented a
personal risk-reduction strategy, 18% of participants reported sex partners who must
spend nights away from home for work and it is possible that the reported abstinence may
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be due to the migratory labor practices in South Africa.
Our analysis demonstrated that men in Soweto reported higher levels of risk
behaviors than females overall during the previous six months, as indicated by the higher
numbers of total sex partners, casual or anonymous sex partners, sex partners known or
suspected to be HIV-positive, and ‘one night stands’; the higher levels of heavy alcohol
and recreational drug use; and, the lower mean age of sexual debut. In adjusted models
for risk behaviors in the previous six months, men were five times more likely than
women to have casual or anonymous sex partners (OR = 4.8; 95% Cl 2.9, 7.8) and twelve
times more likely to have three or more sex partners (OR =12.3; 95% Cl 4.7, 32.4).
While it is possible that men throughout Soweto have higher levels of risky sexual
behavior than women, it is also possible that men with higher risk behaviors or women
with lower risk behaviors were more likely to attend VCT services and subsequently
enroll in this screening protocol for future HIV vaccine trials. Regardless of the
explanation for these findings, the trend for higher risk behaviors amongst male
participants may indicate that they should be targeted for increased risk-reduction
counseling during the course of future African HIV vaccine trials.
Male gender was not the only predictor of higher levels of reported risk behavior.
Reporting any incidence of heavy alcohol use, choosing a partner without regard to
personal safety or HIV status, and reporting at least one partner who traveled away from
home for employment were also significant predictors of having had sex with a casual or
anonymous partner. Any incidence of heavy alcohol use, reporting one or more partners
with an age difference of at least 15 years, and reporting at least one partner who traveled
away from home for employment were additional significant predictors of having had
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three or more sex partners. These outcomes are consistent with research showing that
South African youth with partners with an age difference of only five years were at
increased risk of HIV infection^251 and that rural South African migrant men and their
partners were at an increased risk of contracting STDs compared with non-migrant
men[26].
In adjusted models, female gender, age greater than 25 years, and reporting any
recreational drug use were significant predictors of having had any incidence of
unprotected vaginal or anal sex in the previous six months. Female gender and older age
are not necessarily associated with increased risk behavior, because this relationship
might indicate married older women having unprotected sex with monogamous HIVnegative partners. But this association may be an indication of a form of ‘passive’ high
risk behavior, in which married older women, for example, are forced into having
unprotected sex with husbands who subsequently infect them with HIV[27]—a concept
reinforced by studies showing that married older women are more likely to use condoms
inconsistently1281. Refinement of the survey tool to gather information regarding whether
participants engaged in unprotected sex of their own volition or by force would help to
clarify this association further. Recreational drug use, on the other hand, is clearly
associated with higher risk behavior and was also a significant predictor for having had
any incidence of unprotected vaginal or anal sex with a known or suspected HIV-positive
partner in the previous six months.
Although some of these predictors occurred more frequently in male participants,
they were independently associated with higher risk behavior and might also be used to
target vaccine trial participants for increased risk-reduction counseling. In particular, the
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substance use predictors were associated with all four classifications for increased risk
behavior and may be particularly useful in risk stratification of vaccine trial volunteers:
participants reporting any history of recreational drug use were twice as likely to have
had unprotected sex (OR = 2.3; 95% Cl 1.1,4.8) and five times as likely to have had
unprotected sex with a known or suspected HIV-positive partner (OR = 5.1; 95% Cl 1.4,
18.4), while participants reporting any history of heavy alcohol use were three times as
likely to have had sex with casual or anonymous partners (OR = 3.0; 95% Cl 1.9,4.9)
and three times as likely to have had more than two partners (OR = 3.1; 95% Cl 1.4, 6.9)
in the previous six months.
A study of the risk behavior patterns in a cohort of participants, observed for
evaluating HIV incidence and study retention rates in preparation for HIV vaccine trials,
showed that the cohort engaged in higher levels of sexual risk behavior than similar
participants from the same community112]. It is difficult to ascertain how closely our
sample represents the sexual risk-taking behavior of the general population of Soweto.
Even amongst different populations attending the same hospital, risk behavior patterns
can vary greatly. For example, in a study of HIV-positive adults who were receiving
primary care services at the Chris Hani Baragwanath hospital, reported ‘always’ condom
use was 76% with steady partners and 70% with casual partners[29]. In contrast,
participants in our study at the same hospital reported ‘always’ condom use of only 37%
with steady partners and 60% with casual partners, which is consistent with a national
survey in which men in South Africa were shown to determine their condom use by
whether they perceived their partner as ‘risky’ or ‘safe’, despite the fact that there is little
correlation between an individual’s perception of whether a partner is high risk and
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whether that partner is indeed high risk[30,31]. There may have been a potential bias in
participant enrollment, as knowledge of VCT services and screening for HIV vaccine
trials is communicated by both structured community outreach programs and word of
mouth in Soweto. These discrepancies might be explained by the differences in
motivation and HIV status—participants in our study were initially recruited because
they had sought HIV VCT and were subsequently found to be HIV-negative—but we
were unable to determine whether this is indeed the causative factor. Compared to the
general population, our methods may have selected a group of participants which
practices riskier sex, because individuals at greater risk for HIV infection sought VCT
services, or a group of participants which practices safer sex, because individuals at lower
risk for HIV infection sought assurance that they were not infected. Regardless, it
underscores the need to characterize the baseline behaviors of the actual populations that
are participating in HIV vaccine trials, which was the intent of this study.
While heterosexual vaginal intercourse was the most reported sex act in our study,
care was taken to include all possible categories of sexual activity. In national surveys,
the prevalence of reported anal sex was 2.2% overall[32] and 3.6% amongst South African
youth aged 15-24[33]. Participants in our study reported anal sex with both steady
partners (6%) and casual partners (9%). In another survey of sexually active South
African youth, 0.8% of men and 1.6% of women reported a partner of the same gender
within the past year[32]. Several participants from Soweto in our study also reported
sexual activity with partners of the same gender, which reinforces the need for both
gender-neutral and comprehensive sex act risk behavior questioning techniques.
Our study used self-reported condom use as an important assessment of risk
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behavior in the survey that we developed. While there is a general scientific consensus
that the use of condoms prevents HIV transmission1341, the validity of self-reported
condom use as an accurate measure of behavior has, until recently, been more
contentious. Early studies found that self-reported condom use was not significantly
associated with protection from incident STIs, but postulated that a true association might
be masked by improper condom use, over-reporting due to recall bias or social
desirability bias, and most importantly, by confounding131,35'373. On this issue, Peterman
et al. observed that “persons appear to be more likely to have safe sex with risky partners
and risky sex with safe partners”1373. However, a definitive study which controlled for
confounding by analyzing only patients with known exposure from infected partners
found that self-reported condom use and incident STIs were indeed significantly
associated1233. It is now generally agreed that self-reported condom use is an appropriate
indicator of behavior that puts one at risk of acquiring STIs.
There are several limitations that are inherent to the survey procedures used in this
study. Both the assessment of personal information in a face-to-face interview and the
risk-reduction counseling offered with VCT services prior to risk behavior survey
administration may have influenced the social desirability bias of reported behaviors.
Additionally, although the counselors administering the survey were periodically trained
and monitored, the administration of the survey by multiple interviewers over time and in
a mixture of languages (English, Sotho, Zulu) might have varied between participants.
These problems could be resolved with the future use of audio computer-assisted self
interviewing (ACASI) technology. ACASI has been shown in a longitudinal randomized
trial within an HIV risk behavior study to improve behavior data collection, likely by
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decreasing social desirability bias, removing interviewer bias and error, and standardizing
the interview questions[38]. Another limitation is that participant recall bias might have
prevented accurate risk assessment, although studies have shown that structured
interviews to recall information for the previous three to six months are preferable to
recalling shorter or longer time periods[36]. A further limitation is that behavior may
have been accurately reported by the participant, but not have completely represented
true risk. For example, a person might have reported 100% condom use but not have
used condoms correctly during that time, which would under-represent risky sexual
behavior.
In conclusion, our study provides the first sexual risk behavior data for an African
population participating in HIV vaccine trials to date as well as a baseline reference for
determining whether sexual risk behavior might change in response to participation in
South African HIV vaccine trials. In addition to increased risk-reduction counseling for
the prevention of HIV transmission in targeted groups, the predictors of higher risk
behavior described in this study might also be used to differentiate between participants
more suitable for Phase I and II safety and immunogenicity studies, which require
volunteers at relatively low risk for HIV infection, or Phase III efficacy studies, which
require volunteers at relatively high risk for HIV infection.
Despite multiple HIV vaccine trials being conducted globally, appropriate methods
for assessing risk are still under debate and are particularly important in areas where
baseline sexual practices and customs are not well known. Given the implications for
risk behavior change to adversely affect the potential benefits of a vaccination campaign,
this and other studies stress the importance of observing risk behavior patterns during
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clinical trials. Further, even if population-level risk behavior were to remain unchanged
in a clinical trial overall, individual-level risk behavior change is still important to
monitor. Research on risk behavior and HIV vaccines must proceed together, and risk
behavior education must be an integral part of any future HIV prevention program that
includes an HIV vaccine[3,4].
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TABLE 1. Participant sociodem ographics (n = 488)
Characteristic

n (%)a

Gender
Men
Women

219(44.9)
269(55.1)

Mean age [median age 25; range 18-59]

26.8 years

Race
Black, categorized by ethnicity
Zulu
Xhosa
Northern Sotho
Southern Sotho
Swazi
Venda
Tsonga
Tswana
Other
Colored
White

485 (99.4)
195
52
26
87
4
14
35
62
10
2 (0.4)
1 (0.2)

Highest level of education completed
Primary school
High school
Technical college/trade school
University

17 (3.5)
361 (74.4)
86 (17.7)
21 (4.3)

Currently in school

111 (22.9)

Marital status
Married
Single, never married
Divorced/Widowed/Separated

35 (7.2)
429 (88.5)
21 (4.3)

Employed, categorized by migrant labor
Requires nights away from home
Does not require nights away from home

117 (24.2)
39
76

Mean number of residents in household

5.3 persons**

Occupation of main breadwinner in
household
N o in c o m e fo r h o u s e h o ld

2 8 (5 .8 )

Government grant <ZAR500b
Unskilled labor
Government grant >ZAR500
Small business owner
Skilled labor
Large business owner
Professional

13 (2.7)
55 (11.3)
46 (9.5)

57(11.8)
118 (24.3)
42 (8.7)
126(26.0)
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Mean household monthly per capita income0

ZAR695

Participants from households below poverty
leveld

215 (51.3)

** Statistically significant difference between male and female participants (p
< 0 .01 )
a Results specified as n (% ) and sample size within 1 % of total n = 4 8 8 unless
otherwise noted
bZ A R , South African rands (1 U S D = 6 Z A R )
c n = 419; median monthly per capita income Z A R 4 50 , range Z A R 2 5-4.4 50
d n = 419; poverty level defined as Z A R 5 00 per capita
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TABLE 2. C haracteristics of participants reporting ev er sexually active (n = 471 )a,b
Sexual history variable
Mean age of first sexual encounter (years)
Forced first sexual encounter

Men (%)

Women (%)

p

15.8 y

17.5 y

<0.001**

15.5

23.6

0.028*

Main rationale for partner choice in past 6 months0
Knowing their HIV status
Knowing the partner was faithful
Forced to because of favors/gifts from the partner
Forced to because of marriage/commitment to the
partner
Attracted to the partner

14.6
5.3
0.5
7.8

19.4
8.7
1.2
11.1

71.8

59.7

Reported number of sexual partners in past 6 months
0
1
2
3 or more

15.5
43.7
19.3
21.6

8.2
73.2
16.3
2.3

Mean number of sexual partners in past 6 months

1.7p

1.1 p

< 0.001**®

0.5

3.3

0.044*

Reporting forced sex in the past 6 months'1

0.10

< 0.001**

* p < 0.05, * * p < 0.01
a S ex and sexual activity are defined as any incidence of vaginal, anal, or oral sex
b Sam ple size within 1% of total n = 471 unless otherwise noted
0 n = 459
d n = 449
® M ales also had a higher mean num ber o f sexual partners than fem ales am ongst just those participants
with at least one sex partner in the past six months (2.0 vs. 1.2 partners, t = 6.2, p < 0 .0 0 1 )_____________
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TABLE 3. Sexual partnership risk behaviors in the previous 6 months (n = 408)
Men (%)

Women (%)

P

A steady sex partner

82.3

94.0

< 0.001**

A casual sex partner

49.1

17.2

< 0.001**

An anonymous sex partner

13.7

2.6

<0.001**

A casual or anonymous sex partner

54.9

19.7

< 0.001**

A one-night stand

29.1

4.3

< 0.001**

A partner with an age difference of 15 years or greater3

5.7

1.7

0.028*

A partner of the same genderb

3.4

3.9

0.80

A partner who spends nights away from home for work

16.6

19.7

0.41

A partner with known HIV

4.6

1.7

0.09

A partner with known or suspected HIV

17.7

6.9

<0.001**

Participants reporting at least one of the following:

* p < 0.05, ** p < 0.01
a Including both older men with younger w om en and older w om en with younger men
b n = 406
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TABLE 4. Sexual partnership risk behaviors in th e previous 6 m onths
Sexual risk behavior

wi,h s(, “ d3y5g j1
,r' ners

With casual or anonymous
partners (n = 141)b

Participants reporting vaginal sex
Mean condom use during reported
vaginal sexd
Average number unprotected sex
acts per participant reporting vaginal
sex®

350 (98.3%)°
53.3%

134 (95.7%)
73.0%

32.0 acts

7.2 acts

22 (6.2%)
49.5%

13(9.2%)
73.1%

3.4 acts

0.8 acts

Participants reporting oral sex

142 (40.0%)

46 (32.9%)

Participants reporting other sex acts

38(11.0%)

12(8.8%)

Participants reporting unprotected
vaginal or anal sex with at least one
partner with known or suspected HIV

13(3.7%)

13(9.4%)

Participants reporting anal sex
Mean condom use during reported
anal sexf
Average number unprotected sex
acts per participant reporting anal
sex9

a Sample size for responses: n = 356 (vaginal sex), n = 358 (anal sex), n = 357 (oral sex), n = 347 (other sex
acts), and n = 353 (unprotected sex with known/suspected HIV+ partner)
b Sample size for responses: n = 140 (vaginal sex), n = 141 (anal sex), n = 140 (oral sex), n = 136 (other sex
acts), and n = 139 (unprotected sex with known/suspected HIV+ partner)
c Male participants less likely than female participants, 96.4% vs. 99.5% (p = 0.037)
d Median condom use was 50% for steady partners and 100% for casual/anonymous partners
®Median (range) unprotected sex acts was 5(0-300) for steady partners and 0(0-192) for casual/anonymous
partners
Median condom use was 40% for steady partners and 100% for casual/anonymous partners
9 Median (range) unprotected sex acts was 1(0-48) for steady partners and 0(0-6) for casual/anonymous
partners
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Covariate

Gender®
Male (vs. female)
Age®
< 25 years (vs. £ 25 years)
Marital status
Single (vs. married, divorced, separated, or
widowed)
Education
High school or less (vs. college or university
degree)
Household occupants
> 5 residents (vs. < 5 residents)
Per capita household income
Below poverty level (vs. at or above poverty level)
Employment status
Unemployed (vs. employed)
Alcohol use
>1 day of heavy drinking in past 6 months (vs. 0
days)
Drug use
Any recreational drug use in past 6 months (vs. no
use)
Age of sexual debut
<18 years (vs. £ 18 years)
Sexual debut
Forced first encounter (vs. not forced)
STD history, ever
Yes (vs. no)
Rationale for partner choice
Not HIV knowledge/safety oriented (vs. HIV
protection oriented)
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<100% condom
use
(55.2%, n = 397)a

<100% condom
use w/ HIV+
(3.6%, n = 391 )b

Casual sex
partners
(34.6%, n = 399)°

>2 sex partners
(12.5%, n = 399)d

0.59 (0.39, 0.90)f*

1.44(0.43, 4.87)

4.75 (2.88, 7.81)**

12.33 (4.70, 32.40)**

0.60 (0.40, 0.90)9*

1.04 (0.35, 3.16)

0.97 (0.60, 1.55)

1.47 (0.73, 2.97)

NSh

Nl

NS

Nl

NS

Nl

Nl

Nl

NS

4.15(1.24, 13.89)*

NS

Nl

Nl'

Nl

Nl

Nl

Nl

Nl

NS

Nl

NS

NS

3.01 (1.86, 4.87)**

3.09(1.39, 6.87)**

2.27 (1.08, 4.78)*

5.09(1.41, 18.37)*

NS

NS

Nl

NS

NS

NS

Nl

Nl

Nl

Nl

NS

Nl

Nl

Nl

Nl

Nl

2.09(1.16, 3.76)*

Nl
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TA BLE 5. Multivariate predictors of higher risk sexual behavior in the previous 6 months, Adjusted OR (95% Cl)

2.40 (1.33, 4.34)**

4.53 (2.05,9.99)**

Nl

Nl

NS

NS

* p < 0 .0 5 , * * p < 0.01
a Defined as having any incidence o f unprotected vaginal or anal sex in the previous 6
months
b Defined as having any incidence of unprotected vaginal or anal sex in the previous 6
months with a known or suspected HIV-positive partner
0 Defined as having any incidence of vaginal, oral, or anal sex with a casual or
anonym ous sex partner
in the previous 6 months

d Defined as having 3 or more sex partners in the previous 6 months
e Included in final multivariate model as a potential confounder
regardless of significance level
f O R fo r fem ale gender = 1.7 (1.1, 2 .6 )
9 O R fo r age > 25 years = 1.7 (1.1, 2.5 )
h NS = not significant, p 2 0.05 for adjusted O R in final multivariate
model
' Nl = not included in initial multivariate model because p 2 0.20 in
bivariate analysis

without p erm is sio n .

Nl

prohibited

NS

Further reproduction

5.97(1.54,23.13)*

of the copyright ow ner.

NS

permission

Nl

with

Nl

Reproduced

Partner age
2 1 partner older or younger by at least 15 years
(vs. 0 partners)
Partner’s migrant labor
Travels for work (vs. does not travel for work)
Sex act profile
Includes dry sex, fisting, rimming, or sharing sexual
toys (vs. not)

APPENDIX
The following pages contain the risk behavior assessment survey developed for
in this study.
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LifeStyle Questionnaire (LSQ-1)

Perinatal HIV Research Unit (PHRU)

IPre-Screening
I I I I Protocol
l l (039)
l l LSQI#200
I I I II I I
oTT
Participant Number

n

Visit
C ode

Interview Date
LifeStyle Q uestionnaire

m

m
dd

mm

yy

We are going to ask you some personal questions about your sexual activities in this survey that might be
embarassing. This information will be kept confidential and will not be seen by anyone except for the rele
vant clinical staff and people who review our research to make sure that it is conducted ethically. If at any
point you become uncomfortable and you do not want to continue, please tell me and we will stop the sur
vey at that point. Because we need this information for the phase I/ll vaccine trials, for your own safety we
may not be able to enroll you in a future vaccine trial if you are unable to answer these questions.
We will now start the interview. This survey will take about forty minutes or less to complete. I will read
each question and response to you. If a question is confusing, please ask me to explain it better. Please
answer tiie questions as best as you can. There are no right or wrong answers and we are not looking for
you to give us specific answers.

Q

Q1. Interviewer’s initials:

Q2, Participant’s initials:
dd

mm

yyyy

][

Q3. Participant’s Date of Birth:

male

Q4. Participant’s current age:

female

□ □

Q5. Sex:

Q6. Which of tiie following b est d escribes you:

□
□
□

Colored

I I Black

White

I I Other

Zulu

□
□

Indian/Asian

Xhosa
N. Sotho

□
□
□

S. Sotho
Swazi
Venda

□
□
□

Tsonga
Tswana
Other:

Q7. What Is the highest level of schooling you completed:
□

No schooling

n

College / technikon ’school

O

Primary school

Q

University

I~1 Secondary / high school I 'matric' / grade12

Q8. Are you still in school?

Version 0 G . B D MAY 13, 2004

yes

no

|“ j

[~~j

PHRU
Slafl Initiate/ Date
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Perinatal HIV Research Unit (PHRU)_______________________________ LifeStyle Questionnaire (LSQ-2)

I I 11 I 1111 111 I 111 I a
Pre-Screening Protocol (039)

0 1 1 — S|
Sfte N umber

|

|

□.□

LSQ #205

1 |

LifeStyle Q uestionnaire
C o n tin u e d ...

Participant Number

09. Are you married or have you ever been m arried?
I I Married (includes Western and African/customary marriages)

Q

Widowed

n

Q

Separated

Single ! never married (includes living In relationship)

I I Divorced
do’

go to Q 12

yes
Q10. Do you currently have a Job and receive money for the work that you do?

□

yes

Q11. Does your job require you to travel away from your hom e and sleep else
w here for more than one night a t a time?

no

□ □

Q12. including yourself, w hat is the total num ber of people who live in your house
hold?
Q13. W hat type of work d o e s the main breadwinner - the person who earns the m ost money - In your household do?
(Interviewer: ask this question and then decide which o f the below answers is closest to what the participant says.)

Version

|—|

No one In the household Is employed and there Is no income

□

Child support grant or other small monthly grant (under R500)

□

Unskilled labor (e.g. gardener or domestic worker)

|~~l

Disability grant or old-age pension or other large monthly grant (more than R50Q)

□

Small business enterprise (e.g. spaza shop, hawker, renting out rooms in household)

I

I

Skilled labor (e.g. builder, mechanic)

I

|

Large business enterprise (all business owners that are not ‘small business enterprises')

I

|

Professional

moo
1

U

MAY 13,2004

PHRU
stair initials i Date
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LifeStyle Questionnaire (LSQ-3)

Perinatal HIV Research Unit (PHRU)
Visit
Code

IPre-Screening
I I I Protocol
I l l (039)
l l ILSQI #210
I I I I II
o 1
Site Number

D
Participant N umber

LifeStyle Questionnaire
continued...

Q14, What is the approxim ate m onthly earnings for your household, including everyone th at earns m oney?

□
□
□
□
□
□

□
□
□
□
□
□

Less than R5GQ
R500 - R999
R100Q - R1499
R1500 - R1999
R2000 - R2499
R250Q - R2999

R3000- R3499
R3500- R3999
R4000 - R4499
R4500 - R4999
More than R5000
Don't know

Q15, In the p a st six m onths, have you received blood, blood products o r
organ donations?

yes
I—I
I—■

no
I—I

LJ

The next several questions ask about drug and alcohol use. Many o f the questions In this survey ask about how many
tim es you may have done som ething in the p ast six m onths. If it is difficult to rem em ber exactly how m any tim es, just
give u s your b e st g u e ss or tell u s how m any time you think you do som ething each m onth o r each week on average
and we will adjust for the num ber of m onths.
Q16, In the past 6 m onths, about how m any tim es did you drink m ore than 5 alco
holic drinks in one day?
- This includes home m ade alcohol, e.g. m gqombothl
-- We call ‘one drink’ the am ount of alcohol (beer, wine, cider, mixed alcohol drink)
In a can.
-- If the drink is strong alcohol su c h a s whiskey th at is not mixed with anything
then ‘one drink' Is the sam e a s a ‘tot’.

Q17. in the p ast six m onths, did you sm oke dagga (weed, g ra ss, marijuana,
green veja, pot, m atekwane)?

Q18. In the past six m onths, did you use needles to inject/shoot drugs such
a s cocaine (crack o r mandrax) o r heroine or som ething e lse?

Q19. In the p a st six m onths, did you u se any other drugs by snorting or
sniffing them, sm oking them o r taking them a s pills su c h a s cocaine,
heroin, ecstacy, crystal meth, or o ther recreational drugs.

Version

Q1 1 00

MAY 13,2004

yes

no

yes

no

□ □
□ □
y®s
I—I
*— '

no

I I
—

PHRU
Staff Initials/D ate
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LifeStyle Questionnaire (LSQ-4)

Perinatal HIV Research Unit (PHRU)

I I 11 I 1 1 1 1 1 1 1 11 1 1 1 SSL
Pre-Screening Protocol (039) LSQ #215

m -n

Site Number

LifeStyle Q uestionnaire
Continued...

Participant N umber

The next questions a sk about sexually transm itted d ise ases (STDs) that you may have had and about your sexual
activities. Som e of the questions in the survey may not apply to you, but we m ust a sk you all of the q uestions and we
m ust a sk them exactly a s they are written. Remem ber that all of your answ ers will be kept confidential.
If participant is unsura of specific day o f month for dates in this survey, ask the participant whether the event occured in the
beginning, middle, or end o f the month and then estimate the day by 5,1 5, or 25. If the participant can not state the period of the
month, estimate the day as 15.
If the participant says that something occurred many years ago and can not remember even the month, estimate month with a 6
(June) and estimate day as 15.

Q20. Have you ever In your life been told, specifically by a n urse or doctor or other health care provider, th at you had a
STD (sexually transm itted disease), including any genital so res, ulcers, or genital discharge that required a visit to the
clinic?
R egardless of w hether the answ er is v e s or no. we m ust still go over the STDs th at this might include ju st to m ake sure
none of them are forgotten:
- 'drop' or any abnorm al vaginal discharge that w as treated with m edicine (chlamydia, gonorrhea, or trichom onas)
- herpes (explanation: a blister, similar to blisters on lips from a cold sore, but mi private parts)
- syphilis (explanation: painless sore/wound on private parts)
- painful glands near private parts, following STD (lymphogranulona venereum)
- painful so re on private parts (chancroid)
- sexually acquired hepatitis B (explanation: yeilow eyes/liver dise ase from an STD)
- severe lower stom ach pain associated with abnorm al vaginal d isch arg e-n o t m enstrual pains (pelvic Inflammatory dis
ease, women only)

-- bad - smelling vaginal d ischarge (mucopurulent cervicitis, women only)
- testicular pain, following STD (acute epididymitis, men only)
- anal pains, following STD (acute proctitis)
yes

no

□ □

‘n a ’ go to Q 22

Q21. When w as the last time that you were told th at you had any sexually transm itted d ise ase or Infection?
(if the m ost recent STD is heroes, please give u s the very first time you were told you had herpes)
dd

□
□
Version □ . B D

mm

yyyy

This occurred within the last six months
This did not occur within the last six months

PHRU

MAY 13, 2004

__________
Stan Irabals / Date

-

60

-

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Perinatal HIV Research Unit (PHRU)

LifeStyle Questionnaire (LSQ-5)

IPre-Screening
I I I Protocol
I l l (039}
l l LSQI#220
I I l l l l I Cot
oTTH * l l l l l
Participant Number

LifeStyle Questionnaire
continued...

in the following questions, when I say ‘sex’, I mean three things: vaoinal sex, when a man Inserts his penis into a
woman’s vagina; anal sex, or ‘backdoor sex/ sex from behind’, when a man inserts his penis in his partner’s butt,
regardless of whether that person is a man or a woman; and oral sex, when a person - either a man or a woman • puts
their mouth on their partner’s penis or vagina. Do you have any questions about this definition of sex?
Never had sex —► I£ c h « k « d go to 26

Q22. How old were you the very first time you had sex?

|

j

j

j—j

<223. Did you choose to first start having sex at that age, or was there som e circumstance which forced you to have sex for
the first time?
|—|
■

Yes, there was some circumstance which farced me to have sex at that age. —► 1/checked, a sk
*Do you -want to ta lk
a b o u t i t? ’ before
con tin u in g .

.

I I

No. i chose to start having sex at that age.

no

024. in the iast six months, have you ever been forced to have sex
with som eone because of violence, money, or any other reason?

I f ch ecked, a sk

yes

r-i

|—I

'— '

'— '

^

ab”i«™?Mbrfo™,alk
continuing.

Q25, Which of the following items w as m ost important to you when choosing a sexual partner over the past
six m onths?
□

Knowing whether or not the partner has HiV

I I

Knowing whether or not the partner is having sex with other people besides you

I

|

Feeling I have to have sex (not because I want to) because the partner took me to restaurants and/or bought me gifts

I

I

Feeling I have to have sex (not because I want to) because I am married to the partner or in a commit ted relationship

|

|

Feeling sexually or physically attracted to that partner

Q26. Did you have any partners in the past six m onths with whom you did
not have vaginal, anal, or oral sex?

Version

m.GD

MAY 13, 2004

yes

no

I—I

|—I
■—■

'— '

PHRU
Stall Initials /D a te
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LifeStyle Questionnaire (LSQ-6)

Perinatal HIV Research Unit (PHRU)

I I I I I I I I I I I I I I I I I Col
P re -S c ree n in g P ro to co l (039) LSQ #225

□

m
Participant Number

LifeStyle Questionnaire
continued...

I would like you to now think of all the persons that you had sex with during the past six months. Please give us the ini
tials of those partners.
We are only asking for these initials because we would like to ask you a series of questions about each partner, and
this will help us to remember which partner you are talking about. If you do not know a partner’s Initials or if you do not
want u s to know the partner’s initials, you can use any nickname of your choice (for example: ‘red shirt’, ‘weekend
party’, etc) that will help us to remember which partner you are talking about.
To help you remember all of your partners, we will go through each month or holiday and think of who you were with at
that time. Let’s start with this month:
Number of partners
Month (first 3 letters)
Ust partners

m
this month

Q27. What are the initials or nicknames of the part
ners with whom you had sex this month?

Q
Month (first 3 letters)

Ust additional
partners only

Number of new
partners this month

Q28. Did you have sex with any additional partners
not already mentioned the month before that?
What are the initials or nicknames of these part
ners?
Q28. Did you have sex with any additional partners
not already mentioned the month before that?

Q30. Did you have sex with any additional partners
not already mentioned the month before that?

Q

Q31. Did you have sex with any additional partners
not already mentioned the month before that?

032, Did you have sex with any additlonai partners
not already mentioned the month before that?

033. Did you have sex with any additional partners
not already mentioned the month before that?

The following question is for the interviewer only. Do not ask this question to the partici
pant.
034. What is the total number of sexual partners in the last six m onths?

I f tola) is z«ro, skip
p a r t n e r m o d ule and
con cln d e su rv e y now.

We are now going to ask you questions about your sexual activities with each of these partners. Some of the questions
are personal and might be em barrassing, but it is very Important that you be honest. These questions may not apply to
you, but we m ust ask you all the questions and we m ust ask them exactly a s they are written. Remember that all your
answ ers will be kept confidential.
When we ask you about sex, Include all the times with or without a condom, and with or without ejaculation. When we ask
you about using condom s, do not include tim es when the condom slipped, broke, or w as not u sed for the entire time.

Version

ED.®

MAY 13,2004

PHRU

__________
Staff Initials / Date
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LifeStyle Questionnaire (LSQ-7)

Perinatal HIV Research Unit (PHRU)

I I II I l l l l l l l l I I I I

Visit
Code

Pre-Screening Protocol (039) LSQ #230

o 1
Site Number

Participant Number

n

LifeStyle Q uestionnaire
continued... PARTNER MODULE

Now, I am going to ask you questions about __

1. Is this partner male or female?

2. What is the approximate age of this partner?

3. Was this a “one night stand’?

4. Is this a steady/stable, casual, or anonymous partner? A steadv/stable partner is some
one who is special to you, like a husband/wlfe/boyfriend/girlfriend, or lover. A casual sex
partner Is a person you know but who is not your main sex partner, whether you had sex
only once or many times. An anonvmous sex partner is someone whose name you did not
know the day before you had sex. A sex partner who is a prostitute could be either casual
or anonymous.
5. Does ttils partner have a job that involves travelling away from home and sleeping else
where fbr one or more days at a time, or does this partner live in a different city than you
(long distance relationship)?

Partner Number

male

female

yes

no

□ □
□ □

steadl//steKte

casu, /

□
yes

□

no

anonvmous

□
don’t know

□

□

6. In the last six months, about how many times did you have oral sex with this partner?
if you can not remember, you can think of the average number of times each week or each
month and we will multiply it by the number of months that you were with this partner.

,— | ^ . I f 0 s k ip n e x t q u estion

7. Of those times you had oral sex, how many times did you use a condom or other form of
protection?

8. In the last six months, about how many times did you have vaginal sex with this part

I f 0 skip next qaesiion

ner?
9. Of those times you had vaginal sex, how many times did you use a male or female con
dom before penetration?

10. in the last six months, about how many times did you have anal sex with this partner?
11. Of those times you had anal sex, how many times did you use a condom before pene
tration?
12. In the last six months, about how many times did you and your partner do any of these
activities?
- ‘dry sex" without a condom (sex with a woman without fbreplay so that there is no vagi
nal lubrication, natural or artificial)
-sh a re sexual toys (e.g. vibrators) between both partners
-insert an entire hand (not just the fingers) into the vagina or anus of the partner
-lick the anus of die partner
13. Before the last time you had sex with this partner, had this partner had sex with other
people besides you in the previous six months?

—

0 skip next question

cm
yes

□

don’t know

□

□

14. Do you know if this partner has HiV for sure?
|

| Yes, I know he/she has HiV fbr sure

□

No, but I suspect he/she does not have HIV

Q

Yes, i know he/she does not have HIV (and I have no reason to doubt it)

□

No, but I suspect he/she has HIV (regardless of what he/she has told me)

This section Is to be completed tor each sexual partner. Repeat module for each partner before completing Interview.

Version
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PHRU

__________
Staff Initials/D ate
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PAPER 2

Anticipated Changes in Sexual Risk Behavior Following
Vaccination with a Low-Efficacy Preventive HIV Vaccine:
Survey Results from a South African Township
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INTRODUCTION
With more than 20 millions deaths since the start of the HIV/AIDS epidemic, an
estimated 39 million people currently living with HIV/AIDS globally, and 4 million new
infections occurring each year®, the development of new technologies to control this
pandemic remains a priority. Potential HIV vaccine candidates are being tested in
clinical trials worldwide and many more are under development; therefore, a preventive
vaccine may be available within the next decade®. While the first HIV vaccines will
likely be only partially effective in preventing transmission, even low-efficacy vaccines
will be useful for populations such as those across much of sub-Saharan Africa in which
the risk of HIV infection is high[3,4].
The individual and population benefits from any HIV vaccine which is not 100%
effective in preventing HIV transmission will depend on whether risk compensation—the
notion that individuals might change their sexual risk taking behavior in response to
vaccination—occurs. Little is known about the potential for risk behavior change
associated with mass vaccination campaigns®61. This is particularly true in the African
setting where only an isolated study in Uganda, conducting a contingent valuation survey
for future HIV vaccines, asked whether individuals might change their behavior in
response to hypothetical vaccination®. In a household survey of adults, the Ugandan
study revealed that 18% of respondents did not think (or were not sure) they would need
to use a condom for non-spouse sex partners if they received a 50% effective HIV
vaccine.
There have been no risk behavior studies to date on the potential impact of future
HIV vaccination programs in South Africa. Because of South Africa’s enormous HIV
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epidemic, relatively strong health infrastructure, and political support for HIV vaccine
development and clinical trials, it is likely to be one of the first countries in sub-Saharan
Africa to consider widespread use of a low-efficacy vaccine. Although decreases in risky
sexual behaviors would enhance the benefits of programs using low-efficacy vaccines,
increases in risky sexual behaviors would decrease potential program benefits and merit
further investigation. We developed a survey instrument to investigate the potential for
increases in sexual risk behavior in response to a hypothetical, low-efficacy preventive
HIV vaccine and administered it to participants in a South African cohort undergoing
screening and enrollment into current HIV vaccine trials.

-
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METHODS
Study participants and setting
We collected data on anticipated responses to a hypothetical low-efficacy
preventive vaccine from 158 participants undergoing screening for Phase I/II HIV
vaccine trials in South Africa. The participants were enrolled in the Pre-Screening
Protocol in the HIV/AIDS Vaccine Division of the Perinatal HIV Research Unit (PHRU),
which we have described in detail previously [Dissertation Paper 1].
Briefly, the study took place at the Chris Hani Baragwanath Hospital, which is
located within the township of Soweto, where antenatal HIV prevalence is 30% (personal
communication, Avy Violari, PHRU). The PHRU implemented the Pre-Screening
Protocol to collect participants who are healthy, reliable, at low risk of HIV infection, and
informed about HIV vaccine science and clinical trials for eventual screening and
enrollment into multiple HIV vaccine trials[8,9]. We obtained written informed consent
from all participants under the auspices of the Pre-Screening Protocol, and this study was
approved by the Committee for Research on Human Subjects at the University of the
Witwatersrand in South Africa and the Human Investigations Committee at the Yale
University School of Medicine in the United States.
Assessment of anticipated changes in sexual risk behavior
Sexual risk behaviors may change over time, regardless of whether an HIV vaccine
is eventually available. In order to examine anticipated risk behavior change in a timeindependent manner, we designed a survey in which respondents were asked to consider
a hypothetical situation of immediate vaccine availability. The scripted survey described
a vaccination scenario in which participants were asked to imagine that a low-efficacy

-67-

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

vaccine was available now, rather than at some point in the future, and questions were
posed regarding how they might change their current behaviors if they were to receive
such a vaccine.
We used focus groups and pilot testing to optimize the survey language; we trained
multi-lingual interviewers to administer the survey in private face-to-face encounters;
and, we conducted manual and automated reviews of data for accuracy, as previously
described [Dissertation Paper 1]. The data presented here were collected from
participants scheduled for either initial or follow-up visits in the Pre-Screening Protocol;
however, no participants had prior exposure to this survey. We linked the answers from
this survey to sociodemographic data collected at the same visit in the Pre-Screening
Protocol [Dissertation Paper 1], including gender, age, education level, alcohol use, and
recreational drug use.
The specific vaccine concept we used in this study was a 30% effective vaccine
which provided 100% protection to those individuals in whom the vaccine worked; thus,
the vaccine would provide 100% protection to only 30% of those vaccinated, as opposed
to providing 30% protection to 100% of those vaccinated. The survey involved a
scripted, structured educational component on what is meant by a 30% effective vaccine,
followed by questions to assess comprehension. Similar techniques have been used
elsewhere to assess anticipated changes in sexual risk behavior following hypothetical
vaccination with a partially-effective HIV vaccine[7,10]. After comprehension was
assessed, participants were re-educated if they answered any of the questions incorrectly
or had further questions. We then asked participants questions regarding whether they
predicted that they might change their condom use and number of sex partners in
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response to receiving such a vaccine, as well as whether they predicted that their partners
might change their condom use. Our questions differentiated responses on anticipated
changes in behavior between anonymous, casual, and steady/stable sex partners. The
script and questions used for vaccine comprehension and anticipated changes in sexual
risk behavior are detailed in the Appendix.
Statistical analyses
We employed standard descriptive statistical methods to report frequencies and
used the chi-square test for statistical comparison of categorical variables. We used
logistic regression techniques to estimate odds ratios (OR) and 95% confidence intervals
(Cl) for bivariate and multivariate analyses, as previously described [Dissertation Paper
1]. Age and gender were retained in all final adjusted models due to their potential roles
as confounders. All analyses were conducted with SAS Version 9.1 software (SAS
Institute Inc., Cary, North Carolina).
For bivariate and multivariate analyses, we created covariates as follows: (1) male
gender (vs. female gender); (2) age < 25 years (vs. age > 25 years); (3) education level of
high school or less (vs. technical college or university degree); (4) any heavy alcohol use
in the past 6 months, defined as at least one day of drinking more than 5 alcoholic
beverages (vs. no heavy alcohol use); (5) any recreational drug use (vs. no use); and, (6)
poor initial comprehension of vaccine concept, defined as answering any of the three
vaccine comprehension questions incorrectly (vs. good comprehension, defined as
answering all three questions correctly). We created the following outcome variables to
indicate potential increases in sexual risk behavior predicted by participants following
vaccination with a hypothetical low-efficacy vaccine, dichotomized to reflect increased
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risk behavior vs. unchanged or decreased risk behavior: (1) anticipated decrease in
condom use by participants with either an anonymous, casual, or steady/stable sex
partner; (2) anticipated increase in sex with casual or anonymous partners; and (3)
anticipated decrease in condom use by sex partners of participants, including those who
thought their partners would or might want to decrease condom use.
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RESULTS
Participant characteristics
We collected hypothetical risk behavior responses from 158 participants (91 males,
67 females) in the Pre-Screening Protocol from June 2003 to March 2004. The mean age
was 27.0 years (median, 25 years; range, 18-53 years) and 26% of the participants
reported education beyond high school level. Alcohol use (at least 1 day of heavy
drinking in the previous 6 months) was reported by 54% of participants and recreational
drug use (any use over the previous 6 months) was reported by 18% of participants. The
majority of participants (68%) completed the survey at their first full clinic visit, while
the remainder completed the survey at a follow-up visit. However, results presented here
represent the first time a participant was given the survey, thus there was no prior
exposure to these questions that might have influenced our results.
Comprehension of low-efficacy vaccine concept
Following the scripted description of a low-efficacy vaccine, we assessed initial
comprehension of this concept (Table 1). Overall, 82% of participants answered all three
concept questions correctly. We included the 18% of participants who answered at least
one question incorrectly in the ‘poor comprehension of vaccine concept’ category, used
in the regression analyses described below. Although we have reported initial
comprehension scores for questions answered incorrectly, we counseled all participants
to assure full comprehension before completing the remainder of the survey.
Anticipated changes in sexual risk behavior
We designed this study to examine the potential for increases in sexual risk
behavior predicted by survey participants following hypothetical vaccination. When
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participants were asked about their anticipated behaviors with sex partners if they were to
receive a low-efficacy HIV vaccine, 22% overall reported they might use condoms less
frequently than at present with sex partners (anonymous, casual, or steady/stable) and 9%
overall reported that they might increase their frequency of sex with casual or anonymous
partners. Although significant numbers of participants predicted that they would instead
decrease their risk behavior (use condoms more frequently and/or decrease their
frequency of sex with casual or anonymous partners), we believe that these data are less
reliable than the data on anticipated increases in risk behavior [see Discussion below].
Anticipated behavior changes for specific partner types are presented in Table 2.
Additionally, when asked if their sex partners might want to use condoms less frequently
if they knew the participant had received a vaccine, 37% of participants responded ‘yes’
and an additional 18% of participants responded ‘maybe’.
Predictors of anticipated increases in sexual risk behaviors
Potential decrease in condom use by participants: A total of 22% of participants
reported that they might decrease their condom use with sex partners if they received a
low-efficacy vaccine. Poor vaccine concept comprehension was associated (p < 0.01)
with an anticipated decrease in condom use by participants in bivariate analyses (OR =
3.3; 95% Cl = 1.4, 7.7) whereas gender, age, education, alcohol use, and drug use showed
no association. We included age, gender, and vaccine comprehension in the initial
multivariate model, but poor vaccine concept comprehension was the only factor
associated with an anticipated decrease in condom use by participants in the final
adjusted model (OR = 3.6; 95% Cl = 1.5, 8.8).

-72-

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Potential increase in sex with casual or anonymous partners: Overall, 9% of
participants reported that they might have sex with casual or anonymous partners more
frequently if they received a low-efficacy vaccine. None of the covariates examined
(gender, age, education, alcohol use, drug use, and vaccine concept comprehension) were
associated with this outcome in bivariate or multivariate analyses.
Potential decrease in condom use by partners of participants: Overall, 55% of
participants reported that their sex partners would or might use condoms less frequently if
they knew the participant had received a vaccine, with no significant differences between
male and female participant responses. Poor vaccine concept comprehension was
associated (p < 0.05) with an anticipated decrease in condom use by the partners of
participants in bivariate analyses (OR = 2.4; 95% Cl = 1.04, 5.4) while male gender,
young age, education of high school or less, any heavy alcohol use, and any drug use
were not. We included age, gender, alcohol use, and vaccine comprehension in the initial
multivariate analysis. In the final adjusted model, both poor vaccine comprehension (OR
= 2.7; 95% Cl = 1.2, 6.4) and young age (OR = 2.0; 95% Cl = 1.03, 4.0) were associated
with an anticipated decrease in condom use by the partners of the participants.
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DISCUSSION
Anticipated change in sexual risk behaviors following HIV vaccination has rarely
been studied within the African setting: several Kenyan studies have addressed potential
changes in risk behavior surrounding participation in HIV vaccine trials1n,12], while to
our knowledge only one other study in Uganda—using similar methodology to that
described here—has assessed potential behavior changes surrounding future mass HIV
vaccination campaigns^. We assessed anticipated changes in sexual risk behaviors in
response to vaccination with a hypothetical low-efficacy HIV vaccine in a cohort of
volunteers currently undergoing screening and enrollment into multiple Phase I/II HIV
vaccine trials in South Africa. We developed a scripted, educational survey tool for this
purpose, adapted for local use and pilot-tested in the same population, which also allowed
us to assess comprehension of the low-efficacy HIV vaccine concept. Overall, we found
evidence of the potential for sexual risk behavior to change following vaccination, even
among individuals who understand the concept that a vaccine may only provide
incomplete protection against HIV transmission. We base this conclusion on the
anticipated changes in risk behaviors which volunteers predicted for themselves
following a hypothetical vaccination scenario. Because our study provided repeated
education to assure all participants understood the concept of a low-efficacy vaccine, our
results may represent a lower bound on the actual amount of risk behavior disinhibition
which could be expected in this population.
We found that almost all of the participants (99%) comprehended the idea that they
would not get HIV infections from a low-efficacy vaccine. While this number is
encouraging, it must be remembered that this survey was given to participants already
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enrolled in a Pre-Screening Protocol for HIV vaccine trial screening and enrollment,
which involved general education on HIV vaccines, prior to participation in this study.
Comprehension of the new concept of a low-efficacy vaccine, however, was still
excellent: 82% of participants overall understood that they would not know whether a
low-efficacy vaccine would work at an individual level and that protection from HIV
infection would depend on this factor. While these concepts were newly introduced in
the survey, caution must be taken in extrapolating the ease of comprehension to the
general population because participants were already well-versed in the language and
basics of HIV vaccine science. However, with adequate education, introducing the
concept of partially effective vaccines should be very feasible in the general population
beyond those participating in HIV vaccine trials.
After education to ensure that all participants understood the concept of a lowefficacy vaccine, we assessed anticipated changes in sexual risk behaviors following
hypothetical vaccination within a variety of sexual partnership scenarios. We found that
9% of participants reported that they might have sex with casual or anonymous partners
more frequently if they were to receive such a vaccine, and that this behavior was not
predicted by age, gender, education, alcohol use, recreational drug use, or comprehension
of the vaccine concept. Poor comprehension of the low-efficacy vaccine concept was,
however, significantly associated with reporting an anticipated decrease in condom use
with sex partners, both for participants reporting their own anticipated condom use as
well as for participants reporting anticipated condom use by their sex partners.
Specifically, 22% of participants reported that they would probably decrease their
condom use in sexual partnerships as a result of vaccination. For these participants
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reporting their own anticipated behavior change, the majority of the decrease in condom
use was expected to occur with steady or stable partners, which would not be a significant
factor in HIV transmission in populations with low HIV prevalence. However, in
populations where HIV prevalence is high and a generalized epidemic exists, such as
Soweto and many communities in South Africa and beyond, even a decrease in condom
use with stable partners will likely result in a general increase in HIV transmission. In
addition, 55% of participants reported that their sex partners might want to use condoms
less frequently than at present if they knew that the participant had received the vaccine.
In our sample, there were no significant gender differences in this statistic, despite a body
of literature suggesting that women are less likely to successfully negotiate condom use
in South Africa[13' 16].
Of note, the majority of participants in our study predicted that they would either
maintain their risk behavior at current levels or decrease their risk behavior following
vaccination, e.g. 34% of participants anticipated using condoms more frequently and 41%
of participants anticipated having sex less frequently with casual sex partners. While any
decreases in sexual risk behavior would enhance the benefits of vaccination programs,
the intent of our study was to investigate the potential for increased sexual risk behaviors
which might lessen the benefits of such vaccination programs or lead to potential harms.
We believe that our data showing anticipated increases in risk behaviors are more reliable
than the data showing anticipated decreases in risk behaviors because of the inherent
social desirability bias in our study design. All participants had received prior riskreduction counseling and HIV vaccine education, were motivated to participate in HIV
vaccine trials, and answered our survey questions in a face-to-face interview format.

-76-

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Thus, it is more reasonable to conclude that the number of participants anticipating an
increase in their sexual risk behavior is in fact an underestimate, while the number of
participants anticipating a decrease in their sexual risk behavior is an overestimate, of the
true potential for risk behavior change in this population. Further studies in communities
naive to HIV vaccine trial-related education would assist in elucidating this relationship.
Because an HIV vaccine has not yet been licensed or used in a vaccination
campaign outside of clinical trials, no data exist on the actual changes that might occur in
risk behavior after widespread vaccination. Limited inferences can be made from risk
behavior studies and survey techniques in HIV vaccine trial participants, as clinical trials
are operated under different conditions than mass vaccination campaigns and may
underestimate the true changes that might occur[4], but they represent the only alternative
source of information available at present. Analysis to date of previous and ongoing
large-scale HIV vaccine efficacy trials in the United States, Canada, the Netherlands, and
Thailand indicates that self-reported sexual and injection drug use risk-taking behavior
did not increase, and sometimes decreased, during the clinical trial period[17'21]. By
contrast, though, two small HIV vaccine trials in men who have sex with men in San
Francisco revealed that high-risk sexual behaviors increased significantly during the trial
period[22]. This occurred despite education that these were only Phase I/II safety and
immunogenicity studies with no known vaccine efficacy—implying that the risk behavior
increase that would occur in a Phase III trial or in a general vaccination campaign might
be even greater. And, although risk behavior was not shown to increase in the only Phase
III HIV vaccine efficacy trial conducted thus far, 46% of participants gave joining to ‘get
protection from HIV’ as one of the reasons for participating in the trial[18,231.
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Only limited African data exist, from two cohort studies in Kenya, on changes or
anticipated changes in risk behavior concerning HIV vaccine trial participation. First, in
a cohort of female commercial sex workers (CSW) prospectively maintained in readiness
for future HIV vaccine trials, there was a significant decline in risk behavior during the
period of foliow-up[24]. However, despite the fact that voluntary counseling and testing
(VCT) and follow-up were shown to decrease the incidence of HIV via decreased risk
behavior, predictions can not be made about what might happen when this same
population is actually vaccinated in an HIV trial. Second, a survey of a high-risk
heterosexual cohort of male truck drivers and female CSWs on anticipated participation
in a Phase III HIV vaccine trial revealed that 17% of men and 9% of women thought that
they would increase their risk behavior (via decreased condom use or increased sex
partners) as a result of participation in the trial. This occurred despite intensive
individual HIV counseling during the study, and despite being educated that half of the
participants would receive a placebo[12]. Except for these few examples, there have been
no other African studies either on the characterization of sexual risk behaviors in cohorts
enrolling into HIV vaccine trials or on anticipated sexual risk behavior changes in
response to HIV vaccine trial participation.
Our study had several limitations. We conducted our survey in a face-to-face
interview format and within the context of screening for HIV vaccine trial participation,
in which participants had received prior education and risk-reduction counseling;
therefore, the data we collected on anticipated changes in sexual risk behaviors are
susceptible to social desirability bias as described above. Our results may therefore
underestimate the actual potential for risk-taking behavior to increase, at least amongst
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participants reporting their own anticipated changes in behaviors. Because there was
such a difference in the number of participants reporting that their partners might want to
use condoms less frequently, as opposed to their own reported proposed decrease in
condom use, it is possible that this line of questioning reduces such bias. More than half
of the participants reported that their partners might want to use condoms less frequently,
thus the true number of participants who might decrease their own condom use behaviors
could be much higher. However, it is also possible that social desirability bias causes an
over-estimation of anticipated changes in behaviors reported for sex partners. Future
studies should address this issue, and audio computer-assisted self-interviewing (ACASI)
technology may assist in reducing potential desirability bias as well as standardizing the
survey encounter[25].
Another limitation of our study is that it may be difficult to generalize the results to
the greater population of Soweto. Participants in this pre-screening cohort were recruited
through community outreach methods which included the provision of free HIV VCT,
thus possibly selecting individuals who engaged in higher or lower risk behaviors than
the general population. Higher levels of risky behavior have been demonstrated in a
vaccine trial preparedness cohort in a similar South African community^261. However,
this potential sample bias may have been tempered for the purposes of this survey by the
risk reduction counseling and vaccine education that participants in our study had
previously received.
In summary, the potential for sexual risk behavior to change following vaccination
is a valid concern. In particular, we have shown that individuals predict that they may
increase their risk taking behavior even after successfully understanding the concept that
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a vaccine may provide only incomplete protection against HIV transmission. Our
research also underscores the need for risk reduction counseling and education
surrounding the implementation of future vaccination campaigns with partially effective
vaccines. It may not be sufficient to provide education regarding risk behavior only to
individuals who are vaccinated; their sex partners may also need risk reduction
counseling and mass media education campaigns may be necessary.
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TABLE 1. Comprehension of low-efficacy vaccine concept (n = 158)
n (%) incorrect8

Concept evaluated
One can get HIV from a low-efficacy HIV
vaccine

2(1%)

One will know whether a low-efficacy HIV
vaccine worked on one’s body and is
providing full protection

10(6%)

A 30% effective vaccine will only work on 3
of every 10 people vaccinated (any incorrect
answer)

17(11%)

At least one of the above concepts incorrect

29(18%)

aSample sizes within 2% of total n = 158
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TABLE 2. Anticipated changes in sexual risk behavior (n = 158)a
Less
frequently

About the
same

More
frequently

Condom use with anonymous sex partners

2.5%

57.0%

40.5%

Condom use with casual sex partners

2.6%

63.7%

33.8%

Condom use with steady/stable sex partners

20.4%

65.6%

14.0%

Sex with anonymous partners

37.8%

57.1%

5.1%

Sex with casual partners

40.7%

52.9%

6.5%

Specific risk behavior6

a Sample sizes within 2% of total n = 158
bAll questions assess anticipated risk behavior changes as compared to current levels of behavior for
individual participants, following hypothetical vaccination with a 30% effective vaccine
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APPENDIX
The scripted survey developed for assessing hypothetical risk behavior response to
vaccination with a low-efficacy preventive HIV vaccine is detailed below.

In this questionnaire, we would like to ask some hypothetical questions.
‘Hypothetical’ means that we must imagine a situation that does not actually exist.
These questions will be about what we call a partially effective HIV vaccine.
To help explain what ‘partially effective’ means, let us first discuss the polio vaccine,
which you have probably already received when you were younger. The
effectiveness of the polio vaccine, which is a very good vaccine, is 90-100%. This
means that if you line up 10 people and give each of them the vaccine, it will work in
9 of them or all 10 of them. This means that they will be protected from getting
polio even when they are exposed to the disease. But, it is possible that one of them
is not protected from getting polio because the vaccine did not work in that person.
This is because our bodies are not the same and some medicines work differently in
different people, for example, drinking panados for a headache might help some
people but not other people.
Before we continue, we want to make it very clear that there is no effective HIV
vaccine available anywhere in the world, either commercially or through a research
facility. But we would like to ask you some questions about what you might do if
there were a vaccine. This means imagining a vaccine that has already been tested
in clinical trials and approved for use—which may in reality take 10 more years to
accomplish.
Suppose you were to receive an HIV vaccine that is known (after many tests and

clinical trials in humans) to be 30% effective. This means that if you line up 10
people and give each of them the vaccine, the vaccine will only work in 3 of them. It
will not work in 7 of them. This means that only 3 of them will be protected from
getting HIV if they have sex without protection with a person who has HIV. It also
means that if you get the vaccine yourself, you do not know if you are one of the 3
people who would be protected. You could also be one of the 7 people who are not
protected because the vaccine did not work in them.
Do you have any questions about this? To make sure that I have explained this to
you well, I will now ask you three questions. Do not worry if you get a question
wrong, it just means that I need to explain this better.
Q1.

Please answer yes or no: If you get an HIV vaccine that is 30% effective, will you get
HIV from the vaccine itself?
1

Yes

0

No

I f answer is 1, more discussion is needed
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Q2.

Please answer yes or no. If you get an HIV vaccine that is 30% effective, will you know
whether the vaccine worked on you?
1

Yes

0

No

I f answer is 1, more discussion is needed
Q3.

I will now read a statement and then give you four choices to complete the statement. If
you get an HIV vaccine that is 30% effective, you will be protected from getting HIV
? (Choose one)
1

Never

2

Every time you have sex without protection

3

3 out o f 10 times you have sex without protection

4

It depends on whether you are one of the 3 out of 10 people who the vaccine worked on

I f answer is 1, 2, or 3, more discussion is needed. Please explain to all participants why
answer 4 is right and answers 1,2,3 are wrong before continuing.
We would now like to ask you some questions about what you might do if you were
to get this vaccine. Remember, there is no vaccine available for HIV and there is no
right or wrong answer. We are just interested in what you might think you would
do. Again, these questions are confidential so we will not tell anyone what you have
told us.
In the following questions, we refer to three types of sexual partners: steady/stable,
casual, and anonymous. A steadv/stable partner is someone who is special to you,
like a husband/wife/boyfriend/girlfriend, or lover. A casual sex partner is a person
you know but who is not your main sex partner, whether you had sex only once or
many times. An anonymous sex partner is someone whose name you did not know
the day before you had sex. For the following questions, if you do not currently
have one of these partner types, you can answer hypothetically—what you imagine
you would do.
Q4.

If you received this vaccine, do you think that any o f your sexual partners might want to
use condoms less frequently with you if they knew you had received a vaccine? (Make

sure the participant is talking about their partner’s behavior, not their own behavior)
1

Yes

0

No

8

Maybe

9

Refuse to answer

For the next three questions, if you received this vaccine, how frequently would you
use condoms compared to presently? (Make sure that each answer reflects how the
person would CHANGE their behavior from the way they act at present)
Q5.

With an anonymous sex partner?
1

I would probably use condoms less frequently than I do at present

2

I would probably use condoms about the same as I do at present

3

I would probably use condoms more frequently than I do at present

9

Refuse to answer

-

88-

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Q6.

Q7.

With a casual sex partner?
1

I would probably use condoms less frequently than I do at present

2

I would probably use condoms about the same as I do at present

3

I would probably use condoms more frequently than I do at present

9

Refuse to answer

With a steady/stable sex partner?
1

I would probably use condoms less frequently than I do at present

2

I would probably use condoms about the same as I do at present

3

I would probably use condoms more frequently than I do at present

9

Refuse to answer

For the next two questions, if you received this vaccine, how many partners would
you have sex with compared to presently? (Make sure that each answer reflects how
the person would CHANGE their behavior from the way they act at present)
Q8.

Q9.

If they were anonymous sex partners?
1

I would probably have sex with anonymous partners less frequently than I do at present

2

I would probably have sex with anonymous partners about the same as I do at present

3

I would probably have sex with anonymous partners more frequently than I do at present

9

Refuse to answer

If they were casual sex partners?
1

I would probably have sex with casual partners less frequently than I do at present

2

I would probably have sex with casual partners about the same as I do at present

3

I would probably have sex with casual partners more frequently than I doat present

9

Refuse to answer

Thank you very much for participating in this survey. Do you have any questions
for us or anything you would like to discuss?
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PAPER 3

Predicting the Impact of a Partially Effective HIV Vaccine and
Subsequent Risk Behavior Change on the Heterosexual HIV
Epidemic in Low- and Middle-Income Countries: a South African
Example
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INTRODUCTION
Despite a lack of success in HIV vaccine development to date[1], there are 35 HIV
vaccine candidates currently progressing through various clinical trials around the world,
and many more in developmental Because of the scientific challenges in vaccine
design[3], clinical trials are using a minimum efficacy value of 30% for evaluating the
effectiveness of potential vaccine candidates[4]. Given the urgent need for an HIV
vaccine, it is likely that HIV vaccines with only partial efficacy will be used initially in
populations at high risk for HIV infection[5]. The potential for post-vaccination risktaking behavior to increase poses a significant threat to the successful use of partially
effective vaccines in future vaccination programs[5'8l Individuals might increase their
risk-taking behavior, assuming they are at lower risk for HIV infection when, in reality,
they might have only limited protection from HIV infection or none at all[9'14].
Models have shown that even a partially effective HIV vaccine with minimal
efficacy could have enormous population impact on the HIV epidemic in areas with high
HIV prevalence, such as sub-Saharan Africa115"21], but that the magnitude of this impact
depends on a fine balance between the efficacy of the vaccine, the vaccine coverage
level, and the change in risky behavior1-18,20,22'26]. While decreases in individual risk
behavior would augment the population benefits of such vaccination programs in terms of
HIV infections prevented, increases in risk behavior might negate those benefits or even
worsen the HIV epidemic. Although we are unable to predict what might occur in a
future mass vaccination campaign^, results from the few completed vaccine trials to date
in North America, Europe, and Asia show that risk behavior generally did not increase^27'
31], despite early reports of increased risk behavior in several small trials[32]. However,

-91 -

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

nine African countries are either preparing or already enrolling participants for HIV
vaccine trials[2,33’34] and preliminary studies indicate that sexual risk behavior might
increase in response to vaccination[6,35] [also, Dissertation Paper 2]. To what degree
increased risk behavior might potentially offset the benefits of vaccination remains a
question largely unanswered in the African setting.
The impact of partially effective vaccines and potential risk behavior change on
future vaccination campaigns in South Africa has not yet been examined. With an
estimated 5.5 million people living with HIV/AIDS as of 2006 and HIV prevalence in
some areas as high as 30-40%[36'38], South Africa is experiencing the type of severe HIV
epidemic that is present or developing in many low- and middle-income countries.
Additionally, because of South Africa’s burden of HIV, political support for HIV
vaccines, participation in international HIV vaccine trials, and status as a middle-income
country with a relatively strong health infrastructure for vaccine purchase and delivery, it
may be one of the first countries in sub-Saharan Africa to consider the use of early
generations of licensed HIV vaccines. Therefore, we estimated the effect of various
potential preventiveV1vaccination scenarios on the heterosexual HIV epidemic in the
urban township of Soweto, South Africa with a mathematical simulation modelvu, using
different levels of vaccine efficacy and changes in post-vaccination condom use[39,40].

V1For our study, a preventive vaccine is defined as a vaccine which prevents primary infection with HIV
and a partially effective vaccine (low-efficacy vaccine, imperfect vaccine) is defined as a vaccine with less
than 100% efficacy, or ability to prevent transmission of HIV
™Partial data from this manuscript have been previously reported at the Annual Meeting o f the Society for
Medical Decision Making (Atlanta, 2004) and the 13th Conference on Retroviruses and Opportunistic
Infections (Denver, 2006).
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METHODS
We developed a dynamic, compartmental epidemic model for heterosexual HIV
transmission and disease progression to simulate the impact of various partially effective
preventive HIV vaccination scenarios and subsequent changes in risk behavior in a
population at high risk for heterosexually transmitted HIV in Soweto, South Africa.
Model description
The model defines six ‘compartments’, each representing a particular health ‘state’,
to simulate the process of HIV transmission and disease progression: (1) unvaccinated
HIV-negative, (2) vaccinated HIV-negative, (3) unvaccinated asymptomatic HIVpositive, (4) vaccinated asymptomatic HIV-positive, (5) symptomatic HIV-positive, and
(6) AIDS. There are separate states for males and females, for a total of twelve
compartments overall. Rates of movement between states for individuals are specified by
a set of twelve deterministic differential equations which govern allowable transitions
between the population subgroups. The model considers a population of sexually active
adults, who enter the simulation upon reaching sexual maturity and can leave the
simulation due to death from either non-AIDS or AIDS-related causes. Only
heterosexual transmission of HIV is considered in this analysis (see Appendix for further
details).
The model accounts for both the immunological and behavioral effects of a
preventive HIV vaccine (see Appendix for further details). HIV-negative men and
women who are vaccinated will be protected from HIV infection in sexual partnerships
with HIV-infected individuals a certain proportion of the time, which is the efficacy of
the vaccine. Therefore, if the vaccine is 40% effective, vaccinated HIV-negative
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individuals will then be protected from HIV infection in 40% of partnerships with
infected heterosexual partners. Additionally, individuals may change their sexual risktaking behavior, such as condom use, sex act type and frequency, and number of sex
partners, in response to vaccination. For example, they might increase their risky
behavior because they feel protected by the vaccine or they might decrease their risky
behavior as a response to the counseling that may be given in a mass vaccination
campaign. Specifically, we examine post-vaccination changes in male-negotiated
condom use behavior.
A more detailed description of the model and the assumptions underlying its
specification is provided in the Appendix.
Simulations
We conducted simulations as if a vaccine was currently available and a vaccination
program was implemented for a period of 10 years. We then evaluated the effects of
various vaccination scenarios by examining the total number of HIV infections averted
and the change in population HIV prevalence. We calculated these values by comparing
model outputs under the vaccine program simulation to a simulation without a
vaccination program.
We first simulated a base-case scenario, in which a vaccination program was
implemented using a vaccine with 40% efficacy and in which there was no post
vaccination change in risk behavior (male-negotiated condom use). We compared model
predictions from the base-case scenario to other vaccination scenarios with varying
vaccine efficacies and post-vaccination changes in male condom use. We performed all
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model simulations using Excel® 2003 spreadsheet software (Microsoft Corporation,
Redmond WA).
Input parameters, assumptions, and initial conditions
We derived input parameters for the model from both published data sources and
assumptions. Input parameters are listed in Table 1, along with their associated model
equation symbols. We modeled the urban township population of Soweto using an initial
population size of 823,000 including only men and women aged 17 years or older[41], a
mean age of 25.1 years[42], and a life-expectancy of 60.8 years from birth in the absence
of deaths due to AIDS1-431. Based on regional and national studies of sexual debut in
South Africa, we estimated that all individuals in Soweto are sexually active by this
age[44_47]. Using national and province-specific HIV prevalence data for individuals aged
15-49 years[47], we estimated an initial HIV prevalence of 11.6% for males and 20.0%
for females. We assumed an anti-retroviral (ARV)-nai've population.
We modeled a preventive HIV vaccine that produced an immunological effect in all
recipients (100% take, if/ = 1), provided protection for a mean duration of 50 years
(1 / a = 50), and affected only HIV transmission with no effect on infectivity or disease
progression in those who were HIV-positive[19,24,48,49]. For our base-case scenario, we
used a 40% effective vaccine ( s = 0.4), a figure which was subsequently varied. We
simulated a program in which vaccines were given to unvaccinated asymptomatic men
and women aged 17 years or older, without testing individuals for HIV; therefore,
vaccines were given to both uninfected and asymptomatic HIV-positive individuals. We
assumed that none of the population were vaccinated initially and that the vaccine would
be administered in a highly coordinated and effective mass-vaccination campaign, in
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which 75% of those eligible for vaccination were vaccinated in the first year and in each
year thereafter (v(t) = 0 .7 5 ). Although a high estimate, we felt this coverage level would
be feasible given the apparent devastating epidemic in South Africa and the needs of both
individuals and government for additional HIV prevention methodologies. However, we
also performed additional sensitivity analyses for a more modest coverage level of 50%
(v(0 = 0.5 0 ).
In the model, we varied the number of sexual partners a man or woman has and the
probability of HIV transmission within those sexual partnerships according to disease
stage. We estimated that uninfected and asymptomatic HIV-positive men and women
had on average three sexual partnerships per year ( p 0, p x = 3) [Dissertation Paper 1],
symptomatic HIV-positive men and women had only one sexual partnership per year
( p 2 = 1), and individuals with AIDS had no sex partners ( p i = 0). We used Ugandan
data to estimate the per-partnership probability of HIV transmission from asymptomatic
(

P u \,j ~

0-0684,

j

= 0 .1 1 1 2 )

and symptomatic ( /3M2j

= 0 .1 6 5 7 ,

fi w2j

= 0.2697)

HIV-

positive men and women[18,50'52]. We based our infectivity parameters on monogamous
serodiscordant couple studies, which represent conservative estimates compared to
transmission data from multiple-partnership studies[53]. Because research into the
biologic and social basis for observed gender differences in HIV transmission is
inconclusive to date[18,50,52'56], we performed additional sensitivity analyses in which the
male-to-female (MTF) and female-to-male (FTM) infectivity rates were exchanged and
in which the symptomatic FTM infectivity rate was decreased by two- and ten-fold (see
Appendix for further details).
We used the median time from HIV seroconversion to AIDS in an African setting
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and previously published lengths for HIV disease stages to estimate the duration of both
asymptomatic HIV disease (1 /

; = 6.8 years) and symptomatic HIV disease

(1 / n t J = 2.6years) in the model119,24,571. We used the median time from AIDS
development to death of 9.2 months (1 / ju3J =0.8 years) for the duration of AIDS[57].
These disease progression times were based on studies in the Rakai district of Uganda
prior to the availability of ARV therapy in this area.
From studies of condom use in South Africa144471 [also, Dissertation Paper 1], we
estimated that baseline condom use was 50% in all sexual partnerships ( hi 0 = 0.5). We
used a condom failure rate of 14% over the course of each sexual partnership
( / = 0.14 )1581. For our base-case simulation, we examined a scenario in which post
vaccination condom use did not change from baseline levels of 50% (0% change in
condom use, A = 1.0); subsequent analyses examined values from 25% (50%
decrease, A = 0.5) to 75% (50% increase, A = 1.5) to explore a wide range of potential
changes in risk behavior. In addition, based on research showing a significant gender
difference in the ability of women in many South African settings to successfully
negotiate condom use with their sexual partners159'621, we assumed that condom use was
negotiated exclusively by the male in the relationship. Therefore, we used a likelihood
function for condom use in a given partnership based entirely on the preference of the
male partner (see Appendix for further details).
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RESULTS
We simulated vaccination scenarios for an initial population of 823,000 sexually
active, heterosexual men and women with an HIV prevalence of 12% and 20%,
respectively, of whom 75% were effectively vaccinated each year with vaccines that
provided 50 years of protection. In the absence of HIV prevention interventions in
Soweto, the model predicted that HIV prevalence would increase over the next 50 years
from 16% currently to 26%, with 743,000 new HIV infections occurring during that
period (Figure 1). Within the next 10 years alone, simulations predicted the overall
population prevalence would rise to 20% and 161,000 new HIV infections would occur.
For vaccination scenarios with no change in post-vaccination risk behavior,
increases in vaccine efficacy produced greater numbers of HIV infections averted (Figure
2) with concurrent decreases in overall population HIV prevalence. A vaccination
program using a 20% effective vaccine would avert 34,000 infections over 10 years and
decrease the 10-year overall population HIV prevalence from 20% to 16%. Similarly, a
30% effective vaccine would avert 50,000 infections and decrease prevalence to 15%
over 10 years. In contrast, a 100% effective vaccine would avert 135,000 infections in
the same time period and decrease HIV prevalence to 6%.
We next examined specific combinations of vaccine efficacy and changes in risk
behavior (Figure 3). Figure 3A shows the results for our base-case vaccination scenario
using a 40% effective vaccine with no change in condom use post-vaccination. Over 10
years, this vaccination program could prevent 65,000 new HIV infections in Soweto and
reduce the population HIV prevalence from 20% to 13%.
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We then examined changes in risk behavior by varying post-vaccination condom
use. We simulated a vaccination scenario in which a 40% effective vaccine was used, as
in the base-case scenario, but in which post-vaccination condom use increased by 25%
(Figure 3B). In this case, the beneficial effects of the base-case vaccination program
increased: cumulative infections averted would increase from 65,000 to 80,000 and the
prevalence of HIV would decrease even further, from 20% to 11%. In contrast, a
vaccination scenario in which post-vaccination condom use decreased by 25% would
reduce the beneficial effects of the base-case vaccination program (Figure 3C). The
cumulative number of infections averted would only decrease from 65,000 to 49,000 and
the prevalence of HIV would only decrease from 20% to 15%.
Depending on the particular combination of vaccine efficacy and change in risk
behavior, some vaccination programs we simulated would be detrimental. As an
example, we show a vaccination program which used a 20% effective vaccine but which
resulted in a 50% decrease in post-vaccination condom use (Figure 3D). This scenario
created a perverse outcome in which the negative behavioral effects outweighed the
protective effects of the vaccine. This vaccination program would actually cause an
additional 15,000 infections beyond what would be expected without any vaccination
campaign and would increase the prevalence of HIV over 10 years from 20% to 22%.
Given these observations and the uncertainty of future mass vaccination campaign
conditions, we then examined the relationship between varying vaccine efficacy values
and levels of risk behavior change. We estimated all combinations of vaccine efficacy
and changes in post-vaccination condom use for vaccination scenarios that would prevent
the same 65,000 HIV infections as the base-case scenario over a period of ten years
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(Figure 4A). The base-case scenario is represented by the point at which the curve
crosses the horizontal axis. Other points on the curve map particular combinations of
vaccine efficacy and changes in condom use behavior that would produce identical
results. At one extreme, an imperfect vaccine would be less effective than a program to
change condom use behavior; any HIV prevention program that could increase condom
use to at least 80% (e.g. increase condom use by more than 58% over baseline levels), in
the absence of a vaccine, would prevent more infections than a 40% effective vaccine in
the base-case vaccination scenario. At the other extreme, an imperfect vaccine with
adequate efficacy could offset the negative effects of any decreases in post-vaccination
condom use: if all individuals ceased using condoms entirely after being vaccinated (e.g.
condom use decreased 100%, from baseline levels of 50%), any HIV vaccine that was
more than 65% effective would still prevent more infections than a 40% effective vaccine
in the base-case vaccination scenario.
To examine whether various vaccination programs might be beneficial or harmful at
the population level, we also estimated which combinations of vaccine efficacy and
changes in post-vaccination condom use would result in a net decrease in the number of
HIV infections (Figure 4B). The curve divides the graph area into all combinations of
vaccine efficacy and changes in post-vaccination condom use in vaccination programs
that would either increase the number of infections (the region below the curve) or,
alternatively, decrease the number of infections (the region above the curve). As the
efficacy of the vaccine increased, HIV infections were still reduced even with decreasing
condom use. All vaccination programs which generated any increase in condom use over
baseline levels would be beneficial in terms of infections prevented, regardless of the
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efficacy of the vaccine used. All vaccination programs which used a vaccine with an
efficacy of at least 42% would be beneficial in terms of infections prevented, regardless
of changes in risk behavior—a result that is robust even if condom use were to cease
entirely post-vaccination campaign. Any vaccination programs which used a vaccine
with an efficacy less than 42% and which also caused a decrease in condom use from
baseline levels could be beneficial or harmful in terms of infections prevented, depending
on the particular combination of vaccine efficacy and risk behavior change. The example
of a 20% vaccine with a 50% decrease in post-vaccination condom use, described above,
is one such harmful scenario.
Despite the lack of population HIV prevalence data for Soweto, we validated the
model using overall predicted trends for Gauteng province (which includes Soweto
township) population HIV prevalence3633. In the absence of vaccination programs,
predicted trends for Soweto HIV prevalence in the sexually active population in our
model matched predicted trends for Gauteng province HIV prevalence in adults aged 2064 within 5-15% each year for 10 years (data not shown).
Because of the uncertainty in the published literature regarding the existence of
gender differences in HIV transmission rates, we performed additional sensitivity
analyses in which the MTF and FTM transmission parameters were exchanged. In
addition, we performed sensitivity analyses on the symptomatic FTM infectivity
parameter (0.27 probability of transmission per partnership per year) as our calculations
yielded a relatively high value for this probability (see Appendix for further details). We
examined outcomes for simulations in which the FTM infectivity parameter was reduced
to 50% and 10% of our calculated value. We also explored the effects of a 50%
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vaccination program coverage goal, rather than 75%. In all cases, while the quantitative
benefits of the programs change (data not shown), the analyses remain robust to our
qualitative conclusions regarding the impact of partially effective vaccines.
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DISCUSSION
We designed a mathematical model to simulate heterosexual transmission and
disease progression of HIV in low- or middle-income country populations. We simulated
vaccination programs using preventive vaccines with varying levels of efficacy and post
vaccination changes in risk behavior, which for this study was represented by condom
use. We specifically examined the impact of these vaccination programs on the HIV
epidemic in Soweto, South Africa in terms of HIV infections prevented and changes in
HIV prevalence over time. We found that vaccines with only 30% or 40% efficacy can
confer substantial health benefits, which is significant because most vaccines in use today
for other diseases have much higher efficacies than this. We also found that the effects of
changes in risk behavior, post-vaccination condom use in this instance, can be significant
and condom use will merit close attention in future vaccination campaigns. Finally, we
found that even with increases in risk behavior, sufficiently effective vaccines could still
be beneficial.
Heterosexually-transmitted HIV is responsible for more than 80% of adult HIV
infections worldwide[58], and more than 98% of new HIV infections are occurring in lowand middle-income countries^381. Our analysis represents the first simulation of the
impact of preventive HIV vaccination programs on heterosexual HIV transmission and
disease progression in South Africa, and is one of only a small number of HIV
vaccination program simulations for heterosexually-transmitted HIV in low- and middleincome country populations115' 18’20^. We were able to utilize African data for the majority
of our model input parameters, most of which were specific to this particular South
African population: infectivity values and disease progression times were derived from
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studies in Uganda, Kenya, and Zambia; baseline levels of condom use, mortality rates,
and life expectancy data were derived from several South African studies; adolescent and
adult HIV prevalence values, population mean age, age of sexual debut, and assumptions
of gender differences in condom negotiation were estimated from both national and
province-specific data in South Africa; population size was calculated based on districtspecific census data for Soweto obtained from the city of Johannesburg; and, assumptions
for contact rates, potential risk behavior change, and current condom use were derived
from our studies in Soweto [Dissertation Papers 1 and 2]. Despite using different
methodology and population assumptions, our findings of the beneficial impact of
partially effective vaccines were consistent with previous models, both simple and
complex, of the effects of preventive HIV vaccines115,16,19,21,481 and their sensitivity to
changes in risk behavior118,22,241.
To our knowledge, this also represents the first time that differential condom use
behavior between men and women has been incorporated into a model of HIV disease
transmission. While Western models of HIV transmission have specified that condom
use between two partners with differing practices is the greater of the two (e.g. if one
person uses condoms 70% of the time and another person uses condoms 30% of the time,
then condom use in that partnership will be 70%)[24], we believe that this does not
accurately reflect condom use negotiation in the African setting. We assumed exclusive
male-negotiation of condom use in our model to reflect the decreased ability of South
African women to negotiate condom use in heterosexual partnerships159'621, a
disadvantage which is found in many countries throughout sub-Saharan Africa and in part
explains the shift towards a female-dominated epidemic1381. Therefore, in our model, the
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likelihood of condom use in a given sexual partnership was exclusively linked to the
condom usage rate of the male partner; as a result, changes in risk behavior were linked
to male-determined changes in condom use.
We only varied post-vaccination condom use, despite other changes in risk behavior
that could occur such as changes in the type or frequency of sex acts and changes in the
number of sexual partners. Similar to previous studies1-241, we used changes in condom
use behavior to capture all potential for risk behavior change in this analysis. As such,
decreasing condom use, for example, would have been similar (although not identical) to
increasing the number of sex acts or the number of sex partners. However, other studies
investigating risk behavior effects have instead used changes in the number of sex
partners118,481 or risk behavior summary measures including both sexual partnerships and
condom use[20’221 to capture the potential for risk behavior change. We felt that in the
African setting, particularly when modeling closed populations, gender differences in risk
behavior were easier to capture with condom use behavior than with other behaviors.
Our current analyses have assumed an ARV-naive population, as very few people in
South Africa presently have access to ARV therapy. In addition to prolonging life, ARV
therapy decreases viral loads in HIV-infected individuals, and decreased viral loads have
been shown to result in decreased sexual transmission of HIVtl8,50’52’55]. The effects of
the national plan for widespread public sector distribution of antiretroviral medications to
South Africans infected with HIV1641 will need to be included in future analyses of the
impact of HIV vaccination programs once significant coverage of ARV therapy for HIVpositive individuals is achieved.
We have at present modeled the effects of a preventive HIV vaccine in a South
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African population because (1) preventive vaccines have a larger potential to control the
epidemic than disease-modifying vaccines1251, (2) novel design approaches for preventive
vaccines and clinical trials are still underway12’651, and (3) preventive HIV vaccines have
been previously modeled in a heterosexual African population only in Uganda1181.
Because of scientific challenges in developing preventive vaccines that stimulate broadlyneutralizing antibody responses, disease-modifying vaccines that stimulate cellular
immunity via specific cytotoxic T lymphocyte-based responses are also currently under
development13’661. Similar to ARV therapy, these disease-modifying vaccines might be
able to decrease viral load (and therefore infectivity) and disease progression in those
already infected. While they may not prevent HIV infection at the individual level,
disease-modifying vaccines might decrease HIV transmission, and thus HIV prevalence,
at the population level over time1671. Other models have investigated the impact of
disease-modifying vaccines115,19'21’24'26’48’68’691, and further exploration of the impact of
disease-modifying vaccines on heterosexual HIV transmission in Africa in particular is
merited.
Despite the uncertainty about the efficacy of a vaccine, we have been able to make
general conclusions for communities such as the township of Soweto regarding the use of
partially effective vaccines and the implications of risk behavior change. In addition to
the consideration of potential disease-modifying vaccines and widespread access to ARV
therapy, future analyses would benefit from the incorporation of migration and
heterogeneous risk behavior groups into the model. Vaccination scenarios varying other
parameters such as vaccination coverage levels, vaccine take, and duration of protection
as well as the timing, length, costs and benefits of vaccination campaigns should also be
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considered when a potential vaccine candidate has been identified for use and decisions
must be made regarding its implementation. And, because so little is currently known
about the potential for risk behavior change in the African setting, studies to evaluate
whether risk behavior changes might occur in future vaccination campaigns [e.g.
Dissertation Paper 2] are greatly needed.
Due to the significant effects of changes in risk behavior on the potential benefits of
mass vaccination campaigns, programs to reduce risk behavior will be important
components of successful vaccination campaigns for South Africa and other countries
with similar epidemic profiles, particularly when lower-efficacy vaccines are used.
Programs to reduce risk behavior such as those used during the rollout of ARV therapy or
other HIV prevention campaigns in African countries may serve as templates for risk
behavior reduction strategies^56,701. Because of the decreased ability of women to
negotiate condom use in their relationships and the higher risk behaviors found in men
throughout sub-Saharan Africa[38], programs specifically targeting men should also be
considered.
More immediately, risk behavior assessment [e.g. Dissertation Paper 1] must
remain an important component of HIV vaccine clinical trials as it will provide one of the
only means of predicting changes in risk behavior that might occur at the population level
in an actual mass vaccination campaign. However, the reductions in HIV prevalence and
new HIV infections that can result from using partially-effective vaccines are substantial,
even in the presence of increased risk behavior; therefore development of preventive
vaccines should remain a high priority despite concerns that these vaccines will have only
moderate efficacy.
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TABLE 1. Param eter values3
Parameter name
Preventive vaccine parameters
Percentage of uninfected or asymptomatic HIV+ males and females
vaccinated annually
Vaccine take (proportion of those vaccinated in whom vaccine
stimulates an immune response)
Vaccine efficacy (percent of partnerships protected from infection)
Change in (male-negotiated) condom use after vaccination0
Mean duration (in years) of vaccine protection
HIV transmission parameters
Male infectivity (per-partner probability of transmission to a female)
Asymptomatic period of HIV infection

Symbol

Valueb

v(t)

0.75 (0.50-0.75)

¥

1

E

0.40 (0-1.0)
1.0 (0.5-1.5)
50

A
\ l CD

P u\,j

Symptomatic period of HIV infection

P m 2J

0.0684(0.06-0.11)
0.1657 (0.16-0.27)

Female infectivity (per-partner probability of transmission to a male)
Asymptomatic period of HIV infection

Pw\,j

Symptomatic period of HIV infection

Pw2,j

Contact rate (number of new partners per year) of males or females
Uninfected
HIV infected, asymptomatic period

0.1112(0.06-0.11)
0.2697 (0.03-0.27)
3

Po

3

A

HIV infected, symptomatic period

1

P2

HIV infected, AIDS
Baseline (male-negotiated) condom use for all partnerships (no
vaccination program)
Condom failure rate for all partnerships
HIV disease duration parameters
Asymptomatic HIV infection (years)

0

Pi
h.1,0
n

0.5

/

0.14
6.8

y P\,j

Symptomatic HIV infection (years)

2.6

V/hj

AIDS (years)

0.8

11 Pi, j

Initial population parameters, heterosexual men/women > 16 years
Total population size
Initial HIV prevalence, male population (%)
Initial HIV prevalence, female population (%)
Mean age (years)
Non-AIDS life expectancy (years)
Non-AIDS-related annual mortality rate

823,000
11.6
20.0
25.1
60.8
0.028d

p

3 Model variable term inology ad ap ted from O w ens e t al. an d Edw ards at at., 1998
b S e e text for param eter value references and assumptions; values in parentheses are ranges used in sensitivity
analyses
0 e.g. for A = 1.0, no change in condom use; for
d ecrease in condom use

A

= 1 .2 5 ,2 5 % increase in condom use; for

A

— 0 .7 5 ,2 5 %

d Non-AIDS mortality rate calculated as follows: 1 / / / + (population mean ag e) = (non-A ID S population life
expectancy)

__________________________________________________________________________________________
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Figure 1.

Predicted trends in Soweto adult population HIV prevalence
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Figure 2.

Sensitivity analysis: cumulative infections prevented for varying
vaccine efficacy values
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Figure 3A.

Base case scenario simulation using a vaccine with 40% efficacy,
with no change in risk behavior post-vaccination
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Figure 3B.

Decreased risk behavior simulation using a vaccine with 40%
efficacy, with 25% increased condom use post-vaccination
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Figure 3C.

Increased risk behavior simulation using a vaccine with 40% efficacy,
with 25% decreased condom use post-vaccination
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Figure 3D.

Epidemic worsening simulation using a vaccine with 20% efficacy,
with 50% decreased condom use post-vaccination
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Figure 4A.
Combinations of efficacy and risk behavior change for 65,000
infections prevented (10-year vaccination program has same net
effect as base-case scenario)
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Combinations of efficacy and risk behavior change for zero infections
prevented (10-year vaccination program has no net effect)
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FIGURE CAPTIONS

Figure 1. Model-predicted trends in Soweto population HIV prevalence over 50 years for
sexually active adult population.

Figure 2. Sensitivity analysis showing cumulative HIV infections averted over 10 years
for vaccination programs using vaccines with varying efficacy values (20%, 40%, 60%,
80%, and 100%).

Figure 3. Changes in population HIV prevalence compared to a no-vaccine simulation
over 10 years for various vaccination program scenarios: base-case scenario using a 40%
effective vaccine with no post-vaccination change in risk behavior (panel A); decreased
risk behavior scenario using a 40% effective vaccine with a 25% increase in post
vaccination condom use (panel B); increased risk behavior scenario using a 40% effective
vaccine with a 25% decrease in post-vaccination condom use (panel C); and, a scenario
to demonstrate the potential for epidemic worsening, using a 30% effective vaccine with
a 75% decrease in post-vaccination condom use (panel D).

Figure 4. Equivalence graph showing various combinations of vaccine efficacy and
changes in post-vaccination condom use in vaccination scenarios that would result in the
same number of cumulative infections averted: all combinations of programs preventing
65,000 new HIV infections, which is the number of infections prevented in the base-case
scenario (panel A); and, all combinations of programs with no net effect, or zero
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infections prevented, such that combinations of programs falling above the curve would
prevent infections while those falling below the curve would lead to additional infections
(panel B).

-1 2 4 -

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

APPENDIX
Detailed information on the mathematical model used for the evaluation of various
HIV vaccination program scenarios is provided in this Appendix.
We based the model design on a mathematical model for homosexual HIV
transmission and disease progression simulating the effects of HIV vaccination programs
in men who have sex with men in San Francisco[I9,24], which had incorporated
characteristics of previously published models of HIV disease[48,49,71]. We developed the
current epidemic model for the heterosexual transmission of HIV that occurs in African
populations. We adapted the model in the following ways: (1) to account for two
different populations (male and female) linked by heterosexual HIV transmission; (2) to
account for HIV transmission conditions in sub-Saharan Africa, including male-driven
negotiation of condom use and lack of knowledge of one’s HIV status; and, (3) to assess
the impact of a preventive vaccine only. Model input parameters and assumptions were
also chosen to reflect the African setting.
The model defines six health states, which differ for males and females, for a total
of twelve states overall. Movement of individuals from the unvaccinated HIV-negative
(state 1) to the vaccinated HIV-negative (state 2) compartment and from the unvaccinated
asymptomatic HIV-positive (state 3) to the vaccinated asymptomatic HIV-positive (state
4) compartment is determined by effective vaccination with an HIV vaccine, whereas
movements in the reverse direction are determined by vaccine protection waning over
time. Movement of individuals from the unvaccinated HIV-negative (state 1) to the
unvaccinated asymptomatic HIV-positive (state 3) compartment and from the vaccinated
HIV-negative (state 2) to the vaccinated asymptomatic HIV-positive compartment (state
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4) is determined by acquisition of HIV infection from a heterosexual partner. Movement
of individuals from the unvaccinated and vaccinated asymptomatic HIV-positive (states 3
and 4) compartments to the symptomatic HIV-positive (state 5) compartment and
subsequently to the AIDS (state 6) compartment is determined by disease progression in
those that become infected with HIV. Other movements between compartments in the
model are not allowed. For model simulations, transitions between the twelve population
subgroups were calculated annually to determine the number of men and women in each
compartment.
Table 2 lists a description of the variables used in the model equations. Table 3 lists
the twelve differential equations that define transitions between various health states in
the model. For example, equation (1) describes the rate of change of the male [ M {j ]
unvaccinated [ j = O'], HIV-negative [ i - 0 ] sexually active population at tim er:
0)

dM{)^
at

=/

-^ v (r)M 00(r)-/M /00(r)-/70AM(OM00(0 + « M 01(r)

This rate depends on the following factors, which are each terms in equation (1): (a)
I M0 0, the number of unvaccinated, HIV-negative males who arrive into the sexually
active population each year upon reaching the age of 17 years; (b) y/v(t)M00( t) , the
number of unvaccinated, HIV-negative males [ M 00 (t) ] who are vaccinated each year
[proportion of the population vaccinated, v{t) ] and in whom the vaccine has an effect
[take, y/ ]; (c) juM 00( t), the number of unvaccinated, HIV-negative males [ M00 (t) ]
who die each year due to non-AIDS related causes [non-AIDS mortality rate, // ]; (d)
P o^ m

(t) , the number of unvaccinated HIV-negative males [M 00(t) ] who
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become infected with HIV [per-partnership probability of an unvaccinated male acquiring
HIV from any female at time t , Xu (t) ] each year from a female partner [number of
female partners per year for an uninfected male, p 0]; and, (e) ct)M0l ( t) , the number of
vaccinated [ j = 1 ], HIV-negative males [ M 0l (t) ] for whom protection from the vaccine
wanes each year [rate of vaccine waning, co ], returning them to the immunologic and
behavioral ‘unvaccinated’ state. Rates of change for other population subgroups are
determined in a similar fashion.
We modeled a heterogeneous population with respect to gender and disease stage
and a homogeneous population with respect to risk behavior and vaccination coverage
(e.g. except for changes in behavior based on vaccination or disease progression, sexual
risk behavior was uniform throughout population subgroups, mixing of sexual
partnerships was random, and vaccination was not targeted to individuals at higher risk of
HIV infection). Models with greater complexity generally confirm the insights gained
from those assuming homogeneous populations1201 and random mixing^721.
We assumed, in accordance with the theoretical framework of McLean and Blower,
that a vaccine could fail to protect an individual from HIV infection in three different
ways[49]. The vaccine might not produce an immunological response in the individual
(imperfect, or less than 100%, take y/ ); in those who produce an immunological
response, the vaccine might provide only partial protection to individuals (imperfect, or
less than 100%, degree, or efficacy s ); and, the duration o f protection (mean duration in

years, M m ) afforded by the vaccine may not last for the entire sexually-active life of the
vaccine recipient. However, because this analysis considered a vaccine with 100% take
and 50 years duration of protection, only imperfect vaccine efficacy is examined as a
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significant source of vaccine failure in the current study. As different combinations of
vaccine imperfections produce different outcomes^491, our model allows for fixture
analyses varying vaccine take and duration, in addition to efficacy.
We assumed that an HIV vaccine protected an uninfected individual from acquiring
HIV infection when exposed to an HIV-positive heterosexual partner and that vaccines
with less than 100% efficacy did not provide complete protection from HIV infection.
We modeled this incomplete protection as partial protection on an individual level, e.g. a
40% effective vaccine ( s = 0.4) would only provide protection from 40% of sexual
partnerships with an HIV-positive partner. As shown in equations (3) and (4) in Table 3,
a partially-effective vaccine reduces the rate of HIV infection by a factor of (1 - e ).
Therefore, a 40% effective vaccine will reduce the probability of HIV infection from
sexual partnerships with HIV-positive individuals to 60%.
As detailed in the model equations, the rate of HIV infection for individuals in the
model depends on the following factors: an individual’s vaccination status, the efficacy
of the vaccine used, the number of sexual partners per year, the probability of choosing
an HIV-positive partner from the population at any point in time, the probability that HIV
is transmitted (infectivity) in a particular partnership, the condom use in a particular
partnership, and the change in male-negotiated condom use behavior that occurs post
vaccination. Table 3 also lists the three equations [fo rlM(t) , XMv (t) and Xw (f) ] that
define the ‘force of infection’, or probability of acquiring HIV from any partner at a
given point in time, to which an uninfected man or woman is exposed.
The force of infection partially depends on the probability of transmission of HIV
from a particular sexual partnership. The probability of HIV transmission per sex act
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varies both within and between sexual partnerships1731. Rather than using infectivity
parameters for the probability of HIV transmission per sex act, we use infectivity
parameters for the probability of HIV transmission over the course of a sexual
partnership. The probability of HIV transmission from a given sexual partnership (for
example, from a female to a male partner) is determined by the likelihood of choosing an
HIV-infected partner [

^

WUj (t)

p tWi J (t) ] and the likelihood of HIV being

transmitted during the course of that partnership [

£ J3Wij ] if an HIV-infected partner
1=1 y'=0

is chosen, both of which depend on the disease stage of the HIV-infected partner, given
all possible potential heterosexual partnerships that exist.
The force of infection also depends on condom use. Condom use is captured by the
term nMi j , which is the probability that a particular sexual partnership between a male
with disease stage i and vaccination stage j and a female (with any disease stage and
vaccination status) is not protected by condoms. This is determined by the baseline
condom use hi 0, the change in condom use as a result of a vaccination program A, and
the likelihood of condom failure / (see Table 2 for equations). Because we assume that
condom use is negotiated by the male in the partnership, only changes in male post
vaccination risk behavior affected condom use in heterosexual partnerships. Therefore,
the force of infection which an unvaccinated, uninfected male experiences includes a
condom use term based only on his own condom use behavior, «M0 0. Similarly, the force
of infection which a vaccinated, uninfected male experiences includes a condom use term
based on his own condom use behavior, which may have changed post-vaccination, nMOl .
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However, the force of infection to be applied to an uninfected female (regardless of
vaccination status) includes a condom use term based on the male condom use behaviors
i=3 7=1

for all of her potential partnerships, I I - * , •
(=1 y=0

HIV transmission was modeled to occur only via heterosexual contact; transmission
from mother-to-child and transmission through blood transfusions, intravenous drug use,
or homosexual contact was not included in the model equations. Epidemics driven by
other routes of transmission, such as injection drug use or men who have sex with men,
would be better addressed with models specifying the particular transmission and risks of
HIV in those populations. Of these alternate infection routes, mother-to-child
transmission is a significant contributor to the HIV epidemic in South Africa. However,
we have allowed for early HIV infection in the model by specifying that a proportion of
arriving 17-year olds are already HIV-positive. Adolescents who were infected through
mother-to-child transmission at birth and who have not yet succumbed to AIDS, as well
as adolescents who acquired HIV through early sexual activity, are included in this
group.
HIV transmission was modeled on a per-partnership basis; thus, rates of HIV
transmission were used for the probability of transmission over the entire duration of a
partnership between a male and a female, rather than on a per-contact or per-sex act
basis. We assumed uniform HIV transmission risk across different partnerships, such
that having very risky sex in a partnership (because of chosen partner, type of sex act, or
use of condoms) just a few times might be equivalent to having less risky sex many times
in a different sexual partnership1741. For the per-partnership probability of HIV
transmission calculations, we used MTF and FTM transmission data from serodiscordant
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monogamous couples in rural Uganda[18,50], calculated person-years of follow-up time,
and assumed that transmissions per person per year in a serodiscordant monogamous
sexual relationship would accurately estimate transmissions per partnership per year.
Although European and North American data have indicated that HIV infectivity
from MTF is greater than from FTM, African studies have shown that infectivity either is
equal from MTF and FTM, is greater from FTM than MTF, and/or is instead dependent
on other factors such as age, viral load, genital ulceration, pregnancy, circumcision, and
type of sexual partnership (monogamous vs. casual partner)1-18,50,52'56]. Because of these
other factors, the apparent geographic differences in infectivity data can be partially
resolved (1) by the observation that viral loads in females are significantly lower than in
males for similar disease stages, (2) by the high rate of circumcision in Western
populations, which decreases FTM HIV transmission, and (3) by the varying degrees of
condom use between studies. Due to the discrepancies in the literature, we performed
additional sensitivity analyses in which the MTF and FTM infectivity parameters were
exchanged. We also assumed that males in the model were not circumcised, an issue
which we have addressed elsewhere [Dissertation Paper 4].
We used an HIV viral load of 38,500 copies/mL to distinguish asymptomatic HIV
infection from symptomatic infection, and derived an asymptomatic infectivity parameter
which is 41% of the symptomatic infectivity parameter using this assumption. While
viral load does not directly correlate with clinical HIV symptoms—the same viral load
can result in various ranges of clinical symptoms for different individuals—the viral load
point we used as a cutoff value resulted in an infectivity ratio between asymptomatic and
symptomatic infection which closely approximates ratios from other studies of 39-45%
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using different methodology151,52,711.
Using the Ugandan data and the calculations described above, we derived an
infectivity parameter for asymptomatic and symptomatic MTF transmission probabilities
of 0.07 and 0.17 per sexual partnership per year, respectively. While these values appear
relatively high, a smaller study of MTF transmission in the same Ugandan population
showing that pregnant women were at a two-fold increased risk for HIV infection
revealed that married pregnant women in serodiscordant relationships with HIV-positive
partners became infected with an overall probability of 0.15 per person per year[54].
Because 96% of the women in the study reported never using condoms and couples who
were married reported few extra-marital partners, the transmission data were fairly
reliable and agree with the magnitude of transmission parameters we calculated. We
derived infectivity parameters for asymptomatic and symptomatic FTM transmission of
0.11 and 0.27 per sexual partnership per year, respectively. Although a study on FTM
HIV transmission in a high risk cohort of Kenyan truck drivers reported FTM HIV
infectivity of 0.0128 per coital act for uncircumcised men[531, transmission probabilities
for individual sex acts can not be correlated with transmission probabilities over the
course of a sexual partnership. We performed sensitivity analyses on the symptomatic
FTM infectivity parameter due to its relatively high value and the lack of additional
African transmission studies.
We modeled a stable population size over time except for deaths due to AIDS. In
the simulation, men and women join the sexually active, heterosexual population upon
reaching the age of 17 years, defined as the age by which all individuals are sexually
active^4-471. These new arrivals enter the model at a constant rate (determined by the
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number of men and women who die due to non-AIDS-related causes) into the uninfected
or HIV-infected asymptomatic compartment populations. We assumed that no one was
vaccinated prior to the age of 17 years. Some individuals will have already been infected
with HIV; we estimated that 3% of 17-year-old males and 10% of 17-year-old females
would be HIV-positive145'47,751. Acquisition of HIV infection prior to the age of 17 years
(and therefore prior to entry into the model’s compartment populations) may have
occurred through mother-to-child transmission or other means such as early sexual
activity, as described above. We assumed that all of the arriving HIV-positive 17-yearolds would still be in the asymptomatic stage of the disease, because they either acquired
the infection recently or because individuals infected at birth through mother-to-child
transmission that have developed AIDS would no longer be alive, and that disease
progression to symptomatic HIV and further to AIDS would not occur until after entry
into the model. Individuals can leave the model from any population subgroup due to
non-AIDS mortality, or from the AIDS subgroup population due to AIDS-related death.
We assumed equal numbers of men and women in the initial population. We
assumed that the percentage of people initially in each HIV disease stage was
proportional to the time spent in that stage. We assumed that the vaccine would provide
equal protection against all HIV subtypes. Because we assumed that the vaccine
impacted only on initial HIV transmission, but had no effect on disease progression or
infectivity (such as through a reduction in viral load) in those that became HIV infected
either before or after vaccination, we have not described the vaccinated symptomatic
HIV-positive and AIDS states as separate from the unvaccinated symptomatic HIV-
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positive and AIDS states, respectively, or their respective infectivity values, despite the
model allowing for such differentiation.
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TABLE 2 (APPENDIX). Definition of model variables
Symbol

Description of variable
Disease stage (/)
Uninfected (HIV-negative)
Infected (HIV-positive) asymptomatic
Infected (HIV-positive) symptomatic
AIDS
Vaccination status (/)
Unvaccinated

/=0
i=l
i =2
i =3
j =o
y=i

Vaccinated
Disease-stage specific variables
Number of men in disease stage /' with vaccination status j at time t

M UJ(t)

Number of women in disease stage /' with vaccination status j at time t

Wuj(t)

Probability of a male acquiring the infection at time t from any one female partner

^ m (0

Probability of a male acquiring the infection at time t from any one female
partner, under behavior modifications due to male vaccination
Probability of a female acquiring the infection at time t from any one male
partner, regardless of female vaccination status
Per-partner infectivity (chance of transmitting HIV) of a male in disease stage /'
with vaccination status j
Per-partner infectivity (chance of transmitting HIV) of a female in disease stage i
with vaccination status j
Contact rate (number of new partners/year) of males, females in disease stage /

^Mv (0

^w(0
P M i,j

P w i,j

P i

Mean duration (in years) of disease stage / under vaccination status j

11PiJ

Annual immigration of males in disease stage /' with vaccination status j

^ M iJ

Annual immigration of females in disease stage /' with vaccination status j

I W i, j

Probability a partnership between an uninfected, unvaccinated male and a
female with disease stage /, vaccination status j is not protected by condoms3
Probability a partnership between an uninfected, vaccinated male and a female
with disease stage /, vaccination status j is not protected by condoms3
Probability a partnership between an uninfected female (regardless of
vaccination status) and a male with disease stage /', vaccination status j is not
protected by condoms3
Population variables
Non-AIDS-related annual death rate
Preventive-vaccine variables
Annual percent of uninfected or asymptomatic HIV+ males or females who
receive preventive vaccine
Vaccine take (proportion of vaccinated in whom immune response stimulated)

n M 0,0
n M 0 ,l

n Mi,j

M
v(t)
V

e

Vaccine efficacy (percent of partnerships protected from infection)
Mean duration (in years) of vaccine protection

a nMij = fS ij + (1 “ g hJ) . w here g i 0 = hi 0 and g t l = Ahj 0[f
partnerships;

hi 0 =

1/

co

= condom failure rate for all

baseline condom use for all partnerships, with no vaccination program;

A=

change in

condom use after vaccination; g t j = condom use for all partnerships, following program implementation]
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TABLE 3 (APPENDIX). Model equations3
State Equation

JM oo(0 = J
_
(?) _ jjM (7 ) _ p x (t)M00 (t) + coM0, (?)
at
dW0J t)
(2)
_^>w =j
_w m
(t) _ p W {t) _ p k w (t)W0fi (?) + coW0, (t)
at
dMn, (t)
(3 )
— j — = i//v(t)M00( 0 - fjM 0, ( 0 - p 0(1 - s)AUv ( O M 0a ( 0 - coM0, ( 0
at
dW01(t)
(4)
= ^ v ( 0 ^ o (0 - ^
(0 - P o ( l - S ) K ( tW v (0 (0
dt
dM, n(?)
(5 )— J — = I m\,o~ V^(t)Muo(t) - nM , 0(t) + p 0AM(t)M00 (t) + coMu (0 - p l0M lfi

(1)

(g)d W

= Idt
wifi - yv(!W\fi (0 - PWi,o(0 + PoK (tWofi (0 +

(t)

(0 - M,0 ^ 1,0 (0

dM ,, it)

(7)— j — = y/vit)Ml 0it) - juM,, it) + P q(1 s )AMvit) M 0, ( 0 - coMxxit) - p u M u ( 0

(8)
(9)

(11)

dt
dWxM)
= ¥ vit)WXfi it) - pWu it) + p 0( l - s)Awit)Wv it) - coWxxit) - p hXWu it)
at
dM2J t)
M
----J,----= 1Mlfi + 2
(0 ~
2,0(0 - PlfiM 2,0(0
“t
y=o
dW,„(l)
H
dt
j—
Q
dM, 0(?)
----A---= ^ 0^2,0 (0 - MM3j0(?) - /?3,0M 3,0(0
dt

(12)

dW3J t)
- ^ 1 = p. W (,) _ p W (t) - p
dt
nM0,0^

PiPwiJ^ij it)

( 1 3 ) ,( 1 4 )

* * ( ? ) = ---------- ^

--------------------------

I I / W
i=o

j=o

W ^

nMQ,l ^ j ] PiPwi,j^i,j (0
,

^

v (? ) = ------------------------------------------------

XXpW jio

O

(=o y=o

i=3 ]=1
Y ^ nMi,}PlPMl,jM ,,jit)
(15)
V 0 = --^3
-----------------t.t.p M .jit)
________________________i=0 y^o_____________________________________________________________
a Model equations adapted from O w ens e t at. and Edwards e t a!., 1998
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PAPER 4

The Potential Benefits o f Expanded Adult Male Circumcision
Programs in Africa: Predicting the Population-Level Impact on
Heterosexual HIV Transmission in Soweto
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INTRODUCTION
Twenty-five years into the HIV/AIDS epidemic, 11,000 new infections are still
occurring globally every day111. Although research into preventive tools including
vaccines and microbicides is promising, large-scale implementation of these technologies
is years away. In addition to maximizing the impact of current HIV prevention and
education campaigns, new effective HIV prevention technologies are needed to fight the
epidemic. Recent studies have identified male circumcision, practiced for cultural and
religious reasons in certain populations for centuries, as a novel potential HIV prevention
strategy which could be implemented immediately.
The role of circumcision in reducing heterosexual HIV transmission was first
proposed in the scientific literature 20 years ago[2]. Since that time, a number of
ecological and cohort studies, largely in sub-Saharan Africa, have proposed a relationship
between HIV prevalence or HIV transmission and male circumcision status[3'12]. These
studies laid the foundation for a formal evaluation of the impact of circumcision on
female-to-male (FTM) HIV transmission in three large randomized controlled trials of
adult male circumcision conducted in Kenya, Uganda and South Africa. The first results
came from the South African trial when interim analysis showed that circumcision
decreased FTM transmission of HIV by 61% (95% Cl 34%-77%); the trial was halted on
ethical grounds, allowing all participants to undergo circumcision[13]. Recently8, the
other two trials were also halted when interim analyses showed a decrease in FTM HIV
transmission of 53% in the Kenyan trial and 48% in the Ugandan trial[14].
8 The announcement to halt the circumcision trials in Kenya and Uganda on December 13, 2006 had just
been made at the time o f writing. At that point no further trial results beyond estimates o f efficacy were
available. Both studies were subsequently published on February 24, 2007, during the final drafting o f this
dissertation, in the Lancet. In general, the discussion presented here remains the same, except for the
observation that the trials in Kenya and Uganda found no evidence o f increased risk-taking behavior.

- 138 -

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

In addition to being highly effective, adult male circumcision has been shown to be
safe, affordable, and culturally acceptable to men in many African countries including
South Africa, Malawi, Kenya, Zimbabwe, Uganda, Swaziland, and Botswana113'221. One
modeling study has shown that male circumcision has the potential to prevent millions of
infections across sub-Saharan Africa and decrease HIV prevalence in both men and
women1231. Another study has shown that male circumcision will be a very cost-effective
intervention for HIV prevention in South Africa1241. Yet the success of male circumcision
programs is not guaranteed—as with any partially-effective HIV prevention program, it is
possible that sexual risk behavior might change in response to the intervention, thus
increasing or decreasing the potential benefits of that program1251. Although no analyses
of risk behavior have yet been reported for the Kenyan and Ugandan trials, there was a
moderate increase in risk behavior during the South African trial1131, and we are unable to
predict what might occur outside of clinical trial conditions in an expanded circumcision
program1261. One prospective study in Kenya found no behavioral disinhibition for the
first year in men who underwent voluntary circumcision1271, but whether this represents
permanent and widely applicable behavior patterns in light of the recent public awareness
of male circumcision and HIV prevention remains to be seen.
Governments and international health policy makers are now considering the
addition of large-scale expanded adult male circumcision programs to their current
arsenal of HIV prevention packages128'361. However, because the field is fairly new and
data on outcomes of large circumcision programs will not be available for many years,
there is relatively little information upon which to base policy decisions regarding how
best to implement expanded adult male circumcision programs. In the absence of such
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information, further capacity for potential program evaluation is needed, in particular for
the specific African HIV transmission dynamics within local populations where these
programs will likely be implemented.
We developed a mathematical model9 to examine the potential impact of expanded
adult male circumcision programs in Affica[37]. We selected input parameters to simulate
the late-stage, high-prevalence HIV epidemic in the township of Soweto, South Africa as
an example. Soweto is located southwest of Johannesburg and close to the community of
Orange Farm, where the first male circumcision trial was conducted. We performed
simulations to explore the outcomes of various circumcision programs that could be
implemented, and varied the effectiveness of circumcision in reducing transmission,
program coverage levels, and post-circumcision changes in risk behavior. We assessed
the impact of each of these programs on heterosexual transmission of HIV, and compared
them in terms of HIV infections prevented and changes in population HIV prevalence.

9 Partial data from this manuscript have been previously reported at the XVI International AIDS
Conference (Toronto, 2006).
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METHODS
We created an epidemic model to explore the effects of present circumcision levels
on predicted trends in HIV prevalence and to simulate the impact of expanded adult male
circumcision programs on the HIV epidemic in a population at high risk for
heterosexually transmitted HIV in Soweto, South Africa.
Model description
We formulated the present model to examine the influence of male circumcision on
HIV transmission. The design incorporates characteristics of prior models of HIV
disease^38-421 and includes factors specific to modeling the HIV epidemic in Africa such as
predominantly heterosexual HIV transmission, limited knowledge of HIV infection
status, and gender differences in circumstances surrounding sexual risk, which we have
previously described [Dissertation Paper 3].
The model specifies ten ‘compartments’ or ‘states’ to simulate the process of
heterosexual HIV transmission and disease progression in a population of sexually active
adults. These include HIV-negative females (1), uncircumcised males (2), and
circumcised males (3); asymptomatic HIV-positive females (4), uncircumcised males (5),
and circumcised males (6); symptomatic HIV-positive females (7) and males (8); and,
females (9) and males (10) with AIDS. For this study, we combined the circumcised and
uncircumcised male compartments for both the symptomatic HIV-positive and AIDS
states (see Appendix for further details). Individuals join the model population by
entering into one of the first six compartments, and can leave the model population as a
result of either non-AIDS or AIDS-related mortality. Transitions between these
compartments or population subgroups are defined by a set of ten deterministic
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differential equations which specify the rates of movement for the individuals in the
model. A detailed description of model assumptions, parameters, and equations can be
found in the Appendix.
Effects of circumcision
We incorporated current levels of male circumcision in South Affica[43,44] into both
the initial and arriving populations of sexually active males who were HIV-negative or
asymptomatic HIV-positive. We also incorporated the biological effect of circumcision
on heterosexual transmission of HIV in the model. HIV-negative men who are
circumcised are protected from HIV infection in sexual partnerships with HIV-infected
women a certain proportion of the time, which is the protective effect. Therefore, if the
protective effect of male circumcision were 75% for example, circumcised HIV-negative
men would then be protected from HIV infection in 75% of heterosexual partnerships
with infected women.
We modeled only a reduction in HIV transmission for circumcised HIV-negative
males who have HIV-positive female partners. Although in theory it is possible that male
circumcision may also reduce HIV transmission from circumcised HIV-positive males to
their HIV-negative female partners, we have not incorporated this potential reduction
because a clinical trial to address this question is still under way in Uganda[45]. However,
the model can be adapted to explore this question when the trial is completed10 by
incorporating any male-to-female (MTF) transmission effects of circumcision that are

10 Although the trial in Uganda to assess whether circumcision protected males from infection due to
decreased female-to-male (FTM) transmission has been completed, a separate trial to assess whether
circumcision protects females from infection due to decreased male-to-female (MTF) transmission is still
under way.
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found and by adding additional compartments specifying the circumcised and
uncircumcised HIV-positive symptomatic states.
For our simulations, we used a protective effect from circumcision based on results
from the first randomized controlled trial of circumcision in Africa^131 and performed
additional sensitivity analyses on several possible values for this effect, approximating
the confidence intervals for the trial data. We modeled expanded circumcision programs
which targeted asymptomatic uncircumcised males aged 17 or older without testing them
for HIV, therefore both HIV-negative and asymptomatic HIV-positive males would be
eligible for circumcision while males with symptomatic HIV or AIDS would be
ineligible.
Effects of risk behavior
Individuals could change their sexual risk-taking behavior as a result of the
implementation of a large-scale program for male circumcision. Men targeted in an
expanded circumcision program might increase their risky behavior because they feel
protected following circumcision or they might decrease their risky behavior as a
response to the risk-reduction counseling that may be given in a mass campaign. Men
previously circumcised as infants/youths or before the start of the program might also
increase or decrease their risky behavior in a similar manner, even without participating
in the program. Women, on the other hand, might increase or decrease their risky
behavior because they feel that their male partners have a lower or higher probability of
being HIV-infected, respectively, depending on their circumcision status. Uncircumcised
men might also change their risk behavior due to the general notion that the risk for HIV
infection is decreasing as a result of increased population circumcision prevalence, an
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effect which could extend to all men and women irrespective of personal or partner
circumcision status. Finally, all men and women might change their risk behavior as a
result of the media and public health education outreach programs surrounding the
implementation of an expanded program for adult male circumcision.
A change in risk behavior can be modeled as either a change in the number of sex
partners, a change in the type or number of risky sex acts, or a change in the usage of
protective measures, such as condoms. In our analyses, we modeled the potential effect
of circumcision on behavior by exploring changes in levels of condom use. We
examined changes in condom use for all circumcised men, irrespective of whether they
were circumcised in the expanded program or elsewhere. While it is possible, as
discussed above, that women and uncircumcised men might also change their behaviors,
we assumed behavior change in circumcised males to be the primary influence on
population changes in sexual risk behavior. We modeled exclusive male-negotiation of
condom use in heterosexual partnerships in Soweto [Dissertation Paper 3], as studies
have shown that there are significant imbalances in the ability of South African women
to negotiate condom use with men in sexual partnerships146491. By employing condom
usage levels to explore changes in risk behavior, we were also able to capture this gender
difference.
Simulations
Because most HIV models do not account for the transmission effect of
circumcision, we first simulated the predicted trends for adult HIV prevalence in Soweto
over the next 20 years with and without considering the reduction in HIV transmission
due to current rates of male circumcision. Incorporating current rates of adult male
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circumcision, we then conducted simulations for various expanded circumcision
programs which were implemented for a period of 5 years. We evaluated the effects of
these programs by examining the total number of HIV infections averted (estimated to
the nearest 1,000) and the change in population HIV prevalence (estimated to the nearest
1%) over a 20-year period. To calculate these values, we compared model outputs from
the circumcision program simulation with baseline outputs from a simulation without an
expanded circumcision program. Because predicted infections without circumcision
programs varied according to the population effects of reduced HIV transmission due to
existing prevalent circumcision, baseline outputs for simulation comparisons were
configured for each value of the reduction in HIV transmission due to circumcision used
in the model.
We also simulated scenarios in which risk behavior changed following circumcision
program implementation by varying condom use in circumcised males. Finally, we
explored varying levels of program coverage levels and changes in male condom use for
several values of circumcision efficacy to assess the tradeoff between the true impact on
HIV transmission of male circumcision, the program coverage level achieved, and the
potential for changes in risk behavior with implementation of circumcision programs.
We used Excel® 2003 spreadsheet software (Microsoft Corporation, Redmond WA) for
all model simulations and calculated transitions between various compartments in the
model on an annual basis.
Input parameters and assumptions
We used published data sources for the majority of input parameters incorporated
into the model (Table 1). We used a 61% reduction in FTM HIV transmission for
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circumcised males[13] and assumed that the protection afforded by circumcision would
last for the lifespan of that individual. We did not model a reduction in MTF HIV
transmission for female partners of circumcised males. We performed sensitivity
analyses incorporating circumcision-related reductions in FTM HIV transmission of 20%,
40%, 60%, and 80% to encompass the 95% confidence intervals (34%-77%) from the
South African circumcision trial[13]; confidence intervals for the Kenyan and Ugandan
trials have not yet been published. For some analyses, we also explored circumcisionrelated reductions in FTM HIV transmission of 0% to 100%. We incorporated baseline
male circumcision levels of 35%[43,44] into the model, and performed additional
sensitivity analyses for baseline circumcision levels of 0% and 100% to examine the
influence of initial population circumcision prevalence on program outcomes. We
explored the impact of expanded circumcision programs which targeted an additional 1020% of uncircumcised males each year, with additional sensitivity analyses on all
possible values for program coverage levels. Because circumcision would be done
without testing for HIV, we used the same program coverage levels for uninfected and
asymptomatic infected uncircumcised men. For simulations which considered changes in
risk behavior, we also explored all values (0-100%) of post-circumcision program malenegotiated condom use.
We assumed an anti-retroviral (ARV)-naive population because provision of ARV
therapy in the population covered by the public-sector health system in South Africa is
extremely low at present[50], and thus did not incorporate a reduction in transmission or
increase in length of disease stage for members of the population receiving ARV therapy.
We considered only heterosexual transmission of HIV in this analysis, as it is the

-146 -

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

predominant mechanism for adult HIV transmission in South Africa. We varied the
sexual risk behavior between population subgroups according to disease stage for the
number of sex partners per year and according to gender and circumcision status for
condom use, but did not incorporate further risk stratifications of sexual behavior.
Details on the rationale used for estimates of input parameters which define other
population characteristics, sexual risk behavior, HIV transmission, and disease
progression have been reported elsewhere [Dissertation Paper 3]. Further details on the
rationale and assumptions underlying the model specifications are provided in the
Appendix.
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RESULTS
We first simulated the predicted trends in adult HIV prevalence over the next 20
years in Soweto without considering the reduction in HIV transmission due to current
rates of male circumcision (Figure 1A). The female population HIV prevalence would
increase from 20% to 21% and the male population HIV prevalence would increase from
12% to 25%. The model predicted a total of 318,00 new infections (127,000 female
infections and 191,000 male infections) would occur over this time period. We then
incorporated the reduction in HIV transmission due to current rates of male circumcision
and again simulated the predicted trends in adult HIV prevalence over the next 20 years
(Figure IB). Assuming current levels of male circumcision remain constant and a 61%
reduction in FTM HIV transmission for circumcised males, the female population HIV
prevalence would decrease from 20% to 17% and the male population HIV prevalence
would increase from 12% to 17%. The model predicted 102,000 new female infections
and 142,000 new male infections would occur over this time period. All subsequent
analyses used this model incorporating the HIV transmission effects of circumcision and
current rates of male circumcision as a baseline, although some analyses varied the
reduction in FTM HIV transmission for circumcised males.
We then considered the impact of various 5-year expanded adult male circumcision
programs which targeted an additional percentage of the uncircumcised male population
each year. A program targeting 10% of the uncircumcised adult male population each
year for five years would result in a decrease in predicted HIV prevalence in 20 years
from 17% to 15% for the female population and from 17% to 14% for the male
population (Figure 2A). If instead the program targeted an additional 20% of the
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uncircumcised adult male population each year for five years, the decrease in predicted
HIV prevalence would be more substantial. In 20 years, predicted HIV prevalence would
decrease to 13% for females and 12% for males (Figure 2B). We next calculated the total
number of new HIV infections prevented over a 20-year period by these programs. The
circumcision program with a 10% coverage goal would avert 11,000 female infections
and 22,000 male infections (Figure 3A), while the program with a 20% coverage goal
would avert 18,000 female infections and 36,000 male infections (Figure 3B). For both
program coverage goals, 33% of the total infections prevented over 20 years would be in
females; and, looking at the long-term benefits of these programs, the proportion of
female infections prevented increased to 40% over 50 years.
We also simulated scenarios in which sexual risk behavior changed following
implementation of expanded circumcision programs for circumcised males. We
examined behavior change only in circumcised males, including both those circumcised
under the expanded program and those who had been circumcised previously. If sexual
risk behavior decreased post-circumcision program implementation and condom use were
to increase by 25% (corresponding to an absolute increase in condom use from 50% to
62.5% in circumcised males), then the benefits of the programs would be substantially
greater. The 10% coverage program would avert 21,000 female infections and 33,000
male infections over 20 years (Figure 4A) and the 20% coverage program would avert
30,000 female infections and 49,000 male infections over 20 years (Figure 4B). If
instead sexual risk behavior increased post-circumcision program implementation and
condom use were to decrease by 25% (corresponding to an absolute decrease in condom
use from 50% to 37.5% in circumcised males), then the benefits of the programs would
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lessen substantially and would even cause additional HIV infections. Over 20 years, the
10% coverage program would prevent 9,000 male infections but result in a net additional
1,000 female infections (Figure 4C); the 20% coverage program would prevent 20,000
male infections and 4,000 female infections, despite an initial period of increased
infections in the female population (Figure 4D).
We performed additional analyses for programs with 10% and 20% coverage goals
and risk behavior changes of up to 100% in which the protective effect of male
circumcision was varied from 20% to 80%. Infections prevented were calculated as
compared to a situation in which no expanded circumcision program was implemented;
however, the number of infections expected in the absence of circumcision programs
varied due to the baseline population effects of circumcision on HIV transmission. Over
20 years, the number of infections expected if baseline population circumcision levels
remain constant for circumcision protective effects of 20%, 40%, 60%, and 80% would
be: 295,000 (20%), 271,000 (40%), 246,000 (60%), and 220,000 (80%). These numbers
decrease with increasing ability of circumcision to reduce transmission of HIV in the
population.
Our simulations to increase population circumcision levels with modest expanded
adult male circumcision programs produced a wide variety of program outcomes, positive
and negative (Table 2). As might be expected, both increasing condom use and
increasing program coverage always increases the number of infections prevented for a
given level of circumcision protective effect. However, as the magnitude of the
circumcision protective effect increases, the number of infections prevented can increase
or decrease depending on the magnitude of the change in condom use. While increases in
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circumcision protective effect generally lead to increases in the number of infections
prevented by a given program, increases in condom use of ~50% or greater over baseline
levels can lead to fewer opportunities for additional prevention with increasing
circumcision protective effect (Figure 5). This potentially counterintuitive result is due in
large part to the baseline levels of circumcision in the population and the fact that we are
reporting an incremental outcome measure. Unlike the results from vaccination
simulations [Dissertation Paper 3], the results from circumcision program simulations
differ because (1) there are baseline levels of circumcision (35%) in the population before
adding on expanded circumcision programs, and (2) because of this, the model must be
recalibrated to calculate infections prevented each time the efficacy of circumcision
protective effect changes.
The outcome measure we report in Table 2 and Figure 5 is the number of infections
prevented by a given circumcision program. It is the difference, or “delta value”,
between the number of infections expected given baseline levels of 35% circumcision
prevalence (hereinafter referred to as Value A), and the number of infections expected
under a policy of expanded circumcision (Value B). While both Values A and B
decrease for increasing levels of condom use and for increasing protective effects of
circumcision, as would be expected, the delta value behaves differently. For a given
level of circumcision protective effect, increases in condom use always produce increases
in the delta value. For a given level of condom use, though, the delta value rises with the
circumcision protective effect at decreased and moderate increases in condom use, but
falls with increasing circumcision protective effect at high increases in condom use.
While it might appear that increasing circumcision efficacy makes matters worse in terms
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of infections prevented, this is not the case. Rather, there are fewer infections to be
prevented by an expanded circumcision program when circumcision efficacy increases,
because an increase in circumcision efficacy lowers HIV transmission in the population
already circumcised at baseline. Therefore the delta value might rise or fall as
circumcision efficacy increases, depending on the interaction between the level of
condom use and the baseline circumcision prevalence in the population.
To further our understanding of this somewhat counterintuitive effect, we
performed additional simulations in which we varied the levels of baseline circumcision
prevalence in the male population to extreme values (we used a 10% program coverage
value for these simulations). We first considered the example of no males circumcised at
baseline prior to program implementation (0% baseline circumcision prevalence): The
number of infections expected without expanded programs [Value A] by efficacy was
318,000 (20%), 318,000 (40%), 318,000 (60%), 318,000 (80%). With an expanded
program and no change in condom use, the number of infections prevented [delta value]
by efficacy was 17,000 (20%), 35,000 (40%), 54,000 (60%), 74,000 (80%). With an
expanded program and 100% increase in condom use, the number of infections prevented
[delta value] by efficacy was 94,000 (20%), 97,000 (40%), 100,000 (60%), and 104,000
(80%). In this situation with no baseline circumcision, the number of infections expected
without a program was a constant irrespective of efficacy (since no males were
circumcised) and the number of infections prevented by a program always rose for
increasing efficacy of circumcision (although the increase was not as dramatic at high
levels of condom use).
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We next considered the example of all males circumcised at baseline prior to
program implementation (100% baseline circumcision prevalence): The number of
infections expected without expanded programs [Value A] by efficacy was 263,000
(20%), 207,000 (40%), 153,000 (60%), 101,000 (80%). With an expanded program and
no change in condom use, the number of infections prevented [delta value] by efficacy
was 650 (20%), 1,200 (40%), 1,700 (60%), 2,000 (80%). With an expanded program and
100% increase in condom use, the number of infections prevented [delta value] by
efficacy was 201,000 (20%), 153,000 (40%), 106,000 (60%), 61,000 (80%). In this
situation with all men circumcised at baseline, the number of infections expected without
a program declined rapidly with increasing circumcision efficacy. The number of
infections prevented by a program with no change in condom use was almost zero, as all
males were already circumcised. (The small numbers of infections prevented in this
scenario were due to immigration of new sexually active uncircumcised males into the
population.) Because all males were already circumcised at baseline, the number of
infections prevented was dominated by condom use—but the number decreased with
increasing circumcision efficacy because of the decreasing numbers of infections
available to prevent. Given these two extreme examples, we have shown that there is a
natural switch from increased infections prevented to decreased infections prevented for
increasing circumcision efficacy at higher levels of condom use, as seen in Table 2 and
Figure 5 in the original 35% baseline circumcision prevalence case. In summary, the
benefits of expanded circumcision programs are reduced when the circumcision efficacy
is high and baseline levels of circumcision are already successful at preventing infections.
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Returning to the baseline population circumcision prevalence of 35% and to further
explore these variations in program outcomes, we analyzed all possible combinations of
different program coverage levels and post-program implementation changes in risk
behavior for various levels of circumcision protective efficacy to determine which
programs would be beneficial and which programs might be potentially harmful. While
all circumcision programs in which condom use increased would be beneficial, many
circumcision programs in which condom use decreased would still be beneficial,
regardless of whether the program coverage level was moderate or high (Figure 6)11.
This was particularly true for higher levels of circumcision protective effect.
We then explored the relationship between program coverage level and risk
behavior change for specific levels of circumcision protective effects in greater detail
(Figure 7). If the reduction in FTM HIV transmission due to male circumcision was only
20%, expanded adult male circumcision programs would have a minor impact if condom
usage levels remain the same, regardless of the program coverage level (Figure 7A).
However, these programs would be very sensitive to changes in condom use, with even
small decreases in condom use leading to increased infections. If the reduction in FTM
HIV transmission due to male circumcision was 40%, the program would be less
sensitive to small changes in condom use and more sensitive to the lower values of
program coverage (Figure 7B). If the reduction in FTM HIV transmission due to male
circumcision was 60%, lower program coverage levels would be needed and further
decreases in condom use could be tolerated while still providing a net program benefit
11 While the graphs in Figures 6 and 7 demonstrate areas o f program combinations resulting in increased
versus decreased infections, they do not indicate the magnitude o f these outcomes. Therefore, a program
that prevented 1,000 infections and a program that prevented 100,000 infections would both be labeled
‘decreased infections’.
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(Figure 1C). Finally, if the reduction in FTM HIV transmission due to male circumcision
was 80%, most programs would be beneficial irrespective of coverage level or decreases
in condom use (Figure 7D).
Regardless of the true reduction in transmission due to male circumcision, all
programs which generated an increase in condom use post-circumcision would be
beneficial in terms of infections prevented. For programs which generated a decrease in
condom use post-circumcision, whether a particular program was helpful or harmful was
sensitive to the amount of decreased condom use, the program coverage level, and the
true impact of circumcision on HIV transmission.
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DISCUSSION
We designed a mathematical model to simulate the process of adult heterosexual
HIV transmission which incorporates the effects of male circumcision on FTM HIV
transmission. We chose model input parameters to simulate the HIV epidemic, including
existing levels of male circumcision, in the population of Soweto, South Africa. To
approximate HIV transmission conditions in the African setting, the model design also
specified a gender difference in the ability of women to negotiate safe sex with their male
partners [Dissertation Paper 3]. We simulated the potential impact of expanded adult
male circumcision programs on the HIV epidemic in Soweto, considering different levels
of program coverage goals, protective effects of male circumcision, and changes in risk
behavior. In particular, we examined the dynamic interaction between reduced
susceptibility to HIV infection and subsequent behavioral disinhibition following the
implementation of expanded adult male circumcision programs.
We have shown that the reduction in HIV transmission due purely to current rates
of male circumcision is significant, even without an active effort to expand circumcision
programs, and that male circumcision is already having a tangible impact on the HIV
epidemic. Because the effects of male circumcision substantially affect predicted
outcomes, they should be routinely included in all HIV epidemic models for populations
which practice circumcision and for which heterosexual transmission is the predominant
mode of HIV spread. Additionally, epidemic models which simulate the potential
benefits of expanded circumcision programs must take into account the existing benefits
due to current male circumcision prevalence when estimating the additional impact of
various program scenarios.
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We estimated that modest 5-year expanded circumcision programs with only 1020% coverage goals could produce substantial benefits in terms of infections prevented
over a wide range of values for the effect of circumcision on HIV transmission. Even
though circumcision was modeled to reduce only FTM HIV transmission, a substantial
number of infections would be prevented in women nonetheless as a result of decreased
HIV infections in men. Over twenty years, one-third of all infections prevented by
programs with 10% and 20% coverage goals would occur in the female population.
However, the magnitude of benefits from modest circumcision programs was sensitive to
changes in sexual risk behavior, which we approximated with changes in condom use.
Increased condom use would naturally lead to augmented program benefits but decreases
in condom use would lead to decreased program benefits, while severe decreases in
condom use could lead to a program being potentially harmful by resulting in increased
HIV infections.
Still, the majority of potential program scenarios resulted in a positive net value for
the number of infections prevented. Although more infections would be prevented in
males, infections would also be prevented in females indirectly due to the decrease in
male population HIV prevalence afforded by the circumcision programs and these
discrepancies would diminish over time. However, the discrepancy between benefits to
women versus men became potentially harmful when examining programs resulting in
risk behavior change. For simulations in which risky sexual behavior increased
following program implementation, women might experience a greater number of HIV
infections over 20 years. This could occur despite a positive value for the total infections
prevented because of the difference in magnitude between the outcomes of the program
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for men and women. For this reason, programs must be evaluated on the basis of their
individual benefits to both male and female populations. For the majority of potential
changes in risk behavior, though, transmission of HIV to females was decreased for a
wide variety of program scenarios—although the benefits to females were quantitatively
less than the benefits to males.
Prior to the recent trials of circumcision, most observational studies suggested
protective effects of circumcision clustering around 50%[4,5]. The reduction in FTM HIV
transmission of 61% (95% Cl: 34%, 77%) due to male circumcision used in our analyses
for Soweto was based on the only published randomized controlled trial of adult male
circumcision to date, which was a single site study conducted nearby in Orange Farm, a
similar community in South Africa1-131. The other two trials in Kenya and Uganda have
just been halted, with preliminary results reported as 53% and 48% reductions in FTM
HIV transmission, respectively1141. While circumcision likely reduces other sexually
transmitted infections which in turn contribute to a reduction in HIV transmission, this
effect is likely minimal compared to the effect of circumcision on HIV transmission
itself1511. The true effectiveness of circumcision in preventing HIV transmission likely
lies within the range reported in these three trials, but might vary in other populations and
non-trial conditions. For these reasons, we also explored values for the reduction in FTM
HIV transmission from 20% to 80% which encompass the confidence intervals reported
in the Orange Farm trial. We found that for very low reductions in transmission due to
circumcision (e.g. 20%), the impact of expanded male circumcision programs would be
minimal, regardless of coverage levels, and changes in condom use would ultimately
determine whether the program will provide a net benefit. On the other hand, for high
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reductions in transmission due to circumcision (e.g. 80%), the impact of expanded male
circumcision programs was significant and changes in condom use would have much less
influence on determining whether the program provides a net benefit. Further, high
levels of reductions in transmission due to circumcision allowed programs with even
minimal coverage levels to tolerate large decreases in condom use while still providing a
net benefit.
Because of gender discrepancies in the protective effect of this intervention,
circumcised males receive a direct benefit due to the protective effect of circumcision,
while females receive only an indirect benefit from reduced population HIV prevalence.
Further, because we modeled condom use in sexual partnerships to be determined by
males, changes in sexual risk behavior for men receiving the intervention of circumcision
directly correlated with changes in sexual risk behavior which place women at risk for
HIV infection. In addition to highlighting the differences between potential benefits for
male and female populations, our analyses also emphasize the idea that changes in risk
behavior may be more or less influential in programs where an intervention can provide a
direct benefit to only a fraction of the population (such as the case with male
circumcision), than in programs where an intervention can provide a direct benefit to the
entire population (such as the case with HIV vaccines [Dissertation Paper 3]).
To our knowledge, this analysis represents one of only three modeling simulations
for the impact of male circumcision programs on the HIV epidemic in Africa. Williams
and colleagues simulated the impact of achieving full coverage of male circumcision
across sub-Saharan Africa within the next three to eight years and estimated that 6
million infections could be prevented in the region over a 20-year period[23]. Kahn and
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colleagues estimated the costs of implementing various male circumcision programs in a
South African setting and found them to be extremely cost-effective over a wide range of
values[24]. We have furthered this research by examining the impact of modest expanded
adult male circumcision programs using a detailed model for heterosexual HIV
transmission with well-defined parameters for the population of Soweto and focused our
simulations on exploring the dynamic effects of potential behavioral disinhibition in
depth.
Now that a true protective effect for male circumcision has been shown by three
randomized controlled trials, published estimates of FTM HIV transmission rates will
need to take into consideration the circumcision status of males. For this modeling study,
we calculated HIV infectivity parameters from studies of 170 monogamous
serodiscordant couples in Uganda, which represented the only African transmission data
currently available[52,53]. While the authors of the Ugandan studies noted that male
circumcision status had no impact on MTF HIV transmission, they did not explore the
impact of circumcision on FTM HIV transmission nor did they specify the baseline rates
of male circumcision in their participants. These 170 couples were separated from a
larger cohort of 415 serodiscordant couples based on their status of reporting
monogamous relationships. Data from the larger cohort show that 19% of the men in the
overall study population were circumcised; and, 27% of the men who were the HIVnegative partner were circumcised, of whom none became infected[12]. However, we do
not know which of these participants were included in the sub-study and new analyses of
those data according to circumcision status, in light of our current knowledge regarding
protection from circumcision, would be beneficial to work such as that presented here.
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For these reasons, we are unable to speculate on the true influence of circumcision on
these HIV transmission data as it may be a confounding factor. Thus, if a substantial
proportion of HIV-negative males were circumcised in those studies, FTM HIV
transmission rates may actually be higher than described and should be reflected in future
modeling studies.
We modeled only a decrease in FTM HIV transmission to circumcised HIVnegative males. Although the biologic and epidemiologic evidence is not as strong, it is
also possible that there may be a decrease in MTF HIV transmission from circumcised
HIV-positive males to their female partners'-7’54,55-'. This would be particularly important
in South Africa where the prevalence of HIV in women is greater than in men[56,57]. A
large randomized controlled trial is currently underway in Uganda to address this
question1-451, and further simulation studies should address this possibility when the data
become available.
South Africa has a national plan for widespread distribution of antiretroviral
medication to HIV-infected individuals^81, although progress on implementation has been
slow. Only limited distribution has been accomplished to date within the public sector,
with less than 100,000 HIV-infected individuals receiving ARV therapy1501 out of an
estimated 5.5 million infected individuals in South Africa^1,591. Antiretroviral therapy has
been shown to decrease viral load and subsequent transmission 0f H rv[12,52’53’601 and
therefore should be included, along with the concurrent increase in length of individual
disease stages and overall lifespan for those treated, in future simulations when coverage
levels begin to increase in South Africa.
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We found that for any given level of circumcision protective effect, the impact of
increasing condom use levels was greater than the impact of increasing program coverage
beyond modest levels: for example, increasing condom use by 25% in circumcised men
would be more effective than increasing program coverage levels for circumcision
programs from 25% to 100%. Although it might appear that programs to increase
condom use would be more beneficial than achieving high levels of circumcision
coverage, these results do not take into account the fact that circumcision programs
would involve a one-time intervention while programs to increase condom use require an
intervention that must be exercised with every sex act over the life of the individual.
Therefore, the best manner in which to allocate resources (e.g. between increasing
circumcision program coverage and increasing condom distribution/education program
coverage) can not be determined by our analyses.
Because there is no single intervention that is completely effective in preventing
HIV transmission, interventions which are partially effective in reducing HIV
transmission must be implemented. For heterosexual transmission in African
populations, these currently include male circumcision, education programs, condom use
campaigns, access to HIV volunteer counseling and testing, treatment of HIV-positive
individuals to reduce viral load, stigma reduction, poverty alleviation, and empowerment
of women. Eventually, chemoprophylaxis regimens, diaphragms, microbicides, and
prophylactic or therapeutic vaccines may be added to this arsenal of programs[32l While
we have explored the impact of expanded adult male circumcision programs to address
questions regarding their potential benefits and immediate implementation, further work
on assessing the impact of multiple partially-effective prevention programs in a single
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population is merited to allow for relative comparisons between different intervention
package combinations.
Implementation of pilot male circumcision programs should begin immediately as
male circumcision has been shown to be effective, safe, affordable, acceptable, and will
likely confer lifelong benefits. Given the coverage of male circumcision in the media,
uptake of programs should be successful—many clinics in Africa are already struggling
to cope with the increased demand for circumcision^301. However, programs must ensure
that all male circumcision procedures are both safe and voluntary and must remain
sensitive to the cultural practices of different populations. Nevertheless, even cultures
and ethnic groups which do not currently encourage circumcision may find it acceptable,
as was shown in the South African Zulu and Tswana populations117,211. Risk-reduction
counseling must be provided by these circumcision programs, both to individuals as well
as the community. This is particularly important in the South African context, where
studies have revealed beliefs that circumcised men can increase their sexual risk
behavior1-151 and where risk behavior was already shown to increase slightly during the
circumcision trial[13]. Finally, programs must be evaluated on their effectiveness, with
particular emphasis on whether changes in sexual risk behavior have occurred.
In summary, even modest expanded male circumcision programs can confer
substantial health benefits to males and females in South Africa and other populations
with similar epidemic profiles and these programs should be implemented immediately.
Although these findings were sensitive to the impact of circumcision on subsequent risk
behavior, all programs resulting in decreased risk behavior and even most programs
resulting in increased risk behavior would still be beneficial. Programs to reduce risk

-163 -

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

behavior will remain an important component of successful prevention programs,
including circumcision programs.
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TABLE 1. Param eter values
Value3

Source
Assumption

£

0.10-0.20,
t£5
0, t>5
0.61 (0-1.0)

A

1.0 (0-2.0)

Assumption

0.0684

[12,52,53,61]

0.1657

[12,52,53,61]

0.1112

[12,52,53,61]

0.2697

[12,52,53,61]

3

[62]

3

[62]

1

Assumption

0

Assumption

0.5

[44,56,57,62,63]

0.14

[64]

f

HIV disease duration parameters
Asymptomatic HIV infection (years)

1/ f t

6.8

[38,39,65]

Symptomatic HIV infection (years)

\/jU2

2.6

[38,39,65]

0.8

[65]

25.1
60.8
0.028°
823,000
11.6
20.0
0.35
0.03
0.10
0.35

[66]
[67]

Parameter name
Preventive circumcision program parameters
Percentage of uncircumcised uninfected or
uncircumcised asymptomatic HIV+ males
circumcised annually
Circumcision protective effect (percent of
partnerships protected from infection)
Change in (male-negotiated) condom use following
circumcision, for males circumcised as adults, or
following circumcision program implementation,
for males previously circumcised in childhoodb
HIV transmission parameters
Male infectivity (per-partner probability of
transmission to a female)
Asymptomatic period of HIV infection
Symptomatic period of HIV infection

Symbol
K (t)

PMl,j
P m IJ

Female infectivity (per-partner probability of
transmission to a male)
Asymptomatic period of HIV infection
Symptomatic period of HIV infection

P wi
Pwi

Contact rate (number of new partners per year) of
males or females
Uninfected
HIV infected, asymptomatic period

Po
Pi

HIV infected, symptomatic period

Pi

HIV infected, AIDS

Pi

Baseline (male-negotiated) condom use for all
partnerships (without implementation of an adult male
circumcision program)
Condom failure rate for all partnerships

AIDS (years)

h ..
‘,J

1Ifh

Population parameters, heterosexual men/women > 16
years
Mean age (years)
N o n -A ID S life expectancy (years)
Non-AIDS-related annual mortality rate
Initial population size
Initial HIV prevalence, male population (%)
Initial HIV prevalence, female population (%)
Initial circumcision rate, baseline male population (%)
Arriving male population HIV prevalence (%)
Arriving female population HIV prevalence (%)
Arriving male population circumcision rate (%)

p
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[13]

[66,67]
[44,56,57,63,68]
[57]
[57]
[43]
[44,56,57,69]
[44,56,57,69]
[44]

a Values in parentheses are ranges used in sensitivity analyses
b e.g. for A = 1.0, no change in condom use; for A = 1.30, 30 % increase in condom use; for A = 0 .7 0 , 30%
decrease in condom use
c Calculated [Dissertation Paper 31________________________________________________________________________
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TABLE 2. Sensitivity analysis on potential risk behavior ch an g e and protective
circumcision effect: total infections prevented after 20 years by various 5-year expanded
circumcision program s3____________________________________________________________
Protective effect on HIV transm ission
due to circumcision
Change in condom u se
60%°
80%c
20%c
40%c
post-circum cisionb
Proaram s with 10% coveraae aoals
Condom use increases by 100%

145,000

126,000

107,000

87,000

Condom use increases by 50%

87,000

81,000

74,000

66,000

Condom use increases by 25%

51,000

53,000

54,000

54,000

No change in condom use

11,000

21,000

32,000

41,000

Condom use decreases by 25%

(34,000)

(14,000)

7,000

27,000

Condom use decreases by 50%

(83,000)

(53,000)

(21,000)

12,000

Condom use decreases by 100%

(186,000)

(139,000)

(84,000)

(23,000)

Condom use increases by 100%

175,000

158,000

139,000

119,000

Condom use increases by 50%

109,000

106,000

102,000

96,000

Condom use increases by 25%

67,000

73,000

79,000

83,000

No change in condom u se

18,000

36,000

52,000

68,000

Condom use decreases by 25%

(37,000)

(7,000)

23,000

51,000

Condom use decreases by 50%

(97,000)

(55,000)

(10,000)

33,000

Condom use decreases by 100%

(222,000)

(161,000)

(87,000)

(9,000)

Proaram s with 20% coveraae aoals

Total infections prevented for male and female populations. Numbers in parentheses represent negative
values, which indicate the number of additional infections caused by a particular program.
b Considering an increase or d ec re a se in baseline condom u se levels o f 50%. A 25% difference implies an
absolute increase to 62.5% or decrease to 37.5% in condom use levels. A 50% difference implies an
absolute increase to 75% or decrease to 25% in condom use levels. A 100% difference implies an absolute
increase to 100% or decrease to 0% in condom use levels.
c Total expected infections over 20 years for various circumcision protective effects in the a b se n c e of

expanded circumcision programs: 295,000 (20%); 271,000 (40%); 246,000 (60%); and, 220,000 (80%)
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FIGURE CAPTIONS

Figure 1. Predicted trends in Soweto adult HIV prevalence over 20 years for male and
female populations: model simulation without considering a reduction in HIV
transmission due to current rates of male circumcision (panel A); model simulation
considering a reduction in HIV transmission due to current rates of male circumcision
(panel B)

Figure 2. Predicted trends in Soweto adult HIV prevalence over 20 years for male and
female populations following implementation of expanded adult male circumcision HIV
prevention programs: 5-year programs targeting an additional 10% (panel A) or 20%
(panel B) of uncircumcised adult males each year.

Figure 3. Cumulative HIV infections prevented over 20 years for male and female
populations following implementation of adult male circumcision HIV prevention
programs: 5-year programs targeting an additional 10% (panel A) or 20% (panel B) of
uncircumcised adult males each year.

Figure 4. Cumulative infections prevented over 20 years for male and female populations
following implementation of adult male circumcision HIV prevention programs and
subsequent risk behavior change: effects of a 25% increase in condom use on outcomes
of 5-year programs targeting an additional 10% (panel A) or 20% (panel B) of
uncircumcised adult males each year; effects of a 25% decrease in condom use on
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outcomes of a 5-year programs targeting an additional 10% (panel C) or 20% (panel D)
of uncircumcised adult males each year.

Figure 5. Cumulative number of infections averted after 20 years assuming a range of
values for the protective effect of male circumcision on FTM HIV transmission: results
for 5-year circumcision programs with 20% coverage goals and various levels of change
in condom use behavior following program implementation (50% increased condom use,
25% increased condom use, no change in condom use, 25% decreased condom use, 50%
decreased condom use).

Figure 6. Equivalence graph showing circumcision programs which would result in the
program having no net effect (e.g. the total number of infections prevented 20 years
following program implementation is zero) for combinations of circumcision protective
effect (0% to 100%) and post-circumcision condom use (from a baseline condom use of
50%): results for 5-year circumcision programs with various levels of coverage levels
(25%, 50%, 75%, and 100%) after 20 years.

Figure 7. Equivalence graphs showing all combinations of 5-year program coverage
levels (targeting an additional proportion of uncircumcised males each year) and post
circumcision condom use (from a baseline condom use of 50%) which would result in the
program having no net effect, e.g. the total number of infections prevented 20 years
following program implementation is zero. Results are shown for reductions in FTM
HIV transmission due to male circumcision of 20% (panel A), 40% (panel B), 60%
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(panel C), and 80% (panel D). All programs for adult male circumcision with various
coverage levels and changes in risk behavior values placing them above the curve will
prevent infections, while all programs with various coverage levels and changes in risk
behavior values placing them below the curve will cause additional infections.
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APPENDIX
Further information on the mathematical model used for predicting the impact of
expanded adult male circumcision programs is detailed in this Appendix.
The model defines ten health states, and only certain movements between these
health states are allowed: Women can move from the HIV-negative compartment (state
1) to the asymptomatic HIV-positive compartment (state 4) by acquiring HIV infection
from an infected male partner, and can move to the symptomatic HIV-positive (state 7)
and AIDS (state 9) compartments as a result of subsequent disease progression. Men can
move from the uncircumcised HIV-negative (state 2) and the asymptomatic HIV-positive
(state 5) compartments to the circumcised HIV-negative (state 3) and asymptomatic HIVpositive (state 6) compartments by undergoing a circumcision procedure as a result of an
expanded adult male circumcision program. Men can move from the uncircumcised
(state 2) or circumcised (state 3) HIV-negative compartments to the uncircumcised (state
5) or circumcised (state 6) asymptomatic HIV-positive compartments, respectively, by
acquiring HIV infection from an infected female partner, and can move to the
symptomatic HIV-positive (state 8) and AIDS (state 10) compartments as a result of
subsequent disease progression.
For the symptomatic HIV-positive and AIDS states, circumcised and uncircumcised
males can be analyzed within the same compartment because they are already infected
and thus circumcision does not afford them any further protection, nor does it influence
their ability to transmit HIV to uninfected women. While we modeled risk behavior
changes for men who are circumcised but HIV-negative or in the asymptomatic stage of
HIV infection, we made the assumption that circumcised men in the symptomatic stage
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of infection were aware of their HIV status and thus did not increase their risk behavior.
Men in the AIDS state were modeled to have no sexual partners, but if this value were to
change then this assumption would also be made for the AIDS state.
We define the model variables and the ten differential equations which govern
transitions between the various compartments in the model in Tables 2 and 3. The
equation number corresponds to the rate of change for individuals in the state or
compartment of the same number, as indicated above. As an example, we explain how
equation (2) describes the rate of change of the male [ M i j ] uncircumcised [y = 0], HIVnegative [i = 0] sexually active population at tim et:
(2 )

at

= / „ o,o -

- p 0Zu (<)M 0 „(/)

This rate depends on the following terms: (a) I M0 0, the number of uncircumcised,
HIV-negative males who arrive into the sexually active population each year upon
reaching the age of 17 years; (b) K(t)M00(t), the number of uncircumcised, HIVnegative males [ M 00(t) ] who are circumcised each year [proportion rc(t) of the
uncircumcised HIV-negative or asymptomatic HIV-positive males who are circumcised
each year under the expanded program]; (c) juM 00(t), the number of uncircumcised,
HIV-negative males [ M 0fi (t) ] who die each year due to non-AIDS related causes [nonAIDS mortality rate, // ]; and, (d) p 0/iM(t)M 00(0 , the number of uncircumcised HIVnegative males [M 00(t) ] who become infected with HIV [per-partnership probability of
an unvaccinated male acquiring HIV from any female at time t ■
>A.M {t) ] each year from a
female partner [number of female partners per year for an uninfected male, p 0].
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Additional equations define rates of change for the number of men and women in the
nine other compartments in a similar manner.
We modeled HIV transmission on a per-partnership basis such that the HIV
infectivity parameters simulated the total probability of transmission during the course of
a sexual partnership rather than during a single sex act, as previously described
[Dissertation Paper 3]. We modeled the protective effect of circumcision as partial
protection for males on an individual level. Equation (3) in Table 3 shows that
circumcised males experience a reduced rate of HIV infection by a factor of (1 - s ) when
they are exposed to HIV-positive partners. Therefore, a circumcision protective effect of
61% (e = 0.61) would provide protection from 61% of sexual partnerships between an
uninfected circumcised male and an infected female partner Another way of saying this
is that being circumcised would reduce the probability of HIV infection for males in that
sexual partnership by 61%. Factors influencing the rate of HIV infection for uninfected
men and women in the model, in addition to whether the male in a sexual partnership is
circumcised, include the number of sexual partners they have per year, the condom use
behaviors within each sexual partnership, and the ‘force’ of infection to which an
uninfected individual is exposed.
The force of infection is the probability of acquiring HIV from any partner at a
given point in time and is defined by equations (11), (12), and (13) in Table 3. As an
example, we explain how equation (11) describes the force of infection which an
uncircumcised uninfected male experiences at timer :
i=3
WM 0 ,0

(H )-W 0 = —

-t?--------------

2>,>ro
;=o
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Given all of the potential heterosexual partnerships that are possible, the probability that
this male becomes infected with HIV is determined by the likelihood that he chooses an
1=3

/ i=3

HIV-infected female partner

and the likelihood that HIV is
;=i

/

i=0

i=3

transmitted during the course of that sexual partnership

], both of which depend
i=i

on the disease stage of the female partner. The probability that this male becomes
infected with HIV also depends on the condom use within that partnership, which in this
CHS6 is

qq.

In general, the condom use term nMt j describes the probability that a particular
sexual partnership between a male with disease stage i and circumcision status j and a
female with disease stage i is not protected by condoms, and incorporates the idea that
condom use is male-negotiated (see Table 2 for equations). In equation (11), condom
use nM0 0within a partnership between an uncircumcised uninfected male and any female
is based solely on his own condom use behavior. In equation (12), condom use
nMo,i within a partnership between a circumcised uninfected male and any female is also
based solely on his own condom use behavior, although his condom use behavior may
have changed following the implementation of expanded circumcision programs. On the
i=3 7=1

nm j in a partnership with an uninfected

other hand, in equation (13), condom use
1=1 7=0

female, being male-negotiated, is based on all of the male partners she might encounter
and their summed individual probabilities of condom use behaviors.
We assumed equal numbers of men and women in the population initially. For
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HIV-infected individuals in the starting population, we assumed a distribution of men or
women at various stages of HIV disease which was proportional to the relative length of
each stage. We modeled a constant arriving population of 17-year-old sexually-active
adults, of whom some were already infected with HIV, as previously described
[Dissertation Paper 3]. Arriving females entered either the HIV-negative or
asymptomatic HIV-positive populations, whereas arriving males entered the
uncircumcised and circumcised HIV-negative or uncircumcised and circumcised
asymptomatic HIV-negative populations. We assumed that the proportion of circumcised
males in the arriving population was identical for both uninfected and infected
individuals. While the true circumcision rate likely differs between uninfected and
infected males due to the protective effect of circumcision, the HIV prevalence in
arriving 17-year old males is only 3% and therefore this effect would be minimal. The
model structure allows for this differentiation in the arriving population and thus this
question could be further addressed either with assumptions on the difference in
circumcision rate between these groups or with data collected on circumcision prevalence
in adolescent boys by HIV status when they become available.
Only procedures performed as part of the expanded adult male circumcision
programs described here have been modeled; we did not allow for adult males who might
undergo circumcision independently of these programs. We assumed that the protection
afforded to males by circumcision was uniform for various HIV virus subtypes.
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TABLE 2 (APPENDIX). Definition of model variables

Symbol

Description of variable
Disease stage, males and females (/)
Uninfected (HIV-negative)
Infected (HIV-positive) asymptomatic
Infected (HIV-positive) symptomatic
AIDS
Circumcision status, males only (J)
Uncircumcised

i = 0

i- 1
i-2
f=3
7=0
7=1

Circumcised
Disease-stage specific variables
Number of men in disease stage /' with circumcision status j at time t

M„(0

Number of women in disease stage i at time t

Wt(f)

Probability of a male acquiring the infection at time t from any one female partner

Am (0

Probability of a male acquiring the infection at time t from any one female partner,
under behavior modifications due to male circumcision
Probability of a female acquiring the infection at time t from any one male partner
Per-partner infectivity (chance of transmitting HIV) of a male in disease stage I with
circumcision status j
Per-partner infectivity (chance of transmitting HIV) of a female in disease stage /
Contact rate (number of new partners per year) of males or females in disease
stage /
Mean duration (in years) of disease stage i
Annual immigration of males in disease stage /' with circumcision status j

^ M ir (0

A
Pta,j
Pwi
P i

11 P i
^ M iJ

Annual immigration of females in disease stage /'

IfVi

Probability a partnership between an uninfected, uncircumcised male and a female
with disease stage / is not protected by condoms3
Probability a partnership between an uninfected, circumcised male and a female
with disease stage / is not protected by condoms3
Probability a partnership between an uninfected female and a male with disease
stage /' and circumcision status j is not protected by condoms3
Population variables
Non-AIDS-related annual mortality rate
Condom failure rate for all partnerships

n M 0,0
WA/0,1

nMiJ
P
f

Preventive circumcision program variables
Annual percent of uncircumcised uninfected or uncircumcised asymptomatic HIV+
K(t)
males who undergo adult circumcision procedure
Circumcision protective effect (percent of partnerships protected from infection)_________£
&nMi,j = f g i j + Q - - g i j ) .Where g u0 = h i0

and

g iX =

A

hi{ ; lhtJ -

baseline condom use for all

partnerships; A = change in condom use following circumcision, for males circumcised as adults, or
following circumcision program implementation, for m ales previously circumcised in childhood;

gi . =

post-

intervention condom use for all partnerships, following implementation of an adult m ale circumcision program]
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TABLE 3 (APPENDIX). Model equations
State Equation
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DISCUSSION

- 1 9 6 -

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

My dissertation research contributes to the scientific literature, both in the novel
survey procedures and modeling techniques I developed, as well as my application of
these methods to the population studied. In addition, my research on risk behavior in
HIV vaccine trial participants contributes to the practical and ethical conduct of current
clinical trials for HIV vaccines; my studies of hypothetical behavior and vaccine
modeling contribute to policy decisions that will eventually be made regarding the use of
partially effective vaccines in mass vaccination programs; and, the circumcision
modeling I did contributes in a timely manner to the international debate currently
underway regarding the immediate and worldwide implementation of expanded adult
male circumcision programs in populations at high risk of heterosexual HIV infection.
The data collected in the first paper on the current sexual risk behavior of
individuals volunteering for HIV vaccine trials represent the first description of this
cohort in Soweto, as well as the first characterization to date of a cohort participating in
HIV vaccine trials in sub-Saharan Africa. Soweto is a large, predominantly black urban
township with a mixture of various tribal ethnicities, on which little behavioral and
sociological research has been done. The 2002 Soweto Household Survey111, conducted
by the Perinatal HIV Research Unit (PHRU), is the only large survey of Soweto residents
to date12: 12,000 households were surveyed and detailed socioeconomic data were
collected, but no information on HIV risk behaviors or HIV prevalence was obtained.
My research can not be generalized to the greater community because individuals were
not randomly selected for participation; a study elsewhere in South Africa found the risk
behavior of participants in a cohort recruited for future vaccine trials had higher levels of
risk behavior than individuals in the greater community121. However, in addition to the
12 Results from this household survey have not yet been published.
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substantial geographic and cultural variation in HIV risk behaviors that exist in South
Africa[3'8], the behaviors of individuals enrolling in prevention trials have not been
assessed19"11]. Numerous HIV prevention technologies are being tested in clinical trials in
Soweto, and my study provides a detailed sociodemographic and risk description of the
population that is volunteering for these trials.
The risk behavior assessment survey I developed for use in the first paper has been
permanently incorporated into the Pre-Screening Protocol at the PHRU HIV/AIDS
Vaccine Division, in the Chris Hani Baragwanath Hospital in Soweto[12,13]. The PHRU is
using it as a risk assessment screening tool to determine if participants are at relatively
low risk for HIV infection and should be referred for screening for Phase I (safety) and
Phase II (immunogenicity) HIV vaccine trials. In addition, the PHRU is preparing for
much larger Phase III (efficacy) HIV vaccine trial capacity in Soweto and in Agincourt, a
rural field site114,151, which will require participants who are at relatively high risk for HIV
infection when recruitment for these clinical trials begins. The predictors of higher risk
behaviors identified by my study could potentially be used as fixture screening tools for
different trials needing individuals at different risks of HIV infection.
Behavior assessment survey tools and the criteria used to measure risk can vary
between different HIV vaccine trials, from qualitative interviews to more structured
sxxrvey techniques. Individual vaccine trial protocols generally use a standardized risk
assessment survey to monitor behavior at various trial sites worldwide, without adapting
it to the specific cultural context of a particular trial site. Because many trial sites are
conducting several vaccine trials simultaneously, risk assessment may be undertaken with
several different survey instruments at a single trial site. These instruments have usually
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been formulated by sponsors from high-income countries, where risks for HIV infection
are very different. Further, these surveys have not been published to allow for
comparisons in format and questioning techniques. I hope to publish or distribute the
survey I developed for use in the first paper to allow other trial sites to adapt it for local
needs.
Analysis of sexual risk behavior over time is necessary both for HIV vaccine trials
to ensure that participants do not increase their risk of HIV infection and for the accurate
assessment of vaccine candidate efficacy[16'23]. Standard vaccine trial risk assessment
protocols, which take the time of vaccination as a baseline sexual risk level, are not able
to detect changes in risk behavior that may occur before that time point. Participants can
be monitored in ‘screening’ cohorts for months or even years prior to vaccine trial
enrollment, during which time they can change their risk behavior dramatically124^.
Because of this, an increase or a decrease in self-reported risk behavior during a specific
HIV vaccine trial, following participation in a screening cohort, may be relatively
uninformative without knowing the baseline behaviors of participants prior to entering
such a cohort.
The descriptive data presented in my first paper provide a baseline reference to
assess for potential risk behavior change during the process of enrollment and follow-up
for vaccine trials in Soweto. The PHRU will continue collecting data with this risk
behavior survey every six months for participants enrolled into vaccine trials and
longitudinal analyses can be conducted on these data when they become available.
Future work will assess whether there are any changes in risk behavior changes during
the course of pre-screening, subsequent enrollment into HIV vaccine trials, and follow-
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up. Sexual practices related to HIV risk will be assessed at several time points in
participants undergoing screening for enrollment into an HIV vaccine trial. Sexual risk
behavior will continue to be assessed in participants after their enrollment into one of
several HIV vaccine trials and their subsequent vaccination with a candidate HIV vaccine
or placebo, with follow-up time generally in the range of several years. Eventually,
sexual risk data collected using a standard risk assessment instrument (developed
specifically for this trial site population and given to all participants, from the time of
entry into the Pre-Screening Protocol through HIV vaccine trial enrollment and followup) can be compared with sexual risk data collected using vaccine trial-specific survey
instruments (developed by sponsors of the trial protocols occurring at that site and given
to participants in each trial, from the time of HIV vaccine trial enrollment).
Except for studies which hypothesize risk behavior change scenarios using
modeling simulations, the literature on anticipated changes in risk behavior following
implementation of proposed HIV prevention programs is almost nonexistent—
particularly for sub-Saharan Affica[25]. The survey I developed for use in the second
paper attempts to address this gap as it relates to the future use of low-efficacy vaccines,
with a focus on examining the potential for increases in sexual risk behaviors. This is
particularly relevant given the high likelihood that the first licensed vaccine will have
only minimal efficacy119,26,271. Based on self-reported anticipated changes in sexual
behaviors which participants predicted for themselves, I found that the potential for
individuals to change their risk behavior following vaccination with a low-efficacy HIV
vaccine exists, even when participants understood that a low-efficacy vaccine would not
provide complete protection against HIV transmission. Further, because my survey was
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administered to participants volunteering for HIV vaccine trials, which are operated
under idealized conditions with careful attention to HIV education, the anticipated
increases in sexual risk behavior for the general population may be greater than I have
described[28]. Although a majority of participants in my study actually reported that they
might decrease their risk behaviors following vaccination, I believe these data are less
reliable due to the social desirability bias inherent in my study design: participants were
interviewed in a face-to-face format and were receiving education associated with
screening and enrollment into HIV vaccine trials. Therefore, the anticipated decreases in
sexual risk behavior for the general population may be less than I have described, and
further studies in HIV vaccine trial-naive populations is merited. Additional work might
involve adapting this survey for a variety of other populations and proposed HIV
prevention programs. While my initial study was small, further data collection of this
genre is needed by governments and policymakers for the various HIV prevention
technologies which are under consideration. Moreover, studies of this nature are needed
for the mathematical modeling of epidemic impact (such as that demonstrated in this
dissertation research), which is frequently used to inform policy decisions.
While an HIV vaccine may not be available for at least a decade, countries are
already making resource allocation decisions regarding HIV prevention technologies
which are available now. South Africa, for example, is implementing a package of
various national programs for the prevention of sexual transmission of HIV, including
social mobilization, improvement of nutrition, school-based HIV education, treatment of
other sexually transmitted infections, and condom distribution[29,30]. South Africa is also
attempting to scale up the provision of antiretroviral treatment to those who are
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infected1-311. To effectively tackle the HIV epidemic, resource allocation decisions will
need to be made regarding the implementation of both current and future HIV prevention
programs.
Epidemic modeling can provide useful insights for program policy-making and is
particularly helpful in assessing the impact of HIV prevention programs in low-income
countries with a heavy burden of HIV/AIDS yet limited health care resources. Further,
an analysis of potential changes in behavior is especially pertinent when examining the
impacts of a disease such as HIV in which behavior plays such a significant role in its
transmission. The epidemic model I developed for use in the third and fourth papers is
one of only a handful of models in the vaccine literature and the only model in the
circumcision literature which has considered heterosexual transmission of HIV in African
populations132'381, where there is the greatest need for HIV prevention interventions.
My methodology is also unique for several additional reasons: (1) The model I
developed is the first to address gender differences in the ability of individuals to
negotiate safe sex practices, which is an important consideration when addressing
heterosexual partnerships in which females are affected by cultural and economic barriers
to successfully negotiate condom use with their male partners, as shown by research in
South Africa13’39-411. (2) The simulations I conducted with my model explore the
dynamics of behavior change in greater detail than have been previously reported for
heterosexual HIV transmission. (3) The detailed input data I used was collected for a
specific population in South Africa, thus minimizing the assumptions that had to be
made. By using different input parameters and assumptions, my model could be
initialized for other populations in which the mode of HIV transmission is also primarily
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heterosexual and in which gender differences in safe sex negotiation also exist. Analysis
of program impacts in other regions would require adequate data for input values, which
many low-income countries lack, but the framework described here could assist in
guiding empirical data collection efforts by exploring which of the parameters might be
central to policy decision-making.
At the time that the first partially effective vaccine does become available,
government and health officials will have to make complex national policy decisions
regarding the use of these vaccines in their own populations[19]. In particular, models can
assist in answering many of the ‘what i f scenarios of vaccine program implementation,
such as whether or not to use a first-generation vaccine, whether to target only particular
geographic areas or high risk groups, and, for this study in particular, what might happen
if the vaccination program causes increased HIV transmission through a decrease in
‘safe, preventive’ behavior. In the third paper, I developed a model to address this last
issue, and specifically showed that programs with high coverage using low-efficacy
vaccines would provide substantial benefits in terms of infections prevented at the
population level, even if sexual risk taking behavior were to increase significantly.
The decisions regarding implementation of expanded programs for adult male
circumcision, however, must be made immediately142'501. Good estimates of the efficacy
of circumcision in decreasing transmission of HIV are already available151,521, and the
surgical procedure has been shown to be safe, acceptable, and affordable for many
populations in sub-Saharan Africa151'601. I created the model described in the fourth paper
to assist in informing the urgent choices that now need to be made regarding program
implementation. A simplified model of expanded circumcision programs has already
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been developed and used to examine the impact and cost-effectiveness of these
programs^37,381; I developed my model to examine the impact of expanded circumcision
programs in greater detail and to focus in particular on the dynamic interactions of
reduced HIV transmission and changes in behavior. Using efficacy data from the
circumcision trials which have recently been completed, my simulations predicted that
short programs with even very low coverage goals would provide substantial benefits in
terms of infections prevented at the population level over time for a wide range of
potential changes in condom use following male circumcision. My model for
circumcision programs also emphasized that the benefits to men versus women can be
different and must not be ignored when evaluating potential program outcomes.
Both of the models I developed show that adequate education and risk-reduction
campaigns must be considered when implementing HIV prevention programs with partial
efficacy, as changes in sexual risk behavior can have significant effects on program
outcomes. However, a comparison of the two models shows that a change in risk
behavior was more influential in the implementation of circumcision programs than in the
implementation of vaccination programs, e.g. higher levels of circumcision efficacy
compared to vaccine efficacy were needed to overcome large decreases in condom use.
These differences are due to the interaction between two factors: (1) the direct protection
of vaccination for both men and women compared with the direct protection of
circumcision solely for men, while women receive only indirect protection due to
decreases in population HIV prevalence; and, (2) the male-negotiated condom use which
I have modeled to simulate the inability of many women to negotiate safe sex practices in
the African setting. Circumcision protects men from infection and an increase or

-204-

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

decrease in risk behavior for circumcised HIV-negative males will directly influence their
likelihood of infection from an infected female partner. However, for an HIV-negative
female, sex with a circumcised man will not decrease her chances of HIV infection if he
is HIV-positive; further, if he increases his risk behavior in response to circumcision, she
will be at greater risk of HIV infection than she would be if her partner were
uncircumcised.
By comparing the outcomes between vaccination programs and circumcision
programs, my findings suggest that risk-reduction counseling may be an even more
critical component of partially effective prevention interventions where a certain fraction
of the population at risk for HIV infection receives nothing more than an indirect benefit
from the intervention. Further, the gender discrepancies in negotiation of safe sexual
practices modeled here, combined with analyses of prevention programs providing both
direct and indirect transmission benefits, have shown that changes in risk behavior do not
affect prevention programs uniformly. This interaction is influenced by differences in
power to negotiate safe sex and differences in benefits of reduction in HIV transmission
which, in my analyses, were both gender-based. These results specifically emphasize the
need for more detailed examinations of potential gender differences in outcomes
expected from HIV prevention programs.
More generally, though, these results highlight the need for analyses of the tradeoff
between allocating resources for increased coverage of a specific prevention technology
(such as providing male circumcision) after modest coverage levels have been achieved,
versus using those resources for increased coverage of a behavior-based prevention
program (such as increasing condom use). Because many prevention technologies may
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require only a one-time intervention to confer lifelong protective benefits, while
behavioral prevention programs usually necessitate an intervention which must be
practiced repeatedly for the life of the individual, further research is needed on how best
to allocate resources between various types of prevention programs. My future research
may involve examining the costs and benefits of increasing coverage levels for
prevention programs with inherent differences in the timing and length of the
intervention.
Additionally, the ability to model multiple interventions within the same population
will be needed as governments and policy makers are confronted with numerous HIV
prevention technologies, all with partial efficacy146’50,611. Decisions will need to be made
not only on whether to use a single prevention program, but also on what combination of
prevention programs should be used and the additive effects of multiple programs with
varying coverage and target goals. I hope to adapt this model to allow for the assessment
of other HIV prevention technologies. For example, a large randomized controlled trial
is currently underway in South Africa and Zimbabwe, with Soweto as the South African
site, to assess whether diaphragm use has an impact on male-to-female and/or female-tomale heterosexual transmission of HIV[621. I am currently working with the principal
investigator for the South African trial to develop a model that accurately simulates the
dynamics of HIV transmission surrounding diaphragm use. My future research may
involve developing additional models which can compare multiple HIV prevention
programs simultaneously.
In conclusion, I have used the township of Soweto as an example to describe the
impact of partially effective HIV prevention programs and associated changes in risk
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behavior; but, the implications of my results reach beyond South Africa. The severity of
the HIV/AIDS epidemic in South Africa has been enhanced by a history of apartheid and
migratory labor practices, a lack of political will for HIV education and treatment,
significant poverty and unemployment, and the stigma attached to the disease^3,9’30’63'671.
Although the particular combination of factors contributing to the initial spread of HIV
disease in South Africa was unique, many other populations worldwide are experiencing
similar generalized epidemics, in which HIV transmission is predominantly heterosexual
and gender discrepancies exist in the negotiation of safe sexual practices. This
dissertation research has applications for other low- and middle-income countries with
similar epidemic profiles considering the use of partially effective HIV prevention
programs on a regional or national scale, as well as for high-income countries considering
the implementation of programs in particular groups such as those at high risk for HIV
infection.
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